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ABSTRACT




Co-chairs: Jeremy M.G. Taylor and Michael R. Elliott
Intermediate markers can be useful in clinical trials as either surrogate markers in-
tended to replace the true outcome of interest or as auxiliary variables intended to
improve efficiency in the analysis of the true outcome. We explore methods pertain-
ing to both of these roles of intermediate markers. First, we propose methods for
assessing the validity of a potential surrogate marker. Working under the principal
stratification approach for surrogacy validation proposed by Frangakis and Rubin
(2002), we propose quantities to evaluate surrogacy when the joint distribution of
the potential surrogate and final outcomes is multivariate normal. The multivariate
normality assumption is then relaxed and a Gaussian copula model is used to model
the joint distribution of surrogate and final outcomes, and quantities are derived from
this model to determine surrogacy. For both the multivariate normal model and the
Gaussian copula model, a Bayesian estimation strategy is used and, as some param-
eters are not identifiable from the data, we explore the use of informative priors that
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are consistent with reasonable assumptions in the surrogate marker setting to aid in
estimation.
Methods for utilizing an intermediate marker as an auxiliary variable to improve
efficiency in the analysis of the true outcome are then considered. A multi-state model
with an incorporated cured fraction is used to model recurrence and death in colon
cancer. The model is used to assess how individual covariates affect the probability
of being cured of disease and the transition rates between the various disease states.
Once parameter estimates from the model are obtained, survival probabilities can be
estimated with gains in efficiency obtained as compared to Kaplan-Meier estimates.
The model is then used in a multiple imputation strategy which imputes death times
for censored subjects. By using the joint model, recurrence is used as an auxiliary
variable in predicting survival times. We explore the use of a hierarchical model
and model adaptations that can be made to potentially further the efficiency gains
obtained through the multiple imputation procedure. We demonstrate the potential





There is much interest in the use of intermediate outcome variables as either surro-
gate endpoints or as auxiliary variables for the true outcome of interest in randomized
clinical trials, as they may allow trials to be run more quickly and inexpensively. A
surrogate endpoint (S) is one that is intended to replace the true endpoint (T ) in
evaluating therapy and an auxiliary variable is one that is intended to be used to
improve the efficiency of the analysis of the true endpoint. In this dissertation we
will consider both of these uses of an intermediate marker. First, we explore methods
of validating a surrogate endpoint that is intended to replace a true endpoint. We
propose surrogate validation measures for multivariate normal surrogate and outcome
data, with extensions to non-normally distributed data through the use of a Gaussian
copula model. We then look at methods to jointly model an intermediate outcome and
final outcome with a goal of utilizing the information from the intermediate variable
to improve the analysis on the true endpoint of interest. We propose a multi-state
model with an incorporated cured fraction to jointly model colon cancer recurrence




Chapters II and III consider the use of an intermediate marker, S, as a surrogate
maker for the true endpoint, T , and explore methods of validating S as a surrogate.
In both of these chapters, we work under the principal surrogacy framework of causal
inference proposed by Frangakis and Rubin (2002). In Chapter II, we propose quan-
tities to evaluate surrogacy when the joint distribution of the potential outcomes of S
and T follow a multivariate normal distribution. Many previous methods of surrogate
validation rely on models for the conditional distribution of T given the treatment (Z)
and S. However, S is a post-randomization variable, and unobserved, simultaneous
predictors of S and T may exist. When such confounders exist, these methods will
not have a causal interpretation. Therefore, there has been much recent work in the
area of surrogacy assessment under the principal surrogacy approach, which looks at
the distribution of the potential outcomes of T conditional on principal strata based
on the joint distribution of the potential outcomes of S, which are pre-randomization
variables. Treatment effect estimates that condition on these principal strata are
therefore causal estimates. Existing literature on methods of surrogacy assessment
using principal stratification has examined settings in which both S and T are binary
(Li, et al. 2010), or in which S is continuous with binary T (Gilbert and Hudgens,
2008; Zigler and Belin, 2012). Work in the principal stratification setting when both
S and T are continuous has been discussed in the application to partial compliance
(Bartolucci and Grilli, 2011; Schwartz, et al. 2011), where the conditional distribution
for each of the potential outcomes of T are modeled separately. Here, we consider the
entire joint distribution of the potential outcomes of S and the potential outcomes
of T when both S and T are continuous and their joint distribution is multivariate
normal. Once parameter estimates from this model are obtained, we examine vari-
ous causal quantities that may aid in the assessment of S as a surrogate marker for
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T . As the model is not fully identifiable from the data, we propose some reasonable
prior distributions and assumptions that can be placed on non-identified parameters
to aid in the Bayesian estimation scheme. We explore the relationship between our
surrogacy measures and the surrogacy measures proposed by Prentice (1989). The
method is applied to data from a macular degeneration study where change in visual
acuity at six months is assessed as a surrogate for change in visual acuity at one year,
and to data from an ovarian cancer study where progression free survival is assessed
as a surrogate for overall survival.
In Chapter III, we again consider surrogacy validation measures using the prin-
cipal stratification framework, but relax the multivariate normality assumption. In
this setting, a Gaussian copula model can be used to model the joint distribution of
the counterfactual surrogate and final outcome measures. We address the scenario
of an ordinal categorical variable as a surrogate for a censored failure time true end-
point. The use of a copula model to assess surrogacy in this setting was explored
by Burzykowski, et al. (2004), where a Plackett copula was used to jointly model
observed tumor response and survival in advanced colorectal cancer. De Leon and
Wu (2011) explored the use of the Gaussian copula to jointly model a bivariate dis-
crete and continuous outcome. Here, we extend these ideas by employing a four
dimensional Gaussian copula model to jointly model the potential outcomes of an
ordinal surrogate marker and the potential outcomes of a censored time to event fi-
nal outcome and derive quantities from this model to assess surrogacy. A Bayesian
estimation strategy is used to aid in the estimation of non-identified parameters, and
the use of some prior distributions that are consistent with reasonable assumptions in
the surrogacy setting are assessed. We apply the method to data from an advanced
colorectal cancer clinical trial where tumor response is assessed as a surrogate for
4
overall survival.
Chapters IV and V consider the use of S as an auxiliary variable that is meant to
aid in the efficiency of the estimation of T . In Chapter IV, we propose a multi-state
model with an incorporated cured fraction to jointly model recurrence and death
in colon cancer. The multi-state model and cure model have each been separately
considered with both parametric and non-parametric assumptions. Here our proposed
model combines aspects of both of these models, providing insight into how individual
covariates affect the probability of being cured of disease and the time to recurrence,
time to death and time to death after recurrence, as well as the association of the two
endpoints of interest, recurrence and death. A Bayesian MCMC estimation strategy
is used to obtain parameter estimates. Checks for the adequacy of the model fit
and for the functional forms of covariates are explored through the use of Cox-Snell
residual plots and deviance residual plots, respectively. These model assessments are
natural to consider for multi-state models, but we are unaware of literature on using
them in cure models. The methods are applied to data from 12 randomized Phase III
trials of colon cancer, where there is interest in exploring common covariate effects
on each aspect of the disease process across all 12 trials.
Chapter V uses the proposed multi-state model with a cured fraction detailed in
Chapter IV to explore the use of recurrence as an auxiliary variable for improving
efficiency in estimating the treatment effect on overall survival. Estimates of overall
survival and disease free survival can be derived from the model with efficiency gains,
as compared to Kaplan-Meier estimates, obtained by utilizing recurrence information
and the parametric assumptions of the model. Alternatively, efficiency gains can be
achieved by using the model in a multiple imputation procedure to impute death times
for censored subjects. Treatment effect estimates on overall survival are then obtained
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by combining results from the multiply imputed data sets. As the multi-state model
jointly models time to recurrence and time to death, recurrence is an auxiliary variable
in the imputation procedure, and treatment effect estimates from the imputed data
sets often result in an efficiency gain as compared to the original data, resulting in
the potential to shorten the length of the trial. The multiple imputation procedure
explored here extends that proposed by Conlon, et al. (2011), where recurrence
and death were modeled separately. In their procedure, a cure model was used to
model recurrence and for death, a proportional hazards model with Weibull baseline
hazard and recurrence as a time dependent covariate was used. Here, our proposed
model jointly models recurrence and death, and through the Bayesian estimation
procedure, the use of some restrictive priors can be explored as a way to further the
efficiency gains obtained through the imputation procedure. Additionally, the use
of a hierarchical model to facilitate information sharing of common covariate effects
across the 12 trials is considered as a modeling strategy, with the goal of improving
upon the efficiency gains from the imputed data.
CHAPTER II
Surrogacy Assessment Using Principal
Stratification When Surrogate and Outcome
Measures are Multivariate Normal
2.1 Introduction
A surrogate endpoint (S) is an intermediate outcome variable occurring in between
the treatment (Z) and the outcome of interest (T ). The surrogate is usually known
to be involved in the mechanism of the disease process and can be measured at an
earlier time than the desired outcome. Therefore, there is considerable interest in
the use of surrogate markers in clinical trials, as they offer the potential to run trials
more cheaply and quickly by extracting information regarding the treatment effect
on T through the earlier measured S. Examples of established surrogate markers
include blood pressure under anti-hypertensive drug treatment as a surrogate for
cardiovascular disease (Weir and Walley, 2006), and three year disease free survival
as a surrogate for five year overall survival in colorectal cancer (Sargent, et al. 2007).
We examine two data examples in the application of our method. The first concerns
patients with age-related macular degeneration and considers the use of change in
visual acuity at 6 months after starting treatment as a surrogate marker for change
6
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in visual acuity at 1 year. The second concerns ovarian cancer and assesses progression
free survival as a surrogate for overall survival.
Before a surrogate can be used in practice, it must be shown to be a valid surrogate
for the outcome of interest. In a landmark paper, Prentice (1989) proposed a formal
definition of surrogacy along with a validation strategy. Prentice’s criteria require
that S and T be correlated and the treatment effect on T be fully captured by
S. Other methods for surrogacy evaluation have since been proposed, including the
proportion of treatment effect explained by S (Freedman, Graubard, and Schatzkin,
1992), and individual-level and trial-level surrogacy association measures in meta-
analyses (Buyse, et al. 2000).
Surrogacy assessments like these that rely on adjusting for surrogate markers
measured after randomization result in estimates that will not have a causal inter-
pretation since the markers are measured after randomization (Rosenbaum, 1984).
Therefore, Frangakis and Rubin (2002) (henceforth FR) introduced a definition of a
surrogate endpoint, called a “principal surrogate”, based on a principal stratification
approach. In this framework, each subject has two potential outcomes corresponding
to each treatment, denoted S(Z) and T (Z), for Z = 0, 1. The principal surrogacy
approach looks at the distribution of the potential outcomes of T conditional on prin-
cipal strata based on the joint distribution of S(0) and S(1). The principal strata are
unaffected by treatment, and are thus pre-randomization variables. Treatment effect
estimates that condition on these principal strata are therefore causal estimates when
treatments are randomly assigned.
The rationale for considering whether the principal stratification approach is ap-
propriate for assessing surrogacy has been discussed in the literature, with some
support provided in the discussion by VanderWeele (2011) and by Zigler and Belin
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(2012). In this approach, the value of S as a surrogate for T is determined by the
extent to which the causal effect of treatment on S can reliably predict the causal
effect of treatment on T . The rationale for considering principal surrogacy or more
generally considering the joint distribution of S(0), S(1), T (0), T (1) is most easily ex-
plained in the case where S and T are binary. In this case, the joint distribution
of S(0), S(1), T (0), T (1) amounts to a partition of the population into cells with a
probability attached to each cell. These probabilities completely characterize the
population and from them an assessment of surrogacy can be made. For example,
one can consider the fraction of the population for which T (0) is not equal to T (1)
amongst those who have S(0) not equal to S(1). Then additionally, this fraction
might be contrasted with the fraction of the population for which T (0) is not equal
to T (1) amongst those who have S(0) equal to S(1). As we will describe below, other
summary measures that can be obtained from the joint distribution might also be con-
sidered. When S and T are continuous, the joint distribution of S(0), S(1), T (0), T (1)
again completely characterizes the population, from which summary measures for as-
sessing surrogacy, such as the distribution of T (1) − T (0) given S(1) − S(0), can
be obtained. If one accepts that the joint distribution completely characterizes the
population, then the challenges are determining what useful summary measures to
extract from this distribution, and the estimation of this distribution.
We note that the principal stratification approach to assessing surrogacy uses
a causal framework, but the causal framework it uses differs from the framework
presented by Pearl (1995) and discussed in Joffe and Greene (2009). In the principal
stratification framework, there are only two causal effects, one on S and one on T and
we are interested in the association between these two. The other causal framework,
while it may also be interesting to consider, does require additional consideration of
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the effect of S on T , requiring hypothetical manipulations of S. This alternative
causal framework is more mechanistic and allows notions of direct and indirect effects
of Z on T . We will not pursue it in this paper.
Existing literature on methods for surrogacy assessment using the principal strat-
ification approach has examined settings in which both S and T are binary (Li et
al. 2010), or in which S is continuous with binary T (Gilbert and Hudgens, 2008;
Zigler and Belin, 2012). For a binary S and T , Li, et al. (2010) developed an es-
timation method for the causal quantities associated with the cross classification of
the potential outcomes using a log-linear model and Bayesian estimation procedure.
Gilbert and Hudgens (2008) (henceforth GH) used the framework of FR to develop
an estimand, termed the causal effect predictiveness (CEP) surface for evaluating
surrogacy when S is continuous or categorical and T is binary. Work in the principal
surrogacy framework when both S and T are continuous has been discussed in the
application to partial compliance (Bartolucci and Grilli, 2011; Schwartz, et al. 2011).
In this context, the joint distribution of the potential outcomes of the intermediate
variable, in this case degree of compliance, is modeled either parametrically or semi-
parametrically with principal causal effects measured by comparisons of the potential
outcomes of T conditional on S, where the conditional distributions for T (0) and T (1)
are modeled separately. Qin, et al. (2008) used a principal stratification approach in
the assessment of a continuous surrogate with a time to event outcome.
Here, we consider the entire joint distribution of (Si(0), Si(1), Ti(0), Ti(1)) and
propose estimands to evaluate principal surrogacy when both S and T are continuous
and the joint distribution of the potential outcomes is multivariate normal. Once
parameter estimates for this distribution are obtained, various causal quantities that
may aid in the assessment of S as a surrogate marker for T may be examined. Specific
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quantities of interest include E[T (1)− T (0)|S(1)− S(0)], P (T (1)− T (0) > 0|S(1)−
S(0)), and the correlation between T (1)−T (0) and S(1)−S(0). The use of cor(T (1)−
T (0), S(1)−S(0)) has been discussed by Wang, et al. (2012), who specifically contrast
it with the observable correlation between S and T , given the treatment group.
Because some parameters of the joint distribution are not fully identifiable from
the data, we use a Bayesian estimation procedure with plausible prior distributions
and some reasonable constraints on model parameters to reduce the non-identifiability
problem of modeling counterfactual observations and to aid in estimation of the quan-
tities of interest. In order to facilitate the consideration of reasonable constraints we
found it convenient to decompose the covariance matrix, Σ of (Si(0), Si(1), Ti(0), Ti(1))
as Σ = QRQ (Barnard, McCulloch and Meng, 2000), and place constraints on the
correlations R, rather than on the covariance terms in Σ. We also explore the re-
lationship between some of the proposed surrogacy assessment quantities and those
based on the Prentice criteria. In Section 2.2, we describe the model and possible
constraints that could be made to facilitate estimation. In Section 2.3, we introduce
surrogacy measures based on the potential outcomes framework. Section 2.4 describes
the Bayesian estimation procedure that we use and Section 2.5 provides simulation
results from this procedure. In Section 2.6 we apply these methods to the macular
degeneration data and ovarian cancer data. Section 2.7 concludes with a discussion.
2.2 Potential Outcomes Model
For a randomized trial with treatment assignment Z (Z = 1 or 0), continuous
surrogate marker S and continuous true endpoint T , each subject i, i = 1, ..., n,
has two potential outcomes for each of Si and Ti, denoted by Si(zi) and Ti(zi).
11
Only one outcome, corresponding to the received treatment for subject i in each
of the pairs (Si(0), Si(1)) and (Ti(0), Ti(1)) can be observed. The joint distribution
of (Si(0), Si(1), Ti(0), Ti(1)) describes the causal associations between Z, S and T .
In the continuous setting where (Si(0), Si(1), Ti(0), Ti(1)) is multivariate normal with






















The mean µ and the variances corresponding to the diagonal elements of Σ, along
with the correlations between (Si(0), Ti(0)) and (Si(1), Ti(1)) corresponding to ρ00
and ρ11, are fully identifiable from the data. Because only one of the counterfactual
pairs of outcomes is observed for each subject, ρs, ρt, ρ01, and ρ10 are not identifiable.
However, the identifiable correlation parameters together with the requirement that
Σ be positive definite places boundary constraints on these non-identified parame-
ters, which, along with other plausible assumptions that we can make, aids in their
estimation.
We make the standard assumptions of ignorable treatment assignments (Ru-
bin, 1978) and the stable unit treatment value assumption (SUTVA). Ignorable
treatment assignment implies that Z is independent of (S(0), S(1), T (0), T (1)) and
holds for blinded, randomized trials. SUTVA implies that the potential outcomes
(Si(0), Si(1), Ti(0), Ti(1)) are independent of the treatment assignments of other sub-
jects. This allows us to write the potential outcomes for subject i as a function of Zi
rather than of the entire vector of subject treatment assignments.
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Other context specific constraints can be added, such as all ρ’s ≥ 0, a plausible
assumption for most variables S that would be under consideration as a potential
surrogate for T , and especially when the identifiable Pearson correlation coefficients,
ρ̂00 and ρ̂11, are positive. Other plausible assumptions are ρ01 < min(ρ00, ρ11, ρs, ρt),
and ρ10 < min(ρ00, ρ11, ρs, ρt), indicating a belief that the correlation between the
surrogate response and final outcome response in opposite treatment arms is less
than the correlation between the surrogate response and final outcome response within
the same treatment arm, or the correlation between the surrogate responses or final
treatment responses across treatment arms.
2.3 Assessing Surrogacy Using Potential Outcomes Frame-
work
2.3.1 Definitions of Surrogacy
Because S is a post-randomization variable, unobserved simultaneous predictors
of both S and T may exist. In this case, methods of surrogacy assessment that
require conditioning on S do not result in causal estimates (Rosenbaum, 1984). When
baseline covariates account for all common causes of S and T , surrogacy measures that
condition on S will be causal. However, the assumption of no unmeasured confounders
of S and T is untestable, potentially leading to noncausal estimates (Gilbert, et
al. 2009). Therefore, FR proposed a definition of principal surrogacy (PS), which
uses a principal stratification approach to assess the validity of a surrogate marker.
This framework focuses on the distribution of p(T (0), T (1)|S(0), S(1)). Since S(1)
and S(0) are unaffected by treatment assignment, they can be treated as baseline
covariates. Quantities estimated from this distribution will therefore always have
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a causal interpretation. FR proposed two measures of surrogacy, the “dissociative
effect” given by E(Ti(1)− Ti(0)|Si(1) = Si(0)), and the “associative effect” given by
E(Ti(1)− Ti(0)|Si(1) 6= Si(0)).
For the multivariate normal distribution, the distribution of (T (1)− T (0)|S(1)−
S(0) = s) is normal with mean given by E[Ti(1)−Ti(0)|Si(1)−Si(0) = s] = γ0 +γ1s,
where


























The value of γ0 is then a measure of the “dissociative effect”. Values of γ0 near zero
indicate that the causal effect of treatment on the final outcome is near zero when the
causal effect of treatment on the surrogate is near zero, a characteristic that a good
principal surrogate should possess. When γ0 6= 0, there can be a causal effect of the
treatment on the final outcome even if there is no causal effect of the treatment on the
surrogate, implying that the treatment affects the outcome through pathways that do
not involve the surrogate. The value of γ0+γ1s is a measure of the “associative effect”.
A good principal surrogate should result in a large associative effect, indicating that
as the treatment effect on the surrogate increases, the treatment effect on the final
outcome increases as well, thus this measures the extent to which the effect of Z on
S is associated with an effect of Z on T (VanderWeele, 2011).
GH suggest a refined definition of a principal surrogate endpoint. In their setting
with binary T they define two properties, “average causal necessity” (ACN) and “av-
erage causal sufficiency” (ACS), that a valid surrogate marker should satisfy. ACN
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is satisfied if risk(1)(s1, s0) = risk(0)(s1, s0) for all s1 = s0, where risk(z)(s1, s0) =
p(T (Z) = 1|S(1) = s1, S(0) = s0). ACS is satisfied if there exists some constant
C ≥ 0 such that risk(1)(s1, s0) 6= risk(0)(s1, s0) for all |s1 − s0| > C. In our setting
of continuous T , we can consider the joint conditional distribution of (T (0), T (1)).
Specific summaries of this joint distribution which are of major interest include
E[T (1) − T (0)|S(1) − S(0) = s] for s = 0 and |s| > C for some C ≥ 0, P (T (1) >
T (0)|S(1)−S(0) = s) and the correlation between T (1)−T (0) and S(1)−S(0). Also
of interest is the “causal effect predictiveness (CEP ) surface” proposed by GH which
considers the entire surface of E[T (1)− T (0)|S(1), S(0)]. In the case of a binary out-
come, the definitions of ACN and ACS are equivalent to the conditional expectations
of T (0) and T (1). GH suggest that their framework is also applicable in the setting of
continuous endpoint, with the expressions for P (T (z) = 1 | ·) replaced by E(T (z) | ·).
We can therefore consider ACN satisfied if E[T (1)− T (0) | S(1)− S(0) = 0] = 0 and
ACS satisfied if E[T (1)−T (0) | S(1)−S(0) = s] 6= 0 for all |s| > C, corresponding to
γ0 = 0 and γ1 6= 0. In the setting of a continuous endpoint, we may also consider the
entire conditional distribution of T (1) and T (0). In this case, ACN in distribution is
satisfied if P (T (1) − T (0) > 0 | S(1) − S(0) = 0) = 0.5 and ACS in distribution is
satisfied if P (T (1)−T (0) > 0 | S(1)−S(0) = s) 6= 0.5. For multivariate normal data
this conditional probability is:
Φ10(s) = P (T (1)− T (0) > 0|S(1)− S(0) = s) = Φ









In the multivariate normal setting, the metrics of ACN and ACS based on the
entire conditional distribution and based only on the conditional expectation are
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closely related. If ACN in expectation holds (γ0 = 0), then ACN in distribution will
also hold (Φ10(0) = 0.5 when S(1)−S(0) = 0). If both ACN and ACS in expectation
hold (γ0 = 0 and γ1 6= 0), then Φ10(s) 6= 0.5 for s 6= 0, satisfying ACS in distribution.
Therefore, validation of S as a surrogate can be done by evaluating either γ0 = 0,
γ1 6= 0 or Φ10(0) = 0.5, Φ10(s) 6= 0.5 for s 6= 0.
Another potentially useful measure to assess surrogacy is the correlation between



















When ρST = 0, γ1 will also be 0, hence ACS in expectation will not be met, and S
cannot be a valid principal surrogate for T . When ρST > 0, γ1 > 0, thus satisfying
ACS. A positive value of ρST does not, however, provide information about γ0, and
therefore cannot alone determine whether or not S is a valid surrogate marker. A
final way that we consider summarizing the conditional distribution of T (1) − T (0)
given S(1) − S(0) = s, is through the CEP graph, which is a plot of E[T (1) −
T (0)|S(1)− S(0) = s] versus s, which in the multivariate normal setting, is simply a
plot of γ0 + γ1s versus s.
One issue that arises in the validation of surrogate markers is the presence of
the “surrogate paradox” (Chen et al., 2007; VanderWeele, 2013) where there is a
positive effect of treatment on the surrogate, the surrogate and outcome are positively
correlated, but there is a negative effect of treatment on the outcome. VanderWeele,
(2013) notes that the principal surrogacy criteria capture the notion of surrogacy well
and conceptually avoid the surrogate paradox. However, he also points out that while
theoretically appealing, due to lack of identifiability, the criteria may be difficult to
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use in practice. It is easy to see that if both ACN and ACS hold (γ0 = 0 and γ1 6= 0,
respectively), then E[T (1) − T (0) | S(1) − S(0) = s] will be in the same direction
as S(1) − S(0) = s as long as γ1 > 0, thus avoiding the surrogate paradox. If ACN
is not perfectly satisfied (i.e. γ0 6= 0), then there is a small range of s for which the
surrogate paradox can occur. If γ0 < 0, then E[T (1) − T (0) | S(1) − S(0) = s] < 0
for s ∈ [0,−γ0/γ1]. If γ0 > 0, then E[T (1) − T (0) | S(1) − S(0) = s] > 0 for
s ∈ [−γ0/γ1, 0]. Wu et al. (2011) provide methods for detecting the presence of the
surrogate paradox based on the observed data.
2.3.2 Relationship Between Principal Surrogacy Measures and Prentice
Surrogacy Criteria
The ACN and ACS measures corresponding to conditional expectation can be
linked to the original surrogacy definition proposed by Prentice (1989). Prentice’s
criteria for a valid surrogate require that f(T |Z) 6= f(T ), f(S|Z) 6= f(S), f(T |S) 6=
f(T ), and f(T |S,Z) = f(T |S). In the normal setting, the observed variables have
the following distributions: Si
Ti






















While Z is independent of the (pre-randomization) joint distribution of (S(0), S(1)),
it is not independent of the observed S. Thus, assuming the probability of being
randomized to either Z = 1 or Z = 0 is 0.5, the conditional expectation of T is
















)Si. Furthermore, E[Ti|Zi] =
θ0 + θ1Zi where θ1 = µT1 − µT0 , E[Si|Zi] = α0 + α1Zi where α1 = µS1 − µS0 , and


















. The Prentice criteria are satisfied when θ1 6= 0,
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we have γ1 = β2 = µ1, γ0 = β1 and β3 = 0. Therefore, under these conditions, the
Prentice criteria and the principal surrogacy criteria requiring that both ACN and
ACS be met (or γ0 = 0 and γ1 6= 0) will reach the same conclusions regarding the
validity of S as a surrogate. When the above conditions are not met, conflicting
conclusions may be drawn by the Prentice criteria and principal surrogacy criteria.
As we regard principal surrogacy to be the main objective in surrogacy assessment,
approaching the question of surrogacy using the Prentice criteria in this case may
lead to erroneous conclusions.
In any real setting we would not expect the conditions in equations II.1 and II.2
to be exactly satisfied. However, in many settings we can see that the Prentice
criteria and principal surrogacy criteria will reach similar conclusions. Often σS0 ≈
σS1 , σT0 ≈ σT1 and we might expect ρ00 to be similar to ρ11, thus equation II.1 is
approximately satisfied. Similarly for any candidate surrogate, we may expect the
average of the “across treatment arm” correlations, ρ01 and ρ10, to be less than the
“within treatment arm” correlation ρ00, and the correlation of the surrogate marker
across treatment arms, ρs; thus departures from equality in equation II.2 may not be
large.
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2.3.3 Parameter Identifiability and Restrictions
Given the identified parameters, the positive definite restriction on R, and plausi-
ble assumptions about correlation values, we can gain some insight into the possible
ranges, or “identification regions” (Gustafson, 2010) for the partially identified pa-
rameters and examine scenarios within this space which lead to different surrogacy
conclusions. Under the restriction that all ρ’s are non-negative, and the simplifying
assumptions that ρ01 = ρ10, ρ11 = ρ00, and σS0 = σS1 = σT0 = σT1 , the top half
of Figure 2.1 displays the possible ranges for ρ01 = ρ10 across different values of ρs
and ρt for a given ρ11 = ρ00, where ρ11 and ρ00 are the identifiable Pearson corre-
lation coefficients between Si(1) and Ti(1), and Si(0) and Ti(0), respectively. The
length of the identification region for ρ01 and ρ10 is smallest when ρ11 and ρ00 are
large. For all values of ρ11 and ρ00, the length of the identification region for ρ01 and
ρ10 decreases as ρs and ρt increase. The bottom half of Figure 2.1 provides ranges
for these parameters under the additional restriction that ρ01 < min(ρ00, ρ11, ρs, ρt).
This restriction greatly reduces the range of possible values for the partially identi-
fied parameters, and has implicit effects on the possible ranges for γ0 and γ1. Under
these restrictions, γ1 must be greater than 0, implying that ACS always holds. In
this scenario where ACS always holds, poor principal surrogates can be characterized
by large values of γ0, implying that the treatment can effect the outcome without ef-
fecting the surrogate. Alternatively, a poor surrogate would have a small value of γ1,
implying that there is still a positive, but weak association between causal effects on
the surrogate and causal effects on the outcome. These restrictions seems reasonable,
as S is typically known to somehow be associated with or a relevant aspect of the
disease process, so even if it is not a valid principal surrogate from an ACN and ACS
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perspective, we expect there to be at least a small association of treatment effects on
S with treatment effects on T . The solid points in each figure are parameter values
under which the Prentice criteria and PS criteria are in agreement. In this restricted
space the deviation between the Prentice criteria and the PS criteria are less than in
the unrestricted space, however we see that scenarios can arise in which the Prentice















































































































































(f) ρ00 = ρ11 = 0.3
Figure 2.1: Identification regions of unidentified parameters in MVN model
Plots (a), (b), and (c): under restriction ρ’s ≥ 0
Plots (d), (e), and (f): under restriction ρ’s ≥ 0, ρ01 < min(ρ00, ρ11, ρs, ρt)
Solid points: PS criteria and Prentice criteria in agreement
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2.4 Estimation Procedure
A Bayesian approach is used to estimate parameters. Unobserved potential out-
comes are treated as missing data and imputed from the appropriate posterior distri-
bution at each iteration of the Markov chain. The covariance matrix Σ is decomposed
as QRQ, where Q is the diagonal matrix of standard deviations and R is the cor-
relation matrix. Assuming a priori independence, this allows us to factor the prior
distribution p(µ,Σ) as p(µ)p(R)p(Q) and to place non-informative priors on the fully
identified parameters µ, Q, ρ00, and ρ11. Specifically, the prior for µ is N4(0,Σ0),
where Σ0 = diag(10
6), and the prior for each diagonal element of Q is p(σj) ∝ 1,
for j = (S(0), S(1), T (0), T (1)). We place marginal priors on each of the correlation
parameters in R and explore the use of four different prior assumptions. For each of
these there is the additional assumption that R must be positive definite. The four
priors are
(a) Jointly uniform prior such that for each of the six correlations p(ρ) ∼ Unif(−1, 1)
(b) Jointly uniform prior such that for each of the six correlations p(ρ) ∼ Unif(0, 1)
(c) All ρ′s ≥ 0, ρ01 < min(ρ00, ρ11, ρs, ρt), and ρ10 < min(ρ00, ρ11, ρs, ρt)
(d) Beta priors such that:
• p(ρ11) ∼ Unif(0, 1)
• p(ρ00) ∼ Unif(0, 1)
• p(ρ10) and p(ρ01) ∼ Beta(3α0, 3− 3α0) such that P (ρ01, ρ10 ≤ min(ρ̂00, ρ̂11)) = 0.80
• p(ρs) and p(ρt) ∼ Beta(3α1, 3− 3α1) such that P (ρs, ρt ≥ E[ρ10]) = 0.80
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where ρ̂00 and ρ̂11 are the Pearson correlation coefficients estimated from the observed
data and E[ρ10] is the expected value under the Beta(3α0, 3−3α0) distribution. Prior
assumption (a) is a non-informative prior on all of the correlations. Under scenario
(b), all correlations are constrained to be positive, a plausible assumption especially
when ρ̂00 and ρ̂11 are positive. In scenario (c), in addition to the positivity assumption,
we restrict ρ01 and ρ10 to be smaller than the other four correlation parameters.
This seems reasonable as ρ01 and ρ10 are measures of the correlation between the
surrogate response and final outcome response in opposite treatment arms, which is
unlikely to be larger than the correlation between the surrogate response and final
outcome response within the same treatment arm, or the correlation between the
surrogate responses or final treatment responses across treatment arms. Finally, prior
assumption (d) places similar restrictions on the correlations as assumption (c), but
is a little more flexible as ρ01 and ρ10 are only assumed to be smaller than the other
correlations with a probability of 0.8. Appendix A provides density plots of the Beta
priors when ρ̂00 and ρ̂11 are equal to 0.8, 0.5, and 0.3.
Posterior estimates of the unobserved potential outcomes, parameter values, and
the causal quantities of interest, γ0, γ1, Φ10(0), ρST , and the CEP curve at the points
(µS1 − µS0) ± 2SD(S(1) − S(0)), where SD(S(1) − S(0)) is the standard deviation
of (S(1) − S(0)), are obtained using the Gibbs sampler. Each component of Q and
R are drawn one at a time. When drawing each element of R, the range of possible
values must first be determined in order to satisfy the positive definite requirement,
given that the other correlations are held fixed. The range of values corresponding
to a positive definite matrix are those in the interval determined by the roots of the
quadratic equation that result from solving |R| = 0. The specific equations solved to
obtain parameter ranges are provided in Appendix B.
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As the posterior distributions for the components of Q and R can not be easily
sampled from, draws are made using the griddy Gibbs sampler (Ritter and Tanner,
1992). Details of the Gibbs sampler are provided in Appendix C.
2.5 Simulations
We conduct simulations to evaluate the performance of the above methods of
surrogacy assessment. We consider the scenarios where under the true parameter
values of the simulated data, surrogate validity is the same (S is valid, or S is invalid)
under both the Prentice criteria and PS criteria. We also consider the two cases where,
under the true parameter values of the simulated data, S is valid under Prentice
but not under PS, and S is valid under PS but not under Prentice. In this paper
we interpret the results from the perspective that principal surrogacy is the correct
approach. We investigate whether the wrong conclusions would be reached if the
Prentice criteria were used instead, and whether it is easier to validate a principal
surrogate depending on whether or not the Prentice criteria are also satisfied.
We first explore the sensitivity of the estimation to the plausible prior restric-
tions on R that we might make. For each simulation, we simulate 200 data sets,
each with a sample size of 300. For each of the four different surrogacy scenarios
we perform four simulations, with the estimation procedure done using each of the
priors outlined in Section 2.4. Table 2.1 provides the posterior means and standard
deviations of the Bayesian estimates and means of the posterior standard devia-
tions ( ¯PSD) for the model parameters, the quantities of interest from the Prentice
model, and the causal quantities of interest, γ0, γ1, ρST , Φ10(0) and the CEP curve
at (µS1 − µS0) ± 2SD(S(1) − S(0)). The identified parameters are not sensitive to
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changes in the prior specifications (only results under the Beta priors shown) while
the unidentified parameters are quite sensitive to prior assumptions. In all four sce-
narios, the standard deviation of the Bayesian estimates is smaller than ¯PSD for
the unidentified parameters. There is very little bias in estimating β1, β2, and β3,
while there is some bias in estimating γ0, γ1, ρST , Φ10(0) and the CEP points. The
estimation performed using Beta priors appears to provide the best estimation for the
unidentified parameters across these four models. While this prior does not always
perform best in terms of bias, it has on average better coverage of the parameters
across the different scenarios than the other models.
Using the Beta priors, Table 2.2 provides an estimate of the proportion of times
that S would be considered a valid principal surrogate based on the proposed mea-
sures. This means that 0 is in the 95% credible interval for γ0, and outside of the 95%
credible interval for γ1. For Φ10(0) this means that 0.5 is in the 95% credible interval.
For ρST , we look at the proportion of times that its credible interval is outside of 0, and
for the CEP curve we look at the proportion of times that the 95% credible intervals
at the points (µS1 −µS0) + 2SD(S(1)−S(0)) and (µS1 −µS0)− 2SD(S(1)−S(0)) do
not overlap (denoted by CEPU−2SD < CEP
L
+2SD). Table 2.2 also provides an estimate
of the proportion of times that S would be a valid surrogate based on the Prentice
criteria (0 in the 95% confidence interval for β̂1, and β̂3 and 0 outside of the 95%
confidence interval for β̂2) The entire CEP curve, shown in Figure 2.2, is also used to
visually assess principal surrogacy and the expected treatment effect on T at relevant
values of S(1)− S(0).
Our estimation procedure for γ0 and γ1 reaches the correct conclusion regarding
surrogate validity when principal surrogacy is unmet, regardless of whether or not
the Prentice criteria are met under the true parameters. We correctly identify S as
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Figure 2.2: Simulation results: CEP curves





























































































KEY: ◦ ◦ ◦ True line, − Mean CEP, · · · CEP 95% CI, | (µS1 − µS0),
• (µS1 − µS0)± 2SD(S(1)− S(0))
an invalid principal surrogate 99% of the time in the scenario in which S is invalid
under the Prentice criteria, and 85% of the time when S is valid under the Prentice
criteria. In comparison, the Prentice criteria incorrectly determine S to be a valid
surrogate 26% and 92% of the time, respectively, in these two scenarios. When S is
a valid principal surrogate, our procedure most reliably determines surrogate validity
when the Prentice criteria would also conclude that S is a valid surrogate. In this
scenario, we correctly identify S as a valid principal surrogate 94% of the time, while
the Prentice criteria conclude S to be a valid surrogate 95% of the time. When S is a
valid principal surrogate but the Prentice criteria show S to be invalid, our estimation
procedure and the Prentice approach have a similar ability to detect surrogacy, with
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neither approach providing reliable surrogacy conclusions.
We note that by basing surrogacy assessment on the criteria that γ0 = 0, we do
not avoid the problem in the Prentice criteria of proving a null hypothesis, namely
that certain parameters assume the value of 0. Therefore, we can also examine the
other proposed estimands to aid in validating S as a surrogate. The tests of ρST = 0
and CEPU−2SD < CEP
L
+2SD have similar power to correctly determine surrogacy, and
are nearly equivalent to evaluating surrogacy based on the requirement of ACS in
expectation that γ1 6= 0. The criterion of Φ10(0) = 0.5 being included in the 95%
credible interval is equivalent to evaluating surrogacy based on the requirement of
ACN in expectation that γ0 = 0 and does reasonably well at determining surrogacy
when the Prentice criteria and PS criteria are in agreement, but is unable to reliably
distinguish valid principal surrogates from invalid ones with the two criteria disagree.
We perform additional simulations to assess the robustness of our procedure when
joint normality does not hold. We consider three scenarios. In the first, joint normal-
ity does not hold, but each of the marginal distributions are normal. In the second,
the joint distribution of the counterfactuals is a multivariate t3 distribution, and in
the third, each of the marginal distributions are lognormally distributed. For each of
these scenarios, we generate multivariate normal data with the same mean and covari-
ance structure as the non-normal data to compare the performance of the estimation
procedure. When multivariate normality does not hold, the point estimates of the
Prentice and PS parameters are nearly identical to the multivariate normal models,
but with larger posterior standard deviations and lower coverage rates. There is little
difference between the non-multivariate normal models and the multivariate normal
models in terms of the assessment of S as a valid surrogate marker, indicating that




2.6.1 Visual acuity in age-related macular degeneration
We apply our estimation method to a clinical trial of interferon-α for 183 patients
with age-related macular degeneration (Buyse, et al. 2000). These data come from
a multicenter trial comprised of 36 different centers. The number of patients per
center ranges from 2 to 18. The treatment indicator (Zi) equals 0 for placebo and 1
for the treatment. The surrogate marker (Si) is change in visual acuity at 6 months
after starting treatment and the final endpoint (Ti) is change in visual acuity at 1
year. We subtract off the Best Linear Unbiased Predictor estimates from Si and Ti
to account for random center effects. Appendix E provides histograms and normal
QQ plots of the observed data to assess the marginal normality of S and T in each
treatment group and the bivariate normality of S and T within each treatment group.
The assumption of marginal normality appears to hold, except potentially for T in
the control group. Bivariate normality of S and T within each treatment group
appears to hold approximately. The estimates used in assessing the Prentice criteria
are as follows: θ̂1 = −3.34(SE = 2.13, P = 0.12), α̂1 = −2.03(SE = 1.90, P =
0.29), µ̂1 = 0.65(SE = 0.07, P < 0.0001), β̂1 = −2.67(SE = 1.94, P = 0.17),
β̂2 = 0.69(SE = 0.09, P < 0.0001), and β̂3 = −0.11(SE = 0.14, P = 0.44).
As θ1 and α1 are not statistically significant, the Prentice criteria are not met.
Using our approach with Beta priors for the correlation parameters, we get the fol-
lowing posterior estimates for the principal surrogacy parameters of interest, γ0 =
−1.62(−5.49, 2.16), and γ1 = 0.60(−0.24, 1.43). As γ1 contains 0 within its 95%
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credible interval, we conclude that change in visual acuity at 6 months is not a valid
principal surrogate for change in visual acuity at 12 months. The average Pearson
correlation, ¯ρST of Ti(1)− Ti(0) and Si(1)− Si(0) was 0.48 (-0.16, 0.92), also indica-
tive of a poor principal surrogate. This is in agreement with the conclusion reached
by Buyse, et al. (2000). Figure 2.3(a) shows a plot of the (CEP ) curve, where
CEP = E[T (1)−T (0)|S(1)−S(0) = s] with a 95% credible interval for each value of
s. The middle dashed line indicates the posterior mean of µS1−µS0 , and the outer two
dashed lines show the posterior means of µS1 −µS0 ± 2SDS(1)−S(0), where SDS(1)−S(0)





− 2ρsσS0σS1 . The plot
shows that 0 is contained within the credible interval at almost all values of s, indicat-
ing that there could be large effects of treatment on the surrogate with no expected
effect of treatment on the outcome. Similarly, when there is no treatment effect on
S, there could still be a sizeable treatment effect on T .
2.6.2 Progression free survival as a surrogate for overall survival in an
ovarian cancer trial
This trial was analyzed by Buyse, et al. (2000) using a meta-analytic validation
method. A total of 274 women were treated for ovarian cancer in two treatment
arms. Of these patients, 201 experienced a clinical progression of the disease prior to
death, and 43 died without a clinical disease progression. The remaining 30 patients
were censored for death and not considered in the analysis. There are 126 subjects in
the control arm and 118 in the treatment arm. The surrogate marker is progression
free survival (PFS) time, in months and the final endpoint is overall survival (OS)
time, in months. As both of these outcomes were right skewed, the fourth root
of each was taken to approximately normalize the data, as shown in Appendix F.
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Estimates of parameters used to assess the validity of the Prentice criteria are as
follows: θ̂1 = 0.08(SE = 0.10, P = 0.41), α̂1 = 0.14(SE = 0.09, P = 0.14), µ̂1 =
0.95(SE = 0.02, P < 0.0001), β̂1 = −0.12(SE = 0.13, P = 0.36), β̂2 = 0.94(SE =
0.03, P < 0.0001), and β̂3 = 0.02(SE = 0.04, P = 0.60). θ1 and α1 are not statistically
significant, and the Prentice criteria are therefore unmet. The posterior estimates for
the causal quantities of interest using Beta priors on the unidentified parameters gives
γ0 = −0.05(−0.12, 0.03), and γ1 = 0.93(0.81, 1.07). The 95% credible interval for γ0
contains 0 while the 95% credible interval for γ1 does not and ¯ρST was 0.92 (0.85,
0.96). We therefore conclude that progression free survival time is a marginally valid
principal surrogate for overall survival. This agrees with the findings of Buyse, et al.
(2000). Figure 2.3(b) provides a plot of the CEP curve and 95% credible interval
at each S(1) − S(0) = s, for the fourth roots of S and T . The middle and two
outer dashed lines indicate the posterior mean and 95% credible interval of µS1−µS0 ,
respectively. The plot shows that when there is no treatment effect on S, there is
little or no expected treatment effect on T , and as the treatment effect on S increases,
the treatment effect on T is also expected to increase.
2.7 Discussion
In this chapter, we develop a method for the assessment of surrogate markers
within the principal surrogate framework. We assume a multivariate normal distri-
bution for the potential surrogate outcomes and potential final outcomes and derive
quantities that may be useful in determining the validity of a surrogate marker.
Through our model setup, context specific assumptions can be incorporated into the
prior distributions of unidentified parameters to aid in estimation. The estimation
29




















(a) early change in visual acuity as a surrogate for
late change in visual acuity















(b) PFS time as a surrogate for OS time
Figure 2.3: CEP curves for data examples
KEY: −E[T (1)− T (0)|S(1)− S(0) = s] and 95% CI, −−−(µS1 − µS0 ), · · ·(µS1 − µS0 )± 2SD(S(1)− S(0))
procedure can be extended to scenarios where T is partially missing, or to the multiple
trial setting.
We compare some of the proposed quantities for surrogate validation to the origi-
nal validation criteria put forth by Prentice and show that, in many settings, we might
expect the Prentice and principal surrogacy criteria to be in agreement. Based on our
simulation study, it appears that when principal surrogacy is present, it is most ac-
curately determined in cases where the Prentice criteria would also correctly identify
surrogacy. When principal surrogacy is not present, it can be determined both when
the Prentice criteria are able to correctly identify S as invalid and when the Prentice
criteria incorrectly deem S to be valid. We note that even with the use of informative
priors to aid in the estimation of the partially identified parameters, the coverage
rates in many cases are not ideal. Due to the nonidentifiability of some parameters
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in our model, certain assumptions on the relationships between nonidentifiable as-
sociations were made and informative priors were used for unidentified parameters
to aid in estimation. The use of other priors or other context specific assumptions
about parameters could be made. Zigler and Belin (2012) also explore the effects of
various model assumptions in a principal surrogacy estimation procedure. They use
a Bayesian estimation approach for the CEP surface when S is continuous and T is
binary. In their procedure, priors are placed on the regression coefficients of the CEP
surface, and an independence assumption is made for T (1) and T (0) conditional on
the surrogate and other baseline covariates.
Each of the proposed quantities have merits and drawbacks in terms of their ability
to characterize surrogacy. The proposed γ0 and γ1 quantities are easily interpretable,
but proving that γ0 is equal to 0, a necessary condition for a valid surrogate, is diffi-
cult to do in practice. The correlation measure, ρST , captures the causal correlation
between the treatment effect on the surrogate and the treatment effect on the out-
come, but fails to capture the concept of ACN. The CEP graph provides a way to
estimate expected treatment effects on T when treatment effects on S are at relevant
clinical values, but does not offer a single summary of the value of S as a surrogate.
Finally, the Φ10 quantity provides information about the entire conditional distribu-
tion, as opposed to just the expectation, but is more difficult to estimate and seems
to have poor properties. While no single parameter estimate can completely assess
principal surrogacy, a variety of measures that consider the distribution of the causal
effect of treatment on the outcome conditional on the causal effect of treatment on
the surrogate can be used in combination to provide evidence as to whether or not S
is a valid surrogate for T .
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Table 2.1: MVN model simulation results under different prior specifications
Identified Parameters
S Valid PS, S Invalid PS, S Invalid PS S Valid PS
S Invalid Prentice S Valid Prentice & Prentice & Prentice
Prior True 95% True 95% True 95% True 95%
Parameter Scenario Value Mean (SD) ¯PSD Coverage Value Mean (SD) ¯PSD Coverage Value Mean (SD) ¯PSD Coverage Value Mean (SD) ¯PSD Coverage
µs0 4 4 3.99(0.08) 0.08 0.96 4 4.01(0.08) 0.08 0.95 4 3.99(0.08) 0.08 0.95 4 4.00(0.08) 0.08 0.98
µs1 4 6 6.01(0.08) 0.08 0.95 6 5.99(0.08) 0.08 0.95 6 5.99(0.08) 0.08 0.95 6 5.99(0.09) 0.08 0.91
µt0 4 7.8 7.78(0.08) 0.08 0.95 9 9.00(0.08) 0.08 0.96 8.5 8.49(0.07) 0.08 0.94 8.5 8.40(0.08) 0.08 0.95
µt1 4 10 10.01(0.09) 0.08 0.91 10 10.00(0.08) 0.08 0.94 10 10.00(0.08) 0.08 0.95 10 10.00(0.09) 0.08 0.92
σs0 1 1 0.99(0.06) 0.06 0.93 1 1.01(0.06) 0.06 0.96 1 1.00(0.06) 0.06 0.94 1 0.99(0.06) 0.06 0.96
σs1 4 1 1.00(0.06) 0.06 0.93 1 1.01(0.05) 0.06 0.96 1 1.01(0.05) 0.06 0.98 1 0.99(0.06) 0.07 0.95
σt0 4 1 1.00(0.06) 0.06 0.95 1 1.01(0.06) 0.06 0.97 1 1.01(0.06) 0.06 0.94 1 0.99(0.05) 0.06 0.96
σt1 4 1 1.01(0.06) 0.06 0.94 1 1.00(0.06) 0.06 0.96 1 1.01(0.06) 0.06 0.96 1 0.99(0.06) 0.06 0.96
ρ00 4 0.7 0.68(0.04) 0.04 0.99 0.5 0.48(0.06) 0.06 0.94 0.2 0.20(0.07) 0.07 0.95 0.8 0.79(0.03) 0.03 0.95
ρ11 4 0.7 0.69(0.04) 0.04 0.97 0.5 0.49(0.06) 0.06 0.95 0.2 0.20(0.06) 0.07 0.97 0.8 0.78(0.03) 0.03 0.95
Unidentified Parameters
ρs 1 0.5 -0.35(0.23) 0.33 0.20 0.5 -0.22(0.22) 0.35 0.48 0.2 -0.15(0.23) 0.37 0.93 0.4 -0.35(0.24) 0.34 0.38
2 0.32(0.08) 0.19 0.95 0.39(0.07) 0.22 1 0.37(0.08) 0.22 1 0.24(0.07) 0.15 0.91
3 0.34(0.06) 0.13 0.82 0.45(0.05) 0.16 1 0.46(0.06) 0.21 1 0.22(0.04) 0.10 0.54
4 0.47(0.07) 0.18 1 0.43(0.06) 0.20 1 0.34(0.06) 0.21 1 0.43(0.08) 0.16 0.995
ρ01 1 0.15 -0.45(0.21) 0.29 0.51 0.45 -0.28(0.21) 0.33 0.42 0.04 -0.18(0.23) 0.35 0.97 0.32 -0.48(0.22) 0.29 0.29
2 0.32(0.08) 0.19 0.99 0.39(0.07) 0.22 1 0.37(0.06) 0.22 0.97 0.24(0.07) 0.15 0.995
3 0.14(0.04) 0.11 1 0.16(0.03) 0.10 0.04 0.06(0.02) 0.04 1 0.09(0.03) 0.07 0.25
4 0.40(0.08) 0.20 0.95 0.28(0.07) 0.19 1 0.14(0.04) 0.15 1 0.40(0.09) 0.18 1
ρ10 1 0.15 -0.37(0.21) 0.32 0.63 0.45 -0.28(0.24) 0.34 0.40 0.04 -0.16(0.23) 0.35 0.97 0.32 -0.39(0.21) 0.33 0.44
2 0.34(0.08) 0.19 0.995 0.39(0.07) 0.22 1 0.37(0.07) 0.22 0.94 0.24(0.07) 0.15 1
3 0.15(0.04) 0.11 1 0.16(0.02) 0.11 0.05 0.06(0.02) 0.04 1 0.10(0.03) 0.08 0.25
4 0.42(0.08) 0.19 0.86 0.28(0.07) 0.19 0.995 0.14(0.03) 0.14 1 0.42(0.08) 0.17 0.99
ρt 1 0.18 -0.47(0.19) 0.27 0.43 0.5 -0.32(0.23) 0.32 0.27 0.3 -0.18(0.22) 0.36 0.82 0.4 -0.53(0.18) 0.28 0.14
2 0.31(0.08) 0.19 1 0.37(0.07) 0.22 1 0.37(0.07) 0.22 1 0.24(0.06) 0.16 0.91
3 0.32(0.05) 0.13 0.99 0.44(0.05) 0.16 1 0.46(0.06) 0.21 1 0.21(0.04) 0.09 0.42
4 0.45(0.07) 0.19 0.91 0.42(0.06) 0.20 1 0.34(0.05) 0.21 1 0.42(0.08) 0.17 1
Simulation results: Bias, variability and coverage rate of surrogacy parameters
β1 1 0.8 0.81(0.42) 0.51 0.99 0 0.06(0.60) 0.56 0.93 1.1 1.15(0.59) 0.59 0.96 0 0.05(0.36) 0.47 0.99
2 0.82(0.45) 0.44 0.96 0.02(0.51) 0.52 0.96 1.18(0.54) 0.54 0.96 0.03(0.37) 0.37 0.95
3 0.84(0.44) 0.43 0.94 0.04(0.56) 0.52 0.93 1.07(0.51) 0.55 0.98 -0.01(0.35) 0.07 0.96
4 0.78(0.43) 0.44 0.94 0.004(0.51) 0.52 0.95 1.10(0.54) 0.54 0.96 0.04(0.37) 0.38 0.95
β2 1 0.7 0.68(0.06) 0.07 0.96 0.5 0.49(0.08) 0.08 0.94 0.2 0.19(0.08) 0.08 0.96 0.8 0.78(0.05) 0.07 0.97
2 0.69(0.06) 0.06 0.97 0.49(0.07) 0.07 0.96 0.21(0.07) 0.08 0.97 0.79(0.05) 0.05 0.96
3 0.69(0.06) 0.06 0.96 0.49(0.08) 0.07 0.93 0.20(0.07) 0.07 0.94 0.78(0.05) 0.05 0.93
4 0.68(0.06) 0.06 0.97 0.49(0.07) 0.07 0.94 0.20(0.07) 0.07 0.95 0.79(0.05) 0.05 0.97
β3 1 0 0.004(0.08) 0.10 0.99 0 -0.008(0.12) 0.11 0.95 0 -0.0007(0.11) 0.11 0.96 0 -0.004(0.07) 0.09 0.98
2 0.001(0.08) 0.09 0.96 0.002(0.10) 0.10 0.95 -0.01(0.10) 0.10 0.96 0.001(0.07) 0.07 0.94
3 -0.002(0.08) 0.08 0.95 -0.001(0.11) 0.10 0.92 0.004(0.10) 0.11 0.97 0.007(0.07) 0.07 0.96
4 0.010(0.08) 0.08 0.96 0.006(0.10) 0.10 0.95 0.003(0.10) 0.10 0.96 -0.002(0.07) 0.07 0.96
γ0 1 0 0.54(0.23) 0.38 0.72 0.8 -0.33(0.33) 0.54 0.27 1.1 0.81(0.41) 0.66 0.97 0 -0.25(0.21) 0.33 0.96
2 1.09(0.26) 0.52 0.49 0.64(0.28) 0.70 1 2.07(0.28) 0.65 0.69 0.12(0.17) 0.37 1
3 0.54(0.15) 0.31 0.70 -0.30(0.23) 0.50 0.01 0.82(0.22) 0.45 1 -0.19(0.11) 0.20 0.92
4 1.10(0.26) 0.63 0.60 0.18(0.26) 0.67 0.96 1.30(0.20) 0.48 0.99 0.20(0.22) 0.51 1
γ1 1 1.1 0.83(0.11) 0.19 0.68 0.1 0.66(0.16) 0.26 0.27 0.2 0.34(0.20) 0.32 0.97 0.8 0.92(0.10) 0.16 0.94
2 0.55(0.12) 0.26 0.48 0.28(0.13) 0.35 1 -0.29(0.12) 0.32 0.64 0.74(0.08) 0.18 1
3 0.83(0.06) 0.15 0.63 0.65(0.10) 0.24 0 0.34(0.10) 0.22 1 0.90(0.04) 0.09 0.91
4 0.55(0.12) 0.31 0.60 0.41(0.12) 0.33 0.97 0.11(0.08) 0.23 1 0.70(0.11) 0.25 1
ρST 1 0.86 0.77 (0.06) 0.11 0.97 0.1 0.60 (0.11) 0.18 0.26 0.21 0.31 (0.16) 0.26 0.99 0.8 0.85 (0.04) 0.08 0.95
2 0.53(0.10) 0.20 0.54 0.17 (0.10) 0.29 1 -0.27 (0.10) 0.27 0.63 0.73(0.06) 0.12 1
3 0.81(0.04) 0.09 1 0.62 (0.06) 0.15 0 0.31 (0.07) 0.14 1 0.89 (0.02) 0.05 0.73
4 0.52(0.09) 0.23 0.68 0.38(0.09) 0.26 0.97 0.10(0.07) 0.20 1 0.66(0.08) 0.17 0.99
CEP+2SD 1 4.4 4.86 (0.39) 0.57 0.90 1.2 2.97 (0.49) 0.67 0.27 2.0 2.47 (0.52) 0.80 0.96 3.35 4.59 (0.37) 0.57 0.31
2 3.45 (0.28) 0.50 0.46 1.37 (0.26) 0.64 1 0.89 (0.25) 0.61 0.56 3.40 (0.24) 0.38 0.99
3 4.08 (0.21) 0.32 0.93 2.31 (0.20) 0.39 0 2.10 (0.18) 0.28 1 3.81 (0.18) 0.24 0.49
4 3.31 (0.26) 0.55 0.36 1.82 (0.23) 0.58 0.96 1.74 (0.19) 0.45 1 3.02 (0.27) 0.45 0.96
CEP−2SD 1 0 -0.47 (0.38) 0.57 0.87 0.8 -1.00 (0.47) 0.67 0.25 0.99 0.51 (0.52) 0.79 0.95 -0.15 -1.39 (0.40) 0.57 0.31
2 0.96 (0.30) 0.50 0.44 0.63 (0.27) 0.64 1 2.11 (0.26) 0.61 0.58 -0.19 (0.24) 0.38 0.99
3 0.31 (0.22) 0.32 0.91 -0.30 (0.23) 0.39 0.02 0.88 (0.18) 0.28 1 -0.62 (0.17) 0.24 0.45
4 1.14 (0.26) 0.54 0.32 0.18 (0.25) 0.58 0.96 1.29 (0.20) 0.45 0.97 0.18 (0.25) 0.45 0.96
Φ10(0) 1 0.5 0.69 (0.08) 0.13 0.72 0.79 0.40 (0.09) 0.16 0.24 0.83 0.70 (0.10) 0.16 0.95 0.5 0.39 (0.08) 0.14 0.96
2 0.84 (0.06) 0.13 0.49 0.70 (0.08) 0.20 1 0.95 (0.02) 0.07 0.69 0.55 (0.08) 0.18 1
3 0.77 (0.07) 0.15 0.70 0.38 (0.08) 0.19 0.16 0.78 (0.06) 0.15 1 0.36 (0.07) 0.14 0.92
4 0.85 (0.07) 0.16 0.60 0.56 (0.09) 0.23 0.96 0.86 (0.04) 0.10 1 0.58 (0.10) 0.23 1
1: No restrictions on ρ
2: ρ ≥ 0
3: ρ ≥ 0 and ρ10, ρ01 < ρs, ρt, ρ00, ρ11
4: Beta priors
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Table 2.2: MVN model simulation results: principal surrogacy assessment
Model 1 2 3 4
Truth
PS satisfied Yes No No Yes
Prentice satisfied No Yes No Yes
Estimation Results
γ0 Not Rejected, Reject γ1 = 0 0.37 0.15 0.01 0.94
γ0 = 0 Not Rejected 0.60 1 0.20 1
Reject γ1 = 0 0.57 0.15 0.01 0.94
Reject ρST = 0 0.57 0.17 0.01 0.94
CEPU−2SD < CEP
L
+2SD 0.55 0.15 0.01 0.93
Φ10(0) = 0.5 Not Rejected 0.60 1 0.20 1
Prentice Criteria Not Rejected 0.52 0.92 0.26 0.95
CHAPTER III
Surrogacy Assessment Using Principal
Stratification and a Gaussian Copula Model
3.1 Introduction
In Chapter II we described an approach for assessing surrogacy for multivariate
normal distributions. Here, we extend these ideas by relaxing the multivariate nor-
mality assumption and consider scenarios in which the surrogate marker, S and the
final outcome, T arise from non-normal distributions. A surrogate endpoint (S) is an
intermediate outcome variable occurring in between the treatment (Z) and the out-
come of interest (T ). Surrogate markers offer the potential to run trials more cheaply
and quickly by extracting information regarding the treatment effect on T through
the earlier measured S, however, demonstrating the validity of a given surrogate for
the outcome of interest can be difficult. Prentice (1989) proposed a formal definition
of surrogacy along with a validation strategy, requiring that S and T be correlated
and the treatment effect on T be fully captured by S. Other methods for surrogacy
evaluation include the proportion of treatment effect explained by S (Freedman, et
al. 1992), and individual-level and trial-level surrogacy association measures in meta-
analyses (Buyse, et al. 2000). As these methods rely on estimating treatment effects
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by adjusting for a variable measured after randomization, there may be unmeasured
confounders in the pathway between the surrogate and final outcome. Thus, the
resulting estimates may not have a causal interpretation (Rosenbaum, 1984). There-
fore, much recent work has been done on the evaluation of surrogate endpoints using
the “principal surrogacy” (PS) framework introduced by Frangakis and Rubin (2002)
(henceforth FR). In this framework, each subject has two potential outcomes for each
of the surrogate and final endpoints corresponding to each treatment, denoted by
S(Z) and T (Z), for Z = {0, 1}. The principal surrogacy approach looks at the dis-
tribution of the potential outcomes of T conditional on principal strata based on the
joint distribution of S(0) and S(1). The principal strata are unaffected by treatment,
and are thus pre-randomization variables. Treatment effect estimates that condition
on these principal strata are therefore causal estimates when treatments are randomly
assigned.
Existing literature on methods for surrogacy assessment using the principal strat-
ification approach has examined settings in which both S and T are binary (Li, et al.
2010), or in which S is continuous with binary T (Gilbert and Hudgens, 2008; Zigler
and Belin, 2011). Work in the PS framework when both S and T are continuous
has been discussed in the application to partial compliance (Schwartz, et al. 2011).
Bartolucci and Grilli (2011) used a Plackett copula to model the joint counterfac-
tual distribution of partial compliances, and then proposed separate models for the
conterfacutal outcomes, conditional on compliance. In Chapter II, we explored the
scenario where the joint distribution of the counterfactual observations of S and T is
multivariate normal and proposed quantities derived from this distribution to assess
surrogacy. We extend this work on surrogacy validation in the multivariate normal
setting by relaxing the multivariate normality assumption and considering the sce-
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nario in which S and T arise from non-normal distributions. Given the marginal
distributions of S(1), S(0), T (1), and T (0), a Gaussian copula model can be used
to obtain the joint distribution. In our proposed model, we explore the use of the
Gaussian copula in the setting where S is a discrete ordinal random variable and
T is a continuous time-to-event random variable. The values of S(0) and S(1) are
assumed to arise from separate underlying latent normal random variables, denoted
S̃(0) and S̃(1).
In our data example, we consider the use of the ordinal variable “tumor response”
as a surrogate for overall survival in advanced colorectal cancer. Tumor response
and overall survival are common endpoints of interest in cancer clinical trials, and
there is a large literature on the use of tumor response as a surrogate marker for
overall survival (Ellenberg and Hamilton, 1989; Torri, et al. 1992; Buyse and Pied-
bois, 1996). In this setting of mixed discrete and continuous outcomes, surrogacy
validation methods have been explored by Molenberghs, et al. (2001), where a joint
model for the underlying continuous latent variable of the observed discrete surrogate
marker and the observed continuous final outcome was developed. The use of cop-
ula models in this setting has been explored in by Burzykowski, et al. (2004), who
proposed a bivariate Plackett copula to jointly model tumor response and survival in
advanced colorectal cancer, and assessed surrogacy using a meta-analytic approach.
The application of a Gaussian copula model to jointly model bivariate discrete and
continuous outcomes was examined by de Leon and Wu (2011). Here, we extend
the use of this Gaussian copula model to a four dimensional model, two for the po-
tential surrogate marker values under each treatment arm and two for the potential
outcomes under each treatment arm, and derive quantities from it to determine surro-
gacy. Unlike in the multivariate normal setting explored in Chapter II, these principal
36
surrogacy measures will no longer be analytically estimable, but can be obtained from
the posterior predictive distributions of the potential markers and outcomes under
the Gaussian copula model. Because some parameters of the joint distribution are
not fully identifiable from the data, we use a Bayesian estimation procedure with
plausible prior distributions and some reasonable constraints on model parameters to
reduce the non-identifiability problem of modeling counterfactual observations and to
aid in estimation of the quantities of interest. In Section 3.2, we describe the model.
Section 3.3 outlines the proposed surrogacy measures and Section 3.4 outlines the
estimation strategy. Simulation results are presented in Section 3.5, and in Section
3.6 the estimation procedure is applied to data from a meta-analysis in advanced
colorectal cancer. Section 3.7 concludes with a discussion.
3.2 The Model
3.2.1 Potential Outcomes
For a randomized trial with treatment assignment Z (Z = 1 or 0), surrogate
marker S and true endpoint T , each subject i, i = 1, ..., n, has two potential out-
comes for each of Si and Ti, denoted by Si(Zi) and Ti(Zi). Only one outcome, cor-
responding to the received treatment for subject i in each of the pairs (Si(0), Si(1))
and (Ti(0), Ti(1)) can be observed. The joint distribution of (Si(0), Si(1), Ti(0), Ti(1))
describes the causal associations between Z, S and T . We denote the marginal cumu-
lative distributions of Si(0), Si(1), Ti(0) and Ti(1) by FSi(0), FSi(1), FTi(0) and FTi(1),
respectively. We make the standard assumptions of ignorable treatment assignments
(Rubin, 1978) and the stable unit treatment value assumption (SUTVA).
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3.2.2 Copulas
Sklar (1959) provided the basis for multivariate modeling using copulas. A mul-
tivariate function C = C(u1, ..., uk) is a copula if it is a continuous distribution
function and each marginal is a uniform distribution function. That is, C is a
mapping of (0, 1)k → (0, 1), with C(u) = p(Ui ≤ u1, ..., Uk ≤ uk), where each
Ui ∼ Unif(0, 1). Using known marginal distributions F1(y1), ..., Fk(yk), the func-
tion C(F1(y1), ..., Fk(yk)) = G(y) defines a joint distribution for y1, ..., yk (Nelsen,
2006).
In this paper, we focus on the Gaussian copula, denoted as
CΦ(u|Γ) = Φk{Φ−1(u1), ...,Φ−1(uk)|Γ}
where Φ is the standard normal cumulative distribution function and Φk(x|Γ) is a
k-variate normal cumulative distribution function with covariance matrix Γ. The




where q = (q1, ..., qk)
T with qj = Φ
−1(uj), q ∼ Nk(0,Γ) and Γ is a correlation matrix
(Song, 2000). The copula framework can then be used to obtain a multivariate
distribution with specified marginals.
3.2.3 Gaussian Copula Regression Model
In the setting of a single surrogate and single outcome, each measured at one
time point, we have n observations each of dimension four, corresponding to the four
potential outcomes for each subject. Let yi = (Si(0), Si(1), Ti(0), Ti(1)) represent the
set of observations from subject i. For continuous S and T , the Gaussian copula
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regression model can be obtained by taking qij = hij(yij; θj) = Φ
−1{Fj(yij; θj)} where
θj is the parameter vector for marginal distribution j, where j = 1, ..., 4 corresponds
to the four marginal distributions for Si(0), Si(1), Ti(0), and Ti(1), respectively. By
this construction, we have:
qi = [Φ
−1{F1(Si(0))},Φ−1{F2(Si(1))},Φ−1{F3(Ti(0))},Φ−1{F4(Ti(1))}] ∼ N4(0,Γ)







2 exp{12qi(I4 − Γ
−1)qTi }f1(Si(0); θ1)f2(Si(1); θ2)f3(Ti(0); θ3)f4(Ti(1); θ4)
]
When the marginal distributions of S and T are integer valued, the density can
be found by taking Radon-Nikodym derivative of CΦ(u|Γ) with respect to counting
measure (Song, 2000), so that









(−1)l1+l2+l3+l4CΦ(F1(S(0))l1 , F2(S(1))l2 , F3(T (0))l3 , F4(T (1))l4|Γ)
where Fj(yj)1 = Fj(yj) and Fj(yj)2 = Fj(yj − 1).
In the setting that we consider, S is an ordinal categorical variable and T is
a failure-time random variable. Let Vi(Z) = min(Ti(Z),Wi(Z)) be the minimum
of the observed failure time, Ti(Z), and censoring time, Wi(Z), and let ∆i(Z) =
I(Wi(Z) > Ti(Z)) be the censoring indicator. Then, for each subject we have the
observed data Si(Z), Vi(Z), and ∆i(Z). We make the ignorable censoring assumption,
Ti(Z) ⊥ Wi(Z), reasonable in cases where censoring is administrative and enrollment
times are simultaneous or otherwise unrelated to the outcome. In our estimation
procedure, we iteratively impute survival times for censored subjects so that each
subject has the vector of outcomes yi = (Si(0), Si(1), Ti(0), Ti(1)). Let S̃i(Z) be a





1Z , if S̃i(Z) ∈ (−∞, α1Z )
2Z , if S̃i(Z) ∈ (α1Z , α2Z )
...
MZ , if S̃i(Z) ∈ (α(M−1)Z ,∞)
where α1Z < α2Z < . . . < α(M−1)Z are unknown cutpoints with α0Z = −∞ and
αMZ =∞. We assume a cumulative probit model for the cutpoints of the underlying
continuous random variables of S(0) and S(1) and a proportional hazards model with
a Weibull baseline hazard function for the marginal distributions of T (0) and T (1).
These models are given by:









where λ(Ti(Z)) is a hazard function for a Weibull distribution with scale parameter
λTZ and shape parameter γTZ . Let ỹi = (S̃i(0), S̃i(1), Ti(0), Ti(1)) represent the set of
counterfactual latent surrogate and final outcomes for subject i. We assume that the
joint cumulative distribution of S̃i(0), S̃i(1), Ti(0), Ti(1) is generated by the Gaussian
copula function:
Fỹi(ỹi) = Φ4{Φ−1(F1̃(S̃i(0))),Φ−1(F2̃(S̃i(1))),Φ−1(F3(Ti(0))),Φ−1(F4(Ti(1))) | Γ},
where the subscripts 1̃ and 2̃ correspond to the CDF of the underlying latent variables
of S(0) and S(1), respectively, Φ is the standard normal distribution and Φ4 is the
standard four-variate normal distribution with correlation matrix:
Γ =








As S̃i(Z) is assumed to be Gaussian, the terms Φ
−1(F1̃(S̃i(0))) and Φ
−1(F2̃(S̃i(1)))
are simply S̃i(0) and S̃i(1), respectively. The joint distribution of Si(0), Si(1), Ti(0),
and Ti(1) under these distributional assumptions is then given by:
P (Si(0) = k0, Si(1) = k1, Ti(0) ≤ t0, Ti(1) ≤ t1)
= [Fỹi(αk0 , αk1 , t0, t1)−Fỹi(α(k0−1), αk1 , t0, t1)−Fỹi(αk0 , α(k1−1), t0, t1)+Fỹi(α(k0−1), α(k1−1), t0, t1)].
When both Ti(0) and Ti(1) are uncensored observations, the joint density of Si(0), Si(1), Ti(0),
and Ti(1) is given by: fyi(k0, k1, t0, t1) =
∂2
∂t0∂t1
P (Si(0) = k0, Si(1) = k1, Ti(0) ≤ t0, Ti(1) ≤ t1),
where the derivative of Fỹi(αk0 , αk1 , t0, t1) with respect to t1 and t0 is given by:









































































































































































The scale parameters, λT0 and λT1 , and shape parameters, γT0 and γT1 from the
Weibull models as well as the cutpoints of the latent distributions for S(0) and S(1)
are identifiable from the data. The correlation coefficients ρ00 and ρ11 are the Pearson
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correlation coefficients between S̃(0) and the normally transformed T (0) and between
S̃(1) and the normally transformed T (1), respectively, and can be seen as a proxy
for the polyserial correlations between T (0) and S(0) and between T (1) and S(1)
(de Leon and Wu, 2011). These polyserial correlations are estimable from the data
(Olsson, et al. 1982). Because only one of the counterfactual pairs of outcomes is
observed for each subject, ρs, ρt, ρ01, and ρ10 are not identifiable. However, the
identifiable correlation parameters together with the requirement that the correlation
matrix be positive definite place boundary constraints on these non-identified param-
eters, which, along with other plausible assumptions that we can make, aids in their
estimation.
3.2.4 Prior Distributional Assumptions
We place non-informative priors on the fully identified parameters λTZ , γTZ , and
αkZ ’s. Specifically, the priors for log(λTZ ) and the αkZ ’s are N(0, 10
2) and the priors
for γTZ are gamma distributions with mean 1 and standard deviation 3. We place
marginal priors on each of the correlation parameters in Γ and following Chapter II,
we consider four different sets of prior assumptions. For each of these there is the
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additional assumption that Γ must be positive definite. The four priors are
(a) Jointly uniform prior such that for each of the six correlations p(ρ) ∼ Unif(−1, 1)
(b) Jointly uniform prior such that for each of the six correlations p(ρ) ∼ Unif(0, 1)
(c) All ρ′s ≥ 0, ρ01 < min(ρ00, ρ11, ρs, ρt), and ρ10 < min(ρ00, ρ11, ρs, ρt)
(d) Beta priors such that:
• p(ρ11) ∼ Unif(0, 1)
• p(ρ00) ∼ Unif(0, 1)
• p(ρ10) and p(ρ01) ∼ Beta(3α0, 3− 3α0) such that P (ρ01, ρ10 ≤ min(ρ̃00, ρ̃11)) = 0.80
• p(ρs) and p(ρt) ∼ Beta(3α1, 3− 3α1) such that P (ρs, ρt ≥ E(ρ10)) = 0.80
where ρ̃00 and ρ̃11 are the polyserial correlation coefficients for T (0), S(0) and T (1),
S(1), respectively, estimated from the observed data using the “polyserial” function
in R and E(ρ10) = E(ρ01) is the mean under the Beta(3α0, 3−3α0) distribution. Prior
assumption (a) is a non-informative prior on all of the correlations. Under scenario
(b), all correlations are constrained to be positive, a plausible assumption especially
when ρ̃00 and ρ̃11 are positive. In scenario (c), in addition to the positivity assumption,
we restrict ρ01 and ρ10 to be smaller than the other four correlation parameters.
This seems reasonable as ρ01 and ρ10 are measures of the correlation between the
surrogate response and final outcome response in opposite treatment arms, which is
unlikely to be larger than the correlation between the surrogate response and final
outcome response within the same treatment arm, or the correlation between the
surrogate responses or final treatment responses across treatment arms. Finally, prior
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assumption (d) places similar restrictions on the correlations as assumption (c), but
is a little bit more flexible.
3.3 Measures of Surrogacy from Gaussian Copula Models
To determine the validity of S as a surrogate marker for T , we work within the
principal surrogacy (PS) framework proposed by FR which uses a principal strati-
fication approach to assess the validity of a surrogate marker. This framework fo-
cuses on the distribution of p(T (0), T (1)|S(0), S(1)). Since S(1) and S(0) are un-
affected by treatment assignment, they can be treated as baseline covariates and
quantities estimated by conditioning on them will always have a causal interpreta-
tion. This framework therefore avoids the potentially noncausal estimates that can
result from surrogacy measures that condition on the observed post-randomization
variable S. FR proposed two measures of surrogacy, the “associative effect” and the
“dissociative effect”. In our setting, a measure of the dissociative effect is given by
E(log(Ti(1)/Ti(0))|Si(1) = Si(0)) and a measure of the associative effect is given by
E(log(Ti(1)/Ti(0))|Si(1) 6= Si(0)). Values of the dissociative effect near zero indicate
that the causal effect of treatment on the final outcome is near zero when the causal
effect of treatment on the surrogate is near zero, a characteristic that a good principal
surrogate should possess. When the dissociative effect is large, there can be a causal
effect of the treatment on the final outcome even if there is no causal effect of the
treatment on the surrogate. The value of the associative effect provides information
on how the causal treatment effect on the outcome changes as the causal effect of the
treatment on the surrogate changes. A good principal surrogate should result in a
large associative effect, which would occur if as the treatment effect on the surrogate
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increases, the treatment effect on the final outcome increases as well. Also of interest
is the “causal effect predictiveness’ (CEP) surface proposed by Gilbert and Hudgens
(2008), which considers the entire curve of E[log(T (1))/log(T (0)) | S(1)− S(0)] and
provides a measures of the treatment effect on T within subgroups defined by the
treatment effect on the surrogate.
An additional useful measure to assess surrogacy is the correlation between the
difference in the normal variables, Φ−1(F4(T (1))) − Φ−1(F3(T (0))) and S̃(1) − S̃(0).
Measures of the associative effect, dissociative effect and correlation are not analyti-
cally estimable, but can be obtained from the posterior predictive distributions.
3.4 Estimation Procedure
A Bayesian approach is used to estimate parameters, using the prior assump-
tions detailed in Section 3.2.4. Unobserved potential outcomes are treated as missing
data and imputed from the appropriate posterior distribution at each iteration of the
Markov chain. Posterior estimates of the unobserved potential outcomes and param-
eter values are obtained using a Metropolis Hastings algorithm. When drawing each
element of Γ, the range of possible values must first be determined in order to satisfy
the positive definite requirement, given that the other correlations are held fixed. The
range of values corresponding to a positive definite matrix are those in the interval
determined by the roots of the quadratic equation that result from solving |Γ| = 0.
Each iteration of the Markov chain is done as follows:






= [S̃(0), S̃(1),Φ−1(FTi(0)(T (0))),Φ
−1(FTi(1)(T (1)))]
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= [S̃(0), S̃(1), qi(Ti(0)), qi(Ti(1))]
• Impute death times for censored subjects by drawing from
P (qi(T (Z)) > qi(T (Z))+v | qi(T (Z)) > qi(T (Z)), qi(T (1−Z)), S̃(0), S̃(1), α, θ) =
P (qi(T (Z))>qi(T (Z)))+v,qi(T (1−Z)),S̃(0),S̃(1),α,θ)
P (qi(T (Z))>qi(T (Z)),qi(T (1−Z)),S̃(0),S̃(1),α,θ)
= P (qi(T (Z))>qi(T (Z))+v|qi(T (1−Z)),S̃(0),S̃(1),α,θ)
P (qi(T (Z))>qi(V (Z))|qi(T (1−Z)),S̃(0),S̃(1),α,θ)
.
For each censored subject, we draw a uniform random variable u ∼ Unif(0, 1)
and solve g−1(u) = v, where g(v) = P (qi(T (Z))>qi(V (Z))+v|qi(T (1−Z)),S̃(0),S̃(1),α,θ)
P (qi(T (Z))>qi(V (Z))|qi(T (1−Z)),S̃(0),S̃(1),α,θ)
.
This can be solved analytically for v by v = F−1[1 − u(1 − F{qi(T (Z))})] −



























• Draw missing counterfactual observations of S̃i(Z) and qi(T (Z)) from their con-






















































• For unobserved counterfactuals, transform draws to Si(Z), and Ti(Z):
[S̃i(Z) ≤ α1Z ]→ Si(Z) = 1
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[α1Z < S̃i(Z) ≤ α2Z ]→ Si(Z) = 2
[α2Z < S̃i(Z) ≤ α3Z ]→ Si(Z) = 3
[S̃i(Z) > α3Z ]→ Si(Z) = 4
Ti(Z) = λTZ [−log(1− Φ{qi(Ti(Z))}]1/γTZ
• Draw α’s from posterior distribution using a Metropolis Hastings algorithm.
• For observed Si(Z)’s, draw S̃i(Z)’s from a truncated normal distribution, where:




























S̃i(0) ≤ αk0 )




























S̃i(1) ≤ αk1 )
• Use the Metropolis Hastings algorithm to draw λTZ , γTZ , ρs, ρ00, ρ01, ρ10, ρ11, ρt
from their posterior distributions. The posterior distributions for all of the
parameters can be obtained from the product of the observed data likelihood,
detailed in Section 3.2.3 and the prior distributions, described in Section 3.2.4.
The chain is run for a 3,000 iteration burn-in period, and then 2,000 draws
from the posterior distribution of each parameter are saved. All of the proposal
distributions are normal and centered at the most recent parameter draw. The
proposal distribution for γTZ is truncated at 0 and proposal distribution for
each αkZ is truncated by α(k−1)Z and α(k+1)Z . The proposal distribution for
each of the correlation parameters is truncated by the bounds which results in
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a positive definite matrix. For each parameter, the variance of the proposal
distribution is adjusted so that the resulting acceptance rates are close to 40%.
3.5 Simulations
We conduct simulations to evaluate the performance of the above methods of
surrogacy assessment. We consider three scenarios: one where S is a good prin-
cipal surrogate for T , one where it is a moderately good principal surrogate, and
one where it is a poor principal surrogate. In each scenario, a sample size of 300
is used with 150 subjects in each treatment arm and approximately 30% of the sur-
vival outcomes are censored. We first explore the sensitivity of the estimation to the
plausible prior restrictions on Γ that we might make. Figure 3.1 provides plots of
the true relationship between E[log(T (1))/log(T (0)) | S(1)− S(0) = s] for the three
surrogacy scenarios considered. In the case of a poor principal surrogate, the plot
shows that E[log(T (1))/log(T (0)) | S(1) − S(0) = 0] is greater than 0, indicating
the average causal necessity is not met. In the moderate principal surrogate case,
average causal necessity is close to being met and there is a moderate increasing
trend in E[log(T (1))/log(T (0)) | S(1) − S(0) = s] as S(1) − S(0) increases. For
the strong principal surrogate case, average causal necessity is met and there is a
strong increasing trend in E[log(T (1))/log(T (0)) | S(1) − S(0) = s] as S(1) − S(0)
increases. For each of the three different surrogacy scenarios we perform four sim-
ulations, with the estimation procedure done using each of the priors outlined in
Section 3.2.4. This results in a total of 12 simulations, each with 200 simulated
data sets. Tables 3.1 and 3.2 provide the posterior means and standard deviations of
the Bayesian estimates and means of the posterior standard deviations ( ¯PSD). The
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Figure 3.1: Plots of E[log(T (1))/log(T (0)) | S(1)−S(0) = s] for the three simulation
scenarios






















































identified parameters are not sensitive to changes in the prior specifications, while
the unidentified parameters are quite sensitive to prior assumptions. The standard
deviation of the Bayesian estimates is generally smaller than ¯PSD for the unidenti-
fied parameters, leading to overcoverage of some of the unidentified quantities. Table
3.3 provides the means and standard deviations of the Bayesian estimates and ¯PSD
for the causal quantities of interest, E(log(Ti(1)/Ti(0)) | Si(1) − Si(0) = s) and
cor(Φ−1(F4(T (1))) − Φ−1(F3(T (0))), S̃(1) − S̃(0)). There is some bias in estimating
these quantities, as these depend on the unidentified parameters. Prior scenarios 3
and 4 appear to perform better than scenarios 1 and 2 in terms of bias and cover-
age rates, generally maintaining conservative coverage and small to moderate biases
across all surrogate scenarios. Under both of these priors, the estimation procedure
does reasonably well at distinguishing the validity of S as a principal surrogate. The
estimates of E(log(Ti(1)/Ti(0)) | Si(1)− Si(0) = 0) are near 0 in the case of a mod-
erate or strong PS, and larger when S is a poor principal surrogate. The estimated
correlation of the causal treatment effects on S and T is largest when S is a strong
principal surrogate and smallest when it is a poor principal surrogate.
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Table 3.1: Copula model simulation results under different prior specifications-
indentified parameters
Moderate PS Poor PS Strong PS
Prior True True True
Parameter Scenario Value Mean (SD) ¯PSD Value Mean (SD) ¯PSD Value Mean (SD) ¯PSD
log(λt0 ) 1
1 2 2.01 (0.08) 0.08 2 2.01 (0.08) 0.08 2 2.00 (0.08) 0.08
22 2.00 (0.08) 0.08 2.01 (0.09) 0.08 2.01 (0.09) 0.08
33 2.00 (0.09) 0.08 2.01 (0.08) 0.08 2.01 (0.08) 0.08
44 2.02 (0.08) 0.08 2.01 (0.08) 0.08 2.00 (0.08) 0.08
γt0 1 1.2 1.19 (0.09) 0.10 1.2 1.21 (0.10) 0.10 1.2 1.22 (0.11) 0.11
2 1.21 (0.10) 0.10 1.18 (0.10) 0.10 1.20 (0.11) 0.10
3 1.20 (0.11) 0.10 1.20 (0.09) 0.10 1.21 (0.10) 0.10
4 1.22 (0.10) 0.10 1.20 (0.10) 0.10 1.21 (0.11) 0.10
log(λt1 ) 1 2.3 2.32 (0.10) 0.10 2.5 2.51 (0.11) 0.11 2.3 2.31 (0.09) 0.09
2 2.32 (0.10) 0.10 2.51 (0.11) 0.11 2.31 (0.09) 0.09
3 2.31 (0.10) 0.09 2.52 (0.11) 0.11 2.31 (0.09) 0.10
4 2.31 (0.09) 0.09 2.52 (0.12) 0.11 2.31 (0.09) 0.10
γt1 1 1.2 1.21 (0.12) 0.12 1.2 1.20 (0.14) 0.13 1.2 1.23 (0.13) 0.12
2 1.20 (0.12) 0.12 1.20 (0.13) 0.13 1.23 (0.12) 0.12
3 1.22 (0.12) 0.12 1.20 (0.12) 0.13 1.22 (0.11) 0.12
4 1.21 (0.11) 0.12 1.20 (0.13) 0.13 1.21 (0.11) 0.12
α01 1 -0.67 -0.70 (0.11) 0.11 -0.67 -0.68 (0.12) 0.11 -0.67 -0.69 (0.10) 0.11
2 -0.70 (0.12) 0.11 -0.68 (0.11) 0.11 -0.69 (0.11) 0.11
3 -0.68 (0.10) 0.11 -0.69 (0.11) 0.11 -0.70 (0.11) 0.11
4 -0.70 (0.11) 0.11 -0.68 (0.11) 0.11 -0.69 (0.12) 0.11
α02 1 0 -0.008 (0.10) 0.10 0 0.004 (0.10) 0.10 0 0.003 (0.09) 0.10
2 0.001 (0.10) 0.10 -0.002 (0.10) 0.10 -0.0008 (0.10) 0.10
3 0.009 (0.11) 0.10 -0.01 (0.10) 0.10 -0.009 (0.10) 0.10
4 -0.006 (0.10) 0.10 0.007 (0.10) 0.10 0.009 (0.11) 0.10
α03 1 0.67 0.69 (0.11) 0.11 0.67 0.69 (0.11) 0.11 0.67 0.69 (0.11) 0.11
2 0.69 (0.13) 0.11 0.68 (0.12) 0.11 0.69 (0.12) 0.11
3 0.70 (0.11) 0.11 0.69 (0.11) 0.11 0.68 (0.12) 0.11
4 0.68 (0.11) 0.11 0.68 (0.12) 0.11 0.69 (0.12) 0.11
α11 1 -1.28 -1.32 (0.13) 0.14 -0.67 -0.69 (0.11) 0.11 -1.28 -1.34 (0.16) 0.14
2 -1.32 (0.14) 0.14 -0.69 (0.11) 0.11 -1.32 (0.13) 0.14
3 -1.33 (0.15) 0.14 -0.69 (0.10) 0.11 -1.34 (0.14) 0.14
4 -1.31 (0.14) 0.14 -0.68 (0.10) 0.11 -1.31 (0.15) 0.14
α12 1 -0.52 -0.53 (0.11) 0.11 0 0.003 (0.10) 0.10 -0.52 -0.53 (0.10) 0.10
2 -0.53 (0.10) 0.11 0.006 (0.10) 0.10 -0.54 (0.11) 0.10
3 -0.54 (0.11) 0.11 -0.02 (0.10) 0.10 -0.54 (0.11) 0.10
4 -0.53 (0.11) 0.11 -0.003 (0.10) 0.10 -0.54 (0.11) 0.11
α13 1 0.25 0.26 (0.10) 0.10 0.67 0.69 (0.11) 0.11 0.25 0.26 (0.10) 0.10
2 0.27 (0.10) 0.10 0.68 (0.11) 0.11 0.26 (0.10) 0.10
3 0.25 (0.10) 0.10 0.67 (0.12) 0.11 0.26 (0.10) 0.10
4 0.26 (0.11) 0.10 0.67 (0.11) 0.11 0.25 (0.10) 0.10
ρ00 1 0.6 0.58 (0.06) 0.06 0.2 0.18 (0.09) 0.08 0.8 0.78 (0.04) 0.04
2 0.58 (0.07) 0.06 0.20 (0.08) 0.08 0.78 (0.04) 0.04
3 0.57 (0.07) 0.06 0.20 (0.08) 0.09 0.78 (0.04) 0.04
4 0.58 (0.06) 0.06 0.21 (0.08) 0.09 0.79 (0.04) 0.04
ρ11 1 0.6 0.57 (0.07) 0.07 0.2 0.18 (0.09) 0.09 0.8 0.78 (0.04) 0.04
2 0.58 (0.06) 0.06 0.20 (0.09) 0.09 0.78 (0.04) 0.04
3 0.57 (0.07) 0.06 0.20 (0.09) 0.09 0.78 (0.04) 0.04
4 0.58 (0.06) 0.06 0.20 (0.09) 0.09 0.78 (0.04) 0.04
1: No restrictions on ρ
2: ρ ≥ 0
3: ρ ≥ 0 and ρ10, ρ01 < ρs, ρt, ρ00, ρ11
4: Beta priors
3.6 Application
We apply our estimation method to data from six clinical trials in advanced col-
orectal cancer (Meta-analysis Group in Cancer, 1998) to determine whether cancer
50
Table 3.2: Copula model simulation results under different prior specifications-
unindentified parameters
Moderate PS Poor PS Strong PS
Prior True True True
Parameter Scenario Value Mean (SD) ¯PSD Value Mean (SD) ¯PSD Value Mean (SD) ¯PSD
ρs 1 0.4 0.0006 (0.35) 0.28 0.2 0.004 (0.24) 0.35 0.4 0.08 (0.37) 0.19
2 0.48 (0.12) 0.21 0.41 (0.12) 0.23 0.47 (0.16) 0.17
3 0.51 (0.08) 0.15 0.48 (0.09) 0.22 0.49 (0.14) 0.12
4 0.48 (0.09) 0.20 0.22 (0.07) 0.22 0.57 (0.13) 0.15
ρ01 1 0.3 0.005 (0.34) 0.27 0.04 -0.04 (0.30) 0.33 0.32 0.09 (0.37) 0.18
2 0.46 (0.15) 0.20 0.41 (0.15) 0.21 0.47 (0.18) 0.16
3 0.23 (0.06) 0.12 0.05 (0.03) 0.06 0.33 (0.14) 0.11
4 0.35 (0.12) 0.19 0.12 (0.06) 0.14 0.53 (0.14) 0.15
ρ10 1 0.3 -0.003 (0.34) 0.26 0.04 0.03 (0.31) 0.32 0.32 0.07 (0.37) 0.18
2 0.47 (0.14) 0.20 0.39 (0.13) 0.21 0.49 (0.17) 0.16
3 0.24 (0.06) 0.12 0.05 (0.03) 0.06 0.33 (0.14) 0.11
4 0.35 (0.11) 0.19 0.12 (0.05) 0.14 0.54 (0.15) 0.15
ρt 1 0.4 -0.002 (0.36) 0.26 0.3 -0.01 (0.34) 0.30 0.4 0.08 (0.39) 0.17
2 0.46 (0.14) 0.19 0.41 (0.16) 0.20 0.48 (0.18) 0.15
3 0.52 (0.09) 0.15 0.49 (0.11) 0.21 0.48 (0.15) 0.11
4 0.47 (0.12) 0.18 0.34 (0.09) 0.21 0.57 (0.15) 0.13
1: No restrictions on ρ
2: ρ ≥ 0
3: ρ ≥ 0 and ρ10, ρ01 < ρs, ρt, ρ00, ρ11
4: Beta priors
Table 3.3: Copula model simulation results: bias, variability and coverage rate of
surrogacy parameters
Moderate PS Poor PS Strong PS
Prior True 95% True 95% True 95%
Quantity Scenario Value Mean (SD) ¯PSD Coverage Value Mean (SD) ¯PSD Coverage Value Mean (SD) ¯PSD Coverage
E[log(T (1)/T (0))|S(1)− S(0) =-3] 1 -1.18 -1.60 (0.82) 0.96 0.86 -0.02 -0.02 (0.74) 0.90 0.92 -2.10 -2.18 (0.77) 0.78 0.91
2 -0.37 (0.60) 1.08 0.94 1.32 (0.45) 0.84 0.65 -1.40 (0.69) 0.93 0.87
3 -1.66 (0.34) 0.94 1 -0.17 (0.24) 0.65 1 -2.28 (0.40) 0.79 0.995
4 -0.99 (0.41) 1.07 0.99 0.18 (0.29) 0.75 1 -1.33 (0.62) 0.95 0.88
E[log(T (1)/T (0))|S(1)− S(0) =-2] 1 -0.73 -0.98 (0.54) 0.66 0.89 0.19 0.19 (0.48) 0.58 0.94 -1.39 -1.33 (0.51) 0.48 0.92
2 -0.17 (0.47) 0.81 0.94 1.04 (0.32) 0.56 0.64 -0.91 (0.50) 0.63 0.88
3 -1.16 (0.25) 0.60 0.99 -0.02 (0.22) 0.44 0.99 -1.47 (0.26) 0.44 0.995
4 -0.68 (0.32) 0.77 0.995 0.27 (0.23) 0.47 0.995 -0.88 (0.44) 0.67 0.90
E[log(T (1)/T (0))|S(1)− S(0) =-1] 1 -0.35 -0.47 (0.35) 0.41 0.93 0.33 0.34 (0.28) 0.34 0.96 -0.73 -0.68 (0.32) 0.29 0.91
2 0.006 (0.32) 0.49 0.91 0.80 (0.22) 0.32 0.73 -0.44 (0.33) 0.36 0.87
3 -0.63 (0.18) 0.34 0.98 0.22 (0.17) 0.24 0.98 -0.79 (0.17) 0.23 0.98
4 -0.33 (0.22) 0.46 0.995 0.37 (0.16) 0.27 0.995 -0.43 (0.28) 0.38 0.88
E[log(T (1)/T (0))|S(1)− S(0) =0] 1 0.11 0.07 (0.15) 0.18 0.97 0.49 0.49 (0.14) 0.19 0.99 0.01 -0.001 (0.14) 0.14 0.96
2 0.23 (0.14) 0.17 0.95 0.51 (0.16) 0.16 0.94 0.10 (0.14) 0.14 0.88
3 0.06 (0.11) 0.14 0.98 0.51 (0.13) 0.15 0.98 0.004 (0.10) 0.12 0.96
4 0.13 (0.11) 0.16 0.995 0.50 (0.13) 0.15 0.98 0.11 (0.12) 0.14 0.90
E[log(T (1)/T (0))|S(1)− S(0) =1] 1 0.52 0.55 (0.14) 0.21 0.99 0.69 0.65 (0.28) 0.34 0.95 0.64 0.61 (0.14) 0.16 0.98
2 0.41 (0.16) 0.20 0.94 0.22 (0.23) 0.32 0.73 0.55 (0.14) 0.16 0.92
3 0.60 (0.13) 0.16 0.96 0.79 (0.16) 0.24 0.995 0.66 (0.10) 0.13 0.98
4 0.49 (0.13) 0.19 0.99 0.62 (0.16) 0.28 0.995 0.53 (0.14) 0.16 0.91
E[log(T (1)/T (0))|S(1)− S(0) =2] 1 0.89 1.03 (0.30) 0.37 0.96 0.83 0.80 (0.48) 0.57 0.94 1.24 1.22 (0.28) 0.26 0.91
2 0.58 (0.31) 0.43 0.90 -0.03 (0.33) 0.57 0.66 0.99 (0.29) 0.32 0.87
3 1.13 (0.17) 0.29 0.96 1.03 (0.21) 0.44 0.995 1.30 (0.17) 0.22 0.98
4 0.85 (0.21) 0.40 0.99 0.73 (0.22) 0.47 1 0.95 (0.26) 0.33 0.87
E[log(T (1)/T (0))|S(1)− S(0) =3] 1 1.31 1.69 (0.57) 0.63 0.81 1.01 0.97 (0.74) 0.86 0.94 1.95 2.06 (0.55) 0.45 0.80
2 0.78 (0.48) 0.75 0.95 -0.30 (0.44) 0.83 0.66 1.49 (0.47) 0.58 0.88
3 1.72 (0.25) 0.54 0.98 1.18 (0.22) 0.66 1 2.03 (0.30) 0.42 0.98
4 1.25 (0.33) 0.73 0.99 0.83 (0.28) 0.74 1 1.42 (0.42) 0.62 0.88
cor(q(T (1))− q(T (0)), S̃(1)− S̃(0)) 1 0.50 0.55 (0.20) 0.20 0.81 0.22 0.18 (0.26) 0.28 0.91 0.80 0.74 (0.14) 0.13 0.96
2 0.22 (0.21) 0.31 0.90 -0.35 (0.16) 0.28 0.50 0.57 (0.19) 0.21 0.91
3 0.72 (0.05) 0.16 0.92 0.35 (0.10) 0.17 0.99 0.86 (0.06) 0.10 0.94
4 0.47 (0.13) 0.28 1 0.14 (0.10) 0.23 1 0.57 (0.16) 0.23 0.95
1: No restrictions on ρ
2: ρ ≥ 0
3: ρ ≥ 0 and ρ10, ρ01 < ρs, ρt, ρ00, ρ11
4: Beta priors
progression is a valid surrogate for overall survival. These data, along with 21 ad-
ditional trials comprising four separate meta-analyses, were previously analyzed by
Burzykowski, et al. (2004) where a meta-analytic surrogacy validation method was
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used. All six of the trials considered compared the administration of fluorouracil (5-
FU) by continuous intravenous infusion (CI) to bolus administration of 5-FU. As these
trials all compared the same two treatments and there were no notable differences
in patient characteristics among the trials, we pool the data from these nine trials
in the application of our method. All together, there were 1,216 patients with 609
randomized to the 5-FU by CI arm and 607 randomized to the bolus 5-FU arm. Pa-
tients were followed with tumor response and survival time recorded. Tumor response
was defined by one of four categories: complete response (CR), partial response (PR),
stable disease (SD) and progressive disease (PD). In our analysis, the true endpoint T
is survival time, defined as the time from randomization to death from any cause and
the surrogate end point S is tumor response, defined as a categorical variable with
S = 1, 2, 3, 4 for PD, SD, PR, and CR, respectively. The binary treatment indicator
for treatment Z is set to 0 for 5-FU by CI and 1 for bolus 5-FU. Tumor response was
measured after approximately 3 to six months of follow-up in advance of the recorded
survival time.
The observed tumor response frequencies were 52% for PD, 32% for SD, 14%
for PR and 3% for CR. The response rate (combined percentage of CR and PR) was
higher in the treatment arm, with 20.8% responding compared to 12.8% responding in
the control arm. The odds ratio for response in the treatment vs. control arm was 1.84
(95% CI: 1.35, 2.51). The median survival time was longer for those in the treatment
group (12.1 months) than for those in the control group (11.3 months), with an
estimated hazard ratio of 0.89 (95% CI: 0.79, 1.00) for the treatment vs. control group.
Table 3.4 provides the means and standard deviations of E[log(T (1)/T (0))|S(1) −
S(0) = s] and of the correlation between q(T (1)) − q(T (0)) and S̃(1) − S̃(0) for
each of the four prior scenarios described in the simulation section. We focus on the
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estimation done using priors 3 and 4, as these priors performed better in the simulation
settings. Under these two priors, E[log(T (1)/T (0))|S(1)−S(1) = 0] is approximately
0, indicative of a good principal surrogate, with a fairly large correlation between
the causal standardized treatment effects. We would therefore conclude that tumor
response appears to be a moderately good principal surrogate for overall survival.
Appendix A provides plots of the Kaplan-Meier survival curves for the observed data
and the mean and 95% credible interval of the posterior predictive distribution from
the model for each of the tumor response categories and for each treatment group.
The plots suggest that the model appears to provide an appropriate fit to the data.
We compare the results obtained under the Gaussian copula model to those that
would have been obtained had the data been analyzed as multivariate normal. To
approximately normalize T , we take the third root, and to approximately normalize
S, for each S = s we draw a uniform (s−1, s) random variable. Appendix B provides
histograms and normal QQ plots of this data. Under this model, we assume that the
























To obtain parameter estimates from this distribution, a Bayesian estimation ap-
proach is used as outlined in Chapter II. Additionally, at the beginning of each
iteration of the chain, a new value for each observed S = s is drawn from a Uni-
form (s − 1, s) distribution and death times are imputed for censored subjects. We
draw a death time from the residual survival distribution, P (T (Z)1/3 > t
1/3
Z + b |
T (Z)1/3 > t
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informative priors are placed on the observed parameters. Specifically, the prior for
each µ is N(0, 106), the prior for each σ is ∝ 1, and the priors for ρ00 and ρ11 are
Unif(−1, 1). We place mildly informative Beta priors on the remaining partially
identified parameters, ρs, ρ10, ρ01, and ρt. Table 3.5 provides the results from an-
alyzing the data as multivariate normal. This method of analysis would identify
S as a weaker principal surrogate than under the copula model, as the estimate of
E[log(T (1)/T (0))|S(1)− S(0) = 0] is slightly larger. The results also show a slightly
attenuated increasing trend of E[log(T (1)/T (0))|S(1) − S(0) = s] in s and larger
standard deviations as compared to the estimates obtained from the copula model.
The copula model, therefore provides more efficient estimation of the principal sur-
rogacy quantities when multivariate normality does not hold. Figure 3.2 provides a
plot of E[log(T (1)/T (0))|S(1)− S(0) = s] vs. s estimated from the Guassian copula
model (using the Beta priors) and from the multivariate normal model. The curve
estimated by the copula model is less linear than that estimated by the multivariate
normal model.
Table 3.4: Application of Gaussian copula to colorectal cancer data
ρ’s unrestricted ρ ≥ 0 ρ ≥ 0 and ρ10, ρ01 < ρs, ρt, ρ00, ρ11 Beta priors
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
E[log(T (1)/T (0))|S(1)− S(0) =-3] -1.09 (0.49) -0.47 (0.74) -1.02 (0.53) -1.08 (0.46)
E[log(T (1)/T (0))|S(1)− S(0) =-2] -0.91 (0.30) -0.42 (0.39) -0.79 (0.26) -0.79 (0.20)
E[log(T (1)/T (0))|S(1)− S(0) =-1] -0.67 (0.16) -0.21 (0.21) -0.46 (0.13) -0.49 (0.12)
E[log(T (1)/T (0))|S(1)− S(0) =0] -0.28 (0.08) 0.01 (0.10) -0.005 (0.06) -0.03 (0.07)
E[log(T (1)/T (0))|S(1)− S(0) =1] 0.84 (0.12) 0.43 (0.14) 0.54 (0.12) 0.66 (0.09)
E[log(T (1)/T (0))|S(1)− S(0) =2] 1.74 (0.22) 0.72 (0.26) 0.96 (0.23) 1.22 (0.19)
E[log(T (1)/T (0))|S(1)− S(0) =3] 2.82 (0.38) 1.08 (0.50) 1.35 (0.50) 1.75 (0.44)
cor(q(T (1))− q(T (0)), S̃(1)− S̃(0)) 0.78 (0.10) 0.31 (0.15) 0.63 (0.14) 0.84 (0.10)
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Figure 3.2: Plot of E[log(T (1)/T (0))|S(1)−S(0) = s] vs. s for colorectal cancer data:
estimates from the copula model and from the multivariate normal model

























Copula Model (Beta Priors)
MVN model
Table 3.5: Surrogacy assessment of colorectal cancer data, analyzed as normal
Parameter Posterior Mean (SD)
E[log(T (1)/T (0))|S(1)− S(0) =-3] -0.90 (0.77)
E[log(T (1)/T (0))|S(1)− S(0) =-2] -0.66 (0.30)
E[log(T (1)/T (0))|S(1)− S(0) =-1] -0.31 (0.16)
E[log(T (1)/T (0))|S(1)− S(0) =0] 0.08 (0.08)
E[log(T (1)/T (0))|S(1)− S(0) =1] 0.43 (0.13)
E[log(T (1)/T (0))|S(1)− S(0) =2] 0.73 (0.27)
E[log(T (1)/T (0))|S(1)− S(0) =3] 1.06 (0.58)
3.7 Discussion
In this chapter, we develop a method for surrogacy assessment under the princi-
pal stratification framework for an ordinal surrogate marker and time to event final
outcome. We use a Gaussian copula model to jointly model the potential surrogate
outcomes and potential final outcomes, and propose quantities from this model that
can be used to determine the validity of S as a surrogate marker for T . A Bayesian
estimation strategy is used, allowing the use of context specific prior assumptions
on the unidentified parameters to be explored in order to aid in estimation. Our
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simulation results suggest that the estimation procedure is able to distinguish valid
principal surrogates from invalid ones.
In our data example, we compare the results obtained using the proposed Gaussian
copula model to those obtained using a multivariate normal model. The results
show that there is some efficiency gained by fitting the more appropriate marginal
distributions to the data and using the Gaussian copula than by assuming multivariate
normality when it may not hold.
In our model formulation, we assume a cumulative probit model for S and a
proportional hazards model with a Weibull baseline hazard function for T . The use
of different parametric models for these marginal distributions could be explored.
Semi-parametric or non-parametric alternatives for the marginal distributions could
also be used to model the marginal distributions of S and T .
CHAPTER IV
Using Multi-state Models With a Cured Fraction
to Model Colon Cancer Recurrence and Death
4.1 Introduction
In longitudinal medical studies with a time-to-event final outcome, patients may
experience multiple disease progression events prior to the event of interest. Examples
include CD4 lymphocyte counts in the progression to HIV infection (Foucher, et al.
2005) and cancer progression prior to death in survival studies (Putter, et al. 2006).
The data we examine come from 12 phase III randomized trials in colon cancer where
there is interest in building a joint model for the two event times of interest, time to
recurrence and time to death and investigating how treatment and other covariates
are associated with the event times. A common way to jointly model these disease
progression events is through the use of multi-state models (Anderson and Keiding,
2002; Meira-Machado et al., 2009; Putter et al., 2007), which describe the progressions
and transitions over time to the various disease states. Common forms of multi-state
models include the “progressive three-state model”, in which subjects enter some
intermediate disease state prior to entering the absorbing state, and the “illness-
death model”, where healthy subjects may enter a diseased state prior to death,
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or die without disease. In these models, transition intensities, which can include
covariates, provide the hazards for moving between states. Each disease state that a
subject occupies is either a transient state that can be left, such as cancer recurrence,
or an absorbing state, such as death, that can never be left once it is entered.
Different model assumptions can be made about the dependence of the transition
intensities and time. One approach is to take t = 0 as the start of the study and
then all subsequent times t refer to the time since the beginning of the study. Klein
et al. (1994) make this assumption in their analysis of relapse and death in bone
marrow transplant patients. A second approach is to set the clock back to 0 upon
entry into a new state. This approach assumes that the hazard for entry into each
state depends on the entry time into that state. This type of model, termed a semi-
Markov model, has been explored by Dabrowska, et al. (1994) and Lagakos, et al.
(1978). Additionally, in the semi-Markov model the hazard for entry into a new
state could depend on the time at which the current state was entered (Anderson,
et al. 2000). In our data analysis, we use a semi-Markov model with recurrence
time as a covariate in the hazard model for the transition from recurrence to death.
The hazard for moving between states can be modeled either parametrically or semi-
parametrically. Putter, et al. (2006) explore the use of the semi-parametric Cox
model in their analysis of recurrence and survival in breast cancer. Foucher, et al.
(2005) use a generalized Weibull model for the hazard of transitioning between states.
Here, we use a proportional hazards model with a parametric Weibull baseline hazard
for each of the transition rates. There is interest in using these semi-Markov multi-
state models to jointly model disease progression events as they can be used to assess
how individual covariates affect each of the progression rates, and to estimate overall
survival, given the disease history.
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We propose a semi-Markov model with an incorporated latent cured state to
model colon cancer recurrence and survival. This model structure is motivated by the
disease process of colon cancer. Cure models have been used to model many different
types of cancer where there is known to be a significant proportion of patients whose
tumors are completely eliminated by the treatment, and so will never experience a
clinical recurrence. These patients are considered to be cured of the disease. We
use the mixture model formulation of the cure model, introduced by Berkson and
Gage (1952). This model assumes that a proportion of the population, p will never
experience the event of interest and are therefore cured. The mixture cure model
has been widely discussed in the literature. Yamaguchi (1992) explored the use of a
cure model with a logistic mixture probability model and an accelerated failure time
model with a generalized gamma distribution. Taylor (1995) used a logistic model for
the cure probability and a completely unspecified failure time process. Estimation for
a semi-parametric Cox proportional hazards model for the failure time process has
been explored by Sy and Taylor (2000) and Peng and Dear (2000).
One issue that arises with the use of the cure model is identifiability due to cen-
soring before the end of the follow-up period (Farewell, 1986). Therefore, it can be
difficult to distinguish models with a large population of uncured individuals and long
tails of the failure time process from those with small populations of uncured indi-
viduals and short tails of the failure time process. In general, in order to justify use
of the cure model, there must be sufficient follow-up and a large number of censored
observations after the last event. Problems with identifiability are likely to arise if
the Kaplan-Meier survival plot of all data does not show a clear level plateau. In the
models we propose, the joint modeling of survival time and recurrence time may aid
in the identifiability as subjects with survival times greater than the last observed
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recurrence time are likely to be cured of disease. Additionally, the appropriateness of
the cure fraction in the multi-state model can be assessed through a goodness of fit
comparison with a model that does not assume a cured fraction.
The multi-state model and cure model have each been considered with both non-
parametric and parametric assumptions. Here, our proposed model combines aspects
of both of these models providing insight into the role of covariates on both the curing
of the disease and the disease process, as well as the association of the two endpoints
of interest, recurrence and death. We apply our model separately to each of the 12
colon cancer trials in order to explore which covariates have similar effects on certain
disease aspects across trials performed in different settings. A Bayesian estimation
strategy is used to estimate the parameters of the Weibull model, the covariate effects
for each of the transition times, and the covariate effects for the logistic model for
each trial. As the cured state is only partially observed, we place informative priors
on some model parameters to aid in estimation where there is a scientific rationale for
these parameters to be close to zero. The adequacy of the model fit is assessed through
the use of Cox-Snell residual plots and deviance residual plots are used to determine
the proper functional form of covariates. While these would be natural to consider for
multi-state models (Kneib and Hennerfeind, 2008), we are not aware of any literature
on using them in cure models. The remainder of the paper is organized as follows:
Section 4.2 describes the data and Section 4.3 describes the proposed model. In
Section 4.4, the estimation procedure is outlined and results of the application of the
model to the data from 12 colon cancer clinical trials are provided. Model checking
procedures are described in Section 4.5. Section 4.6 provides simulation results and
Section 4.7 concludes with a discussion.
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4.2 Data Description
The data we consider consist of a total of 13,983 subjects from 12 randomized
phase III adjuvant trials of locally advanced colon cancer. Ten of the trials are
included in the Sargent, et al. (2005) publication, with two additional new trials.
These 12 trials were previously analyzed by Conlon, et al. (2011), where a separate
cure model and Weibull model were used to model time to recurrence and death,
respectively. Trial enrollment spanned from 1977 to 1999. One trial (7) included 210
patients with stage 1 cancer; these subjects were excluded from this analysis. Due to
differences in the long term follow-up practices between trials, subjects in all trials
except trial 1 were censored at 8 years following the time of the last subject accrual.
Subjects in trial 1 were censored 4.3 years from the last subject accrual due to a large
number of patients administratively censored at this time. The median follow-up
time for subjects alive at their last follow up was 8.2 years. In each trial, subjects
were followed with a specific protocol, with cancer recurrences and deaths recorded
as they occurred. We therefore have two censored event times of interest, recurrence
and death. The censoring times for these two events are not necessarily the same,
as ascertaining a recurrence time requires active follow-up usually involving a scan,
while obtaining a dead or alive status could be obtained through other means. The
average proportion of subjects censored for recurrence prior to their last follow up
was 9.5% across all trials, with a maximum of 16.9% in Trial 2 and a minimum of
0% in Trial 3. Of the 4346 observed recurrences, 3448 (79.3%) occurred within three
years, 4075 (93.8%) occurred within five years, and 4281 (98.5%) occurred within
seven years. This type of event time data where very few events happen after a
fixed window of time is characteristic of a cured group, and for which a cure model
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is appropriate. Kaplan-Meier plots of time to recurrence for the 12 trials, provided
in Appendix I, show a clear leveling off providing a strong empirical rationale for
use of a cure model. Baseline covariates of interest include age, cancer stage and
treatment arm. Each trial compared a different pair of treatments, with one defined
as the control arm and the other as the experimental arm. Five of the trials (1, 2,
3, 6 and 7) compared surgery alone to surgery plus some form of chemotherapy. In
the other seven trials, both arms contained surgery plus some form of chemotherapy.
The primary goal of all 12 trials was to compare overall survival between the pairs
of treatments. Based on a simple log-rank test, three of the trials (3, 8, and 9)
showed a statistically significant treatment effect. Table 4.1 provides a summary of
stage, age and treatment distributions in each trial, as well as the number of recorded
recurrences and deaths and longest follow-up time for each trial. As each of these
trials compared different pairs of treatments, we fit the model to each trial separately,
and then assess which of the covariate effects on the various diseases processes are
similar across the 12 trials.
4.3 Multistate model
We model time to recurrence and time to death using a multi-state model for the
semi-Markov process. We also incorporate a latent cured fraction into the model for
subjects who will never experience a recurrence. The cure model is applied to the
recurrence event and assumes that there is a zero probability that some subjects will
recur. In this setting, the treatment may eliminate the cancer, resulting in a cured
group of patients. Curing of the cancer happens at the time of treatment, but is not
immediately observable. If the cancer is not eliminated, the patient is not cured of
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Table 4.1: Data summary of 12 trials of colon cancer
Study N Recurrences Recurrence Death Total Longest % with % in Age
Without Without Deaths Follow-Up Stage 3 Treatment (mean)
Death Recur (years) Cancer Group
1 247 116 14 13 115 9.9 65.6% 49.0% 60.3
2 408 139 11 44 172 9.1 81.6% 62.5% 61.1
3 926 377 31 76 422 11.4 66.1% 49.4% 60.2
4 914 380 36 106 450 9.9 82.5% 75.2% 62.7
5 878 297 33 74 338 12.6 73.8% 49.8% 61.2
6 724 275 10 132 397 13.2 56.8% 48.2% 59.8
7 683 206 32 129 303 12.9 43.4% 50.1% 63.3
8 1040 356 36 67 387 9.7 72.1% 49.8% 56.1
9 2077 605 57 176 724 9.4 58.7% 66.7% 57.0
10 2128 574 66 192 700 10.3 55.9% 49.8% 58.0
11 1549 394 71 115 438 8 53.5% 50.3% 60.5
12 2409 627 189 106 544 6 71.1% 49.8% 57.9
Total 13983 4346 586 1230 4990 13.2 63.8% 54.3% 59.1
disease and will experience a recurrence when the tumor has regrown to a detectable
size. The observed data provides information about whether the patient was cured
by the treatment. Patients with observed recurrences are known to be in the uncured
group. Patients who do not have an observed recurrence may or may not be cured.
For patients censored for recurrence, the model assumes that a proportion of these
subjects would have never experienced a recurrence even if they had been followed
longer, and are therefore cured. Additionally, some subjects who were censored for
recurrence could have experienced a recurrence after their censoring time had there
been longer follow-up and are therefore in the uncured group with an unobserved
recurrence time (Farewell, 1982). Deaths can occur either without a prior recurrence
or following a recurrence. The deaths that occur without a prior recurrence are
known not to be directly due to the regrowth of the cancer, while deaths following
a recurrence may be due to the cancer or other causes. We do not consider cause of
death in our models. We use the multi-state model to model four transition intensities
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which include the transition from the uncured group to death, the transition from
the cured group to death, the transition from the uncured group to recurrence, and
the transition from recurrence to death.
4.3.1 Notation and model specifications
Let Cir and Tir be the censoring and event times for recurrence and let Cid and
Tid be the censoring and event times for death for the ith subject, i = 1, ...n. Then
Yir = min(Cir, Tir) and the event indicator for recurrence, δir = I(Tir ≤ Cir), and
Yid = min(Cid, Tid) and the event indicator for death, δid = I(Tid ≤ Cid), are observed.
Let Zi, Si and Ai represent the baseline values of treatment group, cancer stage and
age for each subject. Each of these covariates is approximately centered prior to
estimation so that Zi = −0.5 or 0.5 for control and treatment, respectively, Si = −0.5
or 0.5 for stage 2 or stage 3 cancer, respectively, and Ai is age, centered at the mean
age for a given study in units of 10 years. Let pi be the probability that the ith
subject is cured of disease. We define State 1 to be alive and cured of disease, State 2
to be alive and not cured, State 3 to be alive with recurrence and State 4 to be dead,
as illustrated in Figure 4.1. States 1, 2 and 3 are transient states while State 4 is an
absorbing state. We model four transition times, 1 → 4, 2 → 3, 2 → 4, and 3 → 4.
The true state progressions for many subjects are not fully observed. Specifically,
those who were censored for recurrence and alive were either in State 1 or State 2 at
the end of their follow-up, and subjects censored for recurrence and dead either made
a 1 → 4 or a 2 → 4 transition at their time of death. Subjects with an observed
recurrence transitioned from 2 → 3 at their recurrence time and then remained in
State 3 if they were censored for death, or made a 3 → 4 transition at their death
time.
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Figure 4.1: Multi-state cure model structure
Dashed lines represent effect of treatment, solid lines represent transitions between
states.
In the standard setting for cure models there is one event time of interest, and the
mixture model formulation assumes that a proportion of the population, p will never
experience the event of interest, in this case recurrence, and are therefore cured. For
the uncured population, the cure model provides information on the estimated time to
event from the survival distribution. The marginal survival function for recurrence,
S(t), for the entire population is given by S(t) = p + (1 − p)S0(t), where S0(t) is
the conditional survival function for recurrence for the uncured group. It is common
to use a logistic model which includes time independent covariates for the incidence
model. Common choices for S0(t) are the exponential and Weibull distributions.
Non-parametric choices for S0(t) have also been explored. In our more complicated
situation with two event times, the structure of the model is more involved, but we
retain similar elements, that of a cured fraction described by a logistic model, and
distributions of event times given cured status described by proportional hazards
models with Weibull baseline hazard functions.
The proposed model can be used to assess how different covariates affect both
the probability of being cured and the hazard of transitioning to recurrence or death.
Other quantities of interest can also be derived from the model, such as five year
survival within each of the treatment arms. Both the models for the time of entry
65
into each state and p can depend on covariates. The probability of being cured, pi, is





where Xi is a vector of subject specific covariates that includes the centered co-
variates of treatment group, stage and age, and γ is a vector of coefficients given
by γ = (γ0, γTreatment, γStage, γAge)
T The multi-state process is characterized through
transition intensities defined as:
λkj(t) = lim∆t→0 pkj(t, t+ ∆t)/∆t
where pkj(s, t) = P (M(t) = j|M(s) = k,Hs−) is the probability of being in State j at
time t, given that the process was in State k at time s and the history of the process
Hs−, for states M(t) and M(s) occupied at times t and s, respectively, and s ≤ t.
λkj(t) is then the instantaneous hazard of entering State j, given that the previous
state occupied was State k. From this hazard, we can define the survival distributions




















where tr is the entry time into state 3.
We use a proportional hazards model with a Weibull baseline hazard function to
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model the distribution of waiting times. Specifically, the hazard for transition k → j










For transitions 1 → 4 and 2 → 4, ti is a death time. For transition 2 → 3, ti is a
recurrence time and for transition 3 → 4, ti is the gap time between entry into the
recurred state and death. Xi represents a vector of subject specific covariates which
includes the centered covariates of treatment group, stage and age for transitions
1 → 4, 2 → 3, and 2 → 4. For transition 3 → 4, Xi includes the centered covaraites
of treatment group, stage, age and time to recurrence, centered at the mean time
to recurrence for those who recur in a given study in units of years. βkj is a vector
of coefficients given by βkj = (βTreatmentkj , βStagekj , βAgekj)
T for kj = {14, 23, 24} and
β34 = (βTreatment34 , βStage34 , βAge34 , βTr)
T . ρkj and αkj are the shape and scale param-
eters, respectively, for each Weibull model. The covariates can be expected to be
associated with each of the model components in differing ways, as each part of the
model describes a different aspect of the disease process. The probability of being
cured provides information about the tumor and the cell killing effect of the treat-
ment. Transitions 1 → 4 and 2 → 4 give information about the person as opposed
to the cancer and transition 2 → 3 provides information about the tumor regrowth.
Finally, transition 3 → 4 provides information about both the person and the re-
growth of the tumor. Six distinct types of people contribute to the likelihood: those
who recur and are either dead or alive at a later time, those censored for recurrence
at Yir = Yid and either dead or alive at Yid, and those censored for recurrence at Yir
prior to death or censoring at a later time Yid. These likelihood contributions can be
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described by the following three equations:
Recur, dead or alive:
(1− pi)λ23(Yir)S2(Yir)λ34(Yid − Yir)δidS3(Yid | Yir)
Censored for recurrence at Yid, dead or alive:
(1− pi)λ24(Yid)δidS2(Yid) + piλ14(Yid)δidS1(Yid)





λ23(u)S2(u)λ34(Yid − u)δidS3(Yid | u)du+
piλ14(Yid)
δidS1(Yid)
In the 12 trials we examine, a small proportion of subjects (0.7% across all trials)
had a recurrence at the same date as their time of death. As these subjects likely truly
recurred prior to this date but for administrative or other reasons these recurrences
were not detected prior to death, their recurrence times were treated as interval
censored and their contribution to the likelihood was:




λ23(u)S2(u)λ34(Yid − u)δidS3(Yid | u)du
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4.4 Estimation
We use a Bayesian MCMC technique to estimate the parameters of the multi-state
cure model. The parameters for each of the 12 trials are estimated separately, with
no mixing of patients across the different trials. There are a total of 25 parameters to
estimate for each of the trials which include a shape (ρ) and scale (α) parameter from
the Weibull model for each of the hazard rates, covariate effects for each of the hazard
models and covariate effects in the logistic model for the probability of cure. As the
cured state is only partially observed, we place informative Normal(0, 0.252) priors
on the treatment and stage coefficients in transition 1→ 4 to aid in estimation. This
seems reasonable as treatment group and cancer stage may affect the likelihood of
cure, but are unlikely to affect the survival of patients conditional on being cured of
disease. Additionally to aid in estimation, we place mildly informative Normal(0, 22)
priors on the log(α)’s and gamma priors with mean 1 and standard deviation 0.6 on
the ρ’s. Normal(0, 1) priors are placed on all of the remaining covariate coefficients
in the hazard models and in the logistic model. At each iteration of the chain the
latent variable representing cured status is simulated. Specifically, subjects without
recurrence are placed in either the cured or uncured group by drawing a Bernoulli















for those censored for recurrence at Yir prior to Yid. As some integrals in the likeli-
hood do not have closed form solutions, numeric integration was used. Specifically,
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λ23(u)S2(u)λ34(Yid − u)δidS3(Yid | u)du
Yid∫
Yir
λ23(u)S2(u)λ34(Yid − u)δidS3(Yid | u)du
All covariates are centered prior to estimation, as described in Section 4.3. The
posterior distributions for all of the parameters can be obtained from the product of
the observed data likelihood and prior distributions. The Metropolis Hastings algo-
rithm is used for parameter estimation. Appendix J provides the full data likelihood
and details of the algorithm.
For each parameter, we obtain 5000 draws from its posterior distribution. Table
4.2 provides the posterior mean and standard deviation estimates for all model pa-
rameters for each of the 12 trials. Covariate effect estimates that are greater than two
times the posterior standard deviation are shown in bold. We estimate the parame-
ters of each of the 12 trials separately, and compare the estimates of each parameter
across trials in order to examine which aspects of the disease process have common
covariate effects across all of the trials, and which have varying effects. The results
show very consistent effects of most covariates on the probability of cure and on each
of the transition times across all 12 studies. Stage is seen to have a consistent and
strong effect on the probability of being cured and on the time to recurrence and a
modest effect on the time to death after recurrence, with higher stage people more
likely to recur, recurring earlier and dying sooner after recurrence. The effects of stage
on time to death for those who don’t recur are smaller in the cured group, with mixed
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effects across trials. Age has a strong effect on time to death for both those who are
cured and those who are not cured but die before recurrence, with older people dying
sooner. There is a mild positive effect of age on time to death after recurrence and
mild negative effect of age on time to recurrence. There is also a consistent effect of
time to recurrence on time to death, with those recurring quickly dying sooner. The
shape parameter, ρ, and scale parameter, α, of the Weibull model are also consistent
across trials within each transition. The shape parameter of the Weibull distribution
determines the shape of the density curve. When ρ < 1, the failure rate decreases
with time. Weibull distributions with ρ close to or equal to 1 have a fairly constant
failure rate and distributions with ρ > 1 have a failure rate that increases with time.
For all of the trials, ρ is greater than 1 in the transition from no cure to recur, indi-
cating a short tail in the distributions of recurrence times. This is characteristic of an
event with a cured group, as events become unlikely after a certain amount of time.
The intercept in the logistic model for the probability of cure indicates that the trials
where the control arm was surgery alone tend to have lower cure rates on the control
arm than the trials where the control arm included chemotherapy.
As the 12 trials compared different combinations of treatments, the treatment
effects vary for one trial to the next. Based on log-rank p-values for overall survival,
Trials 3, 8 and 9 had a significant effect of treatment on overall survival, with log-
rank p-values equal to 0.004, 0.0003, and 0.04, respectively. Trials 2, 7, and 12 had
near significant treatment effects on overall survival with log-rank p-values of 0.09,
0.07, and 0.09, respectively. Additionally, Trials 1, 3, 8, 9, and 12 had a significant
treatment effect on time to recurrence, with log-rank p-values of 0.01, < 0.0001, 0.001,
0.04, and 0.03, respectively. The treatment effect estimates from the Markov model
show some consistencies with these results, with effects of treatment primarily seen
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on the probability of cure and time to recurrence. There is a significant effect of
treatment on the probability of cure for Trials 3 and 8. Trial 8 and Trial 1 both have
a significant treatment effect on time to recurrence. All trials, except Trial 3 show no
effects of treatment on time to death after a recurrence, or on time to death without
recurrence for either the cured or uncured group. There is a small adverse effect of
treatment on the time to death after a recurrence in Trial 3. Appendix K provides
plots of each of the treatment effect estimates across the trials.
4.5 Model Checking and Model Extensions
4.5.1 Checking Goodness of Fit of the Model
Once parameter estimates for the model have been obtained, the model can be
used to estimate five year overall survival (OS), traditionally the final endpoint of
interest in trials of locally advanced colon cancer. Similarly, three year disease free
survival (DFS) which is the minimum of recurrence and death times and has been
shown to be an alternative endpoint to five year OS in these types of trials (Sargent, et
al. 2007), can also be estimated from the model. The point estimates for five year OS
and three year DFS for each treatment arm can be compared with the Kaplan-Meier
estimate to check the model fit and the standard error estimate can be compared
with that of the Kaplan-Meier estimate to assess gains in efficiency through use of
the multi-state model. For each subject we can calculate their five year OS probability
as:





and three year DFS probability as:
P (DFSi > 3 | Xi, θ) = piS1(3) + (1− pi)S2(3)
where θ is the vector of parameter values, and the probability is averaged across the
age and stage covariate values for each subject and across all of the parameter draws.
Table 4.3 provides the Kaplan-Meier and multi-state model five year OS and three
year DFS estimates and standard errors. For the 12 trials considered, both the five
year OS and three year DFS estimates from the multi-state model are similar to the
Kaplan Meier estimates, indicating that the model is an appropriate fit to the data
as measured by predictions of OS at five years and DFS at three years. There is also
some efficiency gained in estimating these quantities, as seen by the smaller standard
errors in the multi-state model estimates as compared to the Kaplan-Meier estimates.
Also noticeable from the estimates are the general improvement in five years OS from
the chronologically early trials (trials 1,2 and 3) to the more recent trials (10, 11 and
12).
Additional model fit assessments can be made by examining Cox-Snell residual
plots. For each subject, we calculate the Cox-Snell residual for time to death. Let
wi = −logŜ(Yid), where:




If the model is correct, the pairs (wi, δid) should be like a sample from a censored
Exp(1) distribution. Therefore, a plot of wi vs. the Nelson-Aalen estimator for the
pairs of (wi, δid) should yield a straight line through the origin with slope 1. Figure
4.2 provides the Cox-Snell residual plots for overall survival for the 12 trials. For
most of the trials, the proposed model appears to provide an adequate fit to the data.
73
The above Cox-Snell residuals involve all five model components. Cox-Snell residuals
can also be used to check the model fit for some selected aspects of the overall model,
specifically for the time to recurrence and for the transition from recur to death.
For the time to recurrence, the residual is wi = −logŜ(Yir), with the pair (wi, δir)
compared to the Exp(1) distribution, where:







exp(βtrt23Zi + βst23Si + βage23Ai)
)
and for the recur to death transition the residual is wi = −logŜ(Yid − Yir), with the
pair (wi, δid) compared to the Exp(1) distribution, where:







exp(βtrt34Zi + βst34Si + βage34Ai + βTr34Yir)
)
where wi is calculated only for those who recur. Appendix L provides the Cox-
Snell residual plots for the time to recurrence transition and the recurrence to death
transition. The residual plots for the individual transitions show that the model
fits for the time to recurrence fairly well, but there may be some lack of fit in the
transition from recurrence to death in some trials.
Deviance residuals are a standard way of assessing the functional form of covariates
in survival analysis models. Here, we adapt them to the multi-state cure model. For

















The Martingale residuals can be viewed as the difference between the observed num-
ber of deaths for subject i between time 0 and Yid and the expected number based
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Figure 4.2: Cox-Snell residual plots for time to death. Results from 12 trials.
























































































































































































































































































































































































































































on the model. As the Martingale residuals have an asymmetric range, the de-
viance residuals are often preferred. The deviance residuals are defined as Di =
sign(ri)
√
−2[ri + δidlog(δid − ri)]. Plots of the deviance residuals against covariates
should be symmetric about a horizontal line at 0.
In addition to checking the Deviance residuals for overall survival, we can also use
them to assess the functional forms of covariates for time to recurrence and for time
to death after recurrence. In the first case, we have: ri = δir − Λ̂(Yir) where:
Λ̂(Yir) = −log
(











−2[ri + δirlog(δir − ri)]






exp(βtrt34Zi + βst34Si + βage34Ai + βTr34Yir)
Di = sign(ri)
√
−2[ri + δidlog(δid − ri)]
where ri is only calculated for those who recur. Results of these deviance residuals are
shown in Appendix M. Deviance residuals plots are in general hard to interpret. The
plots suggest that a linear function of age is not inadequate for both the recurrence
transition and the death after recurrence transition and for the overall model fit. The
covariate for recurrence time in the death after recurrence transition also appears to
be adequately modeled by a linear function. The graphs suggest that there is no
obvious, consistent departure across the 12 trials.
4.5.2 Model Adaptations
While we have shown a good fit of the multi-state cure model with meaningful
interpretation of the parameters, a natural question is could we have obtained an
76
adequate fit with a simpler model. To compare the full multi-state model to simpler
models we use the DIC statistic (Spiegelhalter et al., 2002). The DIC value for
each study is calculated as DIC = 2E[D(θ)]−D(θ̄), where D(θ̄) is -2 times the log-
likelihood calculated at the mean value of each parameter, and E[D(θ)] is the mean
of -2 times the log-likelihood across all parameter draws. A multi-state model is fit to
these data without including a cured group. This results in a simpler model with 16
as opposed to 25 parameters, and may be a better choice if there is uncertainty about
the existence of the cured population and may give an adequate fit. In this case the
multi-state model would be fit without modeling the cured fraction and there would
be only one path from the alive state to the death state for subjects who died without
recurrence. Therefore, we only consider transitions 2→ 3, 2→ 4 and 3→ 4. Another
simpler model that may provide an adequate fit to the data is one in which all of
the parameters in the 1 → 4 transition and in the 2 → 4 transition are forced to be
the same. Subjects making a 1→ 4 transition are those who die after being cured of
disease and those who make a 2→ 4 transition are those who are not cured of disease
but die prior to recurrence. In both of these cases, the subjects are dying from causes
other than the cancer, so it is plausible that the parameters of these two hazard rates
may be similar. This simpler model has 5 fewer parameters to estimate than the full
model. The fit of the models without a cured fraction and with the parameters in
transitions 1 → 4 and 2 → 4 constrained to be the same can be compared to the
full model through a comparison of DIC values. Table 4.4 provides the DIC values
for each of these models for the 12 trials, with the DIC of the best fitting model in
bold. In all 12 trials, the model with a cured group and different parameter values
for the 1 → 4 and 2 → 4 transitions is preferred over the simpler models, with the
model having no cured fraction providing the worst fit. The Cox-Snell residual plots
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for time to death can also be compared between the two models to visually assess
the adequacy of the model fits. Appendix N provides the Cox-Snell residual plots for
the model with no cured fraction. These plots show a larger deviation from the line
through the origin than the plots made using the complete model, indicating a poorer
fit to the data.
4.5.3 Recurrence only model
The multi-state Markov model provides a convenient way to deal with the com-
peting risk nature of the recurrence and death events. In colon cancer, recurrence
substantially changes the risk of death, and some non-cured patients die from other
causes prior to experiencing a recurrence. Therefore, for these patients, their re-
currence time is unobservable and some caution must be taken in interpreting the
probability of recurrence in the presence of death as a competing risk. If we are only
interested in the recurrence event, we can empirically examine the effect of ignoring
death by comparing the estimates obtained from the proposed multi-state model to
those from a standard cure model for recurrence with a marginal proportional hazard
model with Weibull baseline function for the hazard of recurrence. In this model,
subjects who die without recurrence are censored for recurrence at their death time.
A comparison of the estimates from the multi-state cure model and the simpler cure
model provides insight into whether or not it is necessary to build the entire joint
multi-state model for recurrence and death if we are only interested in the recurrence
event. Figure 4.3 provides plots of the parameter estimates for treatment, stage and
age in the logistic model and hazard model for recurrence from both the multi-state
model and from a standard cure model for recurrence. The plots show similar es-
timates of covariate effects with similar standard errors of effect estimates for both
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parts of the model, indicating that if we are only interested in the recurrence end
point, a simpler model that ignores the time to death endpoint provides adequate
estimation of parameters for these data sets. It can be shown algebraically that if
we assume that λ14(t) = λ24(t) then the maximum likelihood estimates from the full
multi-state cure model are equivalent to the maximum likelihood estimates from the
simple cure model, if the censoring times for recurrence and death do not differ. The
deaths in the 1→ 4 and 2→ 4 transitions are both primarily due to causes other than
cancer, so it might be reasonable to expect λ14(t) and λ24(t) to be similar although in
the previous section we showed better DIC values for the full model compared to the
model with λ14(t) = λ24(t). While the points estimates from the data for transitions
1 → 4 and 2 → 4 are dissimilar, there is wide uncertainty in the estimation of these
quantities. Thus it is not too surprising that there is considerable similarity in the
estimates for the logistic model and for the λ23(t) parameters from the full multi-state
cure model and simple cure model.
4.6 Simulations
A small simulation study was conducted to assess the performance of the estima-
tion procedure and the impact of the prior distributions and sample size. The first
simulation uses the same prior distributions as were used in the estimation of the
colon cancer data, with a sample size of 1000. In the second simulation, the variance
of all prior distributions is increased. The third simulation has the same prior distri-
butions as the first simulation with the sample size decreased to 500 to assess how the
prior distributions used in our data analysis performed among the varying trial sizes.
In each of these three cases, half of the subjects were assigned to be in the treatment
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Figure 4.3: Comparison of estimates from full multi-state cure model to recurrence
only model.
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Results shown for 12 trials. The lower line for each trial is the posterior mean and 95% credible interval for the
coefficient from the full multi-state cure model. The upper line is the posterior mean and 95% credible interval for
the coefficient from the cure model that does not incorporate death times.
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arm and half were assigned to be in the control arm. Two-thirds of subjects were
assigned to have stage three disease, and the remaining one-third were assigned to
have stage two disease. Subjects were accrued over a four year period with six years
of additional follow-up.




where Zi denotes treatment group and Si denotes stage. Each of these covariates are
centered at 0 so that Zi is equal to -0.5 for the control group and 0.5 for the treat-
ment group and Si is equal to -0.75 for stage two disease and 0.25 for stage three
diseases. For those who are cured of disease, we then generate a death time using the
hazard model for transition 1 → 4 with treatment as the only covariate. For those
who are not cured of disease, we generate a recurrence time using the hazard model
for transition 2 → 3 and a death time using the hazard model for transition 2 → 4
with treatment as the only covariate in each of these hazard rates. If the death time
for uncured subjects is less than the recurrence time, then a 2 → 4 transitions is
made at the death time. If the recurrence time is less than the death time, then a
2 → 3 transition is made at that time. For those who recur, the time between their
recurrence and death is generated using the hazard model for transition 3 → 4 with
treatment and recurrence time as covariates. Subjects are censored six years after the
last accrual.
Table 4.5 provides posterior means, standard deviations, average posterior stan-
dard deviations ( ¯PSD) and coverage rates from 200 simulations. As the parameters
in the hazards for transition for subjects with a recurrence are fully identified, the
parameters in transitions 2→ 3, and 3→ 4 are estimated with little bias in all three
simulations. Parameters in the logistic model for the probability of being cured are
also consistently estimated. When the sample size remains the same, but the vari-
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ance on the priors is increased, the parameters in transition 1→ 4 have slightly lower
coverage rates and slightly higher standard deviations and ¯PSD’s. The parameters
in transition 2→ 4 also have slightly lower coverage rates and noticeably higher stan-
dard deviations and ¯PSD’s. When the priors are kept the same but the sample size is
decreased, the parameter estimates remain similar, but the standard deviations and
¯PSD’s are increased across all parameters. Simulation 1, which uses the priors that
were used in obtaining estimates for our 12 trials and a large sample size, appears
to provide the best estimation across all parameters. We note however, that even in
this simulation there is some bias and large uncertainty in estimating the parameters
for transition 2→ 4 due to the small number of subjects who are uncured of disease
but die prior to a recurrence.
4.7 Discussion
In this paper, we have used a multi-state Markov model to formulate a joint model
for recurrence and death in colon cancer with an incorporated cured fraction. The
proposed model is complex with a large number of parameters to estimate, however
it is well motivated by the context of the disease process of colon cancer, where it is
likely that a proportion of the population will be cured of disease, and recurrence is
known to influence survival time. The parameter estimates obtained from the model
provide meaningful interpretations as to how different covariates affect the various
disease elements. We presented methods for assessing the adequacy of the model fit
and the functional form of covariates, both for the overall model and individual model
components, which can aid in choosing an appropriate model. A Bayesian estimation
strategy was used to estimate parameters, with informative priors placed on some
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parameters to aid in estimation. As our simulation results show, some parts of the
model are more sensitive to the choice of the prior due to a lack of identifiability.
Adaptations to this model are possible. For example, we have used fully paramet-
ric models in this article. Semi-parametric alternatives for the Weibull model could
be explored (Saten and Sternberg, 1999), however the Weibull model appeared to
provide an adequate fit to the data in this setting, except, possibly for the transition
from recurrence to death. To explore this, we fit the proposed model with a gener-
alized Weibull baseline hazard, as described by Foucher, et al. (2007) for the 3 → 4
transition. Based on a comparison of DIC values, this model provided a slightly bet-
ter overall fit to the data for all 12 trials, and the Cox-Snell residual plots for the
3 → 4 transition appeared to provide a better fit. However, the covariate coefficient
estimates and posterior standard deviations for this model were nearly identical to
those obtained by the model presented in this paper, indicating that the proposed
model is somewhat robust to slight model misspecification.
Maximum likelihood estimation could be used to obtain parameter estimates as
opposed to our Bayesian approach; however this is computationally more difficult, and
the Bayesian estimation approach facilitates placing informative priors on selected
parameters. In our model formulation, recurrence times are treated as known, when
more realistically they occur sometime within an interval of scheduled clinic visits,
but, the left hand end of this interval is unknown to us. However, if this information
were available, the models could be formulated to reflect this by treating recurrence
time as interval censored. An additional useful extension to the proposed model for
current clinical trial practice would be the ability to return to the disease-free state
after recurrence. This now appears to occur for about 10% of patients who recur
but then live for a long time after the recurrence, presumably due to subsequent
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therapy. The model could also be adapted to consider cause specific mortality if this
information were available in the data.
As the models demonstrated, there were common effects of age, stage and the
Weibull shape parameter across studies within the logistic model and within the
transition rates. Therefore, information from these covariates could be borrowed
across trials with estimates shrunk towards common values by fitting a Hierarchical
model to the 12 trials examined. Estimates from the Hierarchical model could then be
applied to data from a new trial during follow-up to aid in the estimation and analysis
of treatment effects on overall survival. This will be described in future research.
The proposed model also has the potential to be used to use recurrence as an
auxiliary variable for overall survival. As recurrence time is often an informative
marker in predicting a patient’s overall survival time, recurrence information along
with the parameter estimates from the joint model could be used to impute death
times for censored subjects and potentially improve the efficiency in the analysis of
overall survival. This strategy could also result in the shortening of the length of the
trial, if the information lost due to early censoring could be correctly recovered by




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 4.3: Five year OS and three year DFS estimates: Kaplan-Meier, and Multi-state
model
P (T > 5|Zi = 1, Xi, θ) P (DFS > 3|Zi = 1, Xiθ) P (T > 5|Zi = 0, Xi, θ) P (DFS > 3|Zi = 0, Xi, θ)
Kaplan-Meier Multi-state Model Kaplan-Meier Multi-state Model Kaplan-Meier Multli-state Model Kaplan-Meier Multi-state Model
Est. (SE) Est. (SE) Est. (SE) Est. (SE) Est. (SE) Est. (SE) Est. (SE) Est. (SE)
Trial 1 0.651 (0.044) 0.657 (0.037) 0.669 (0.043) 0.690 (0.036) 0.561 (0.044) 0.552 (0.036) 0.548 (0.044) 0.540 (0.038)
Trial 2 0.695 (0.029) 0.705 (0.025) 0.721 (0.028) 0.727 (0.025) 0.638 (0.039) 0.653 (0.034) 0.665 (0.038) 0.659 (0.035)
Trial 3 0.693 (0.022) 0.694 (0.019) 0.700 (0.021) 0.702 (0.020) 0.620 (0.022) 0.622 (0.020) 0.590 (0.023) 0.589 (0.021)
Trial 4 0.635 (0.018) 0.632 (0.017) 0.641 (0.018) 0.650 (0.017) 0.658 (0.032) 0.656 (0.029) 0.637 (0.032) 0.665 (0.031)
Trial 5 0.693 (0.022) 0.698 (0.019) 0.697 (0.022) 0.705 (0.020) 0.716 (0.022) 0.730 (0.019) 0.712 (0.022) 0.722 (0.020)
Trial 6 0.639 (0.026) 0.626 (0.022) 0.682 (0.025) 0.675 (0.022) 0.601 (0.025) 0.618 (0.021) 0.634 (0.025) 0.642 (0.021)
Trial 7 0.748 (0.024) 0.735 (0.020) 0.731 (0.024) 0.731 (0.021) 0.668 (0.026) 0.697 (0.021) 0.693 (0.025) 0.691 (0.023)
Trial 8 0.762 (0.019) 0.756 (0.016) 0.749 (0.019) 0.759 (0.017) 0.656 (0.021) 0.661 (0.019) 0.665 (0.021) 0.657 (0.019)
Trial 9 0.738 (0.012) 0.746 (0.011) 0.743 (0.012) 0.747 (0.012) 0.704 (0.017) 0.712 (0.016) 0.711 (0.017) 0.707 (0.016)
Trial 10 0.765 (0.013) 0.775 (0.011) 0.767 (0.013) 0.770 (0.012) 0.761 (0.013) 0.762 (0.012) 0.760 (0.013) 0.760 (0.012)
Trial 11 0.788 (0.015) 0.794 (0.013) 0.778 (0.015) 0.779 (0.013) 0.788 (0.015) 0.783 (0.013) 0.783 (0.015) 0.783 (0.014)
Trial 12 0.802 (0.012) 0.797 (0.011) 0.780 (0.012) 0.775 (0.011) 0.783 (0.012) 0.781 (0.011) 0.748 (0.013) 0.743 (0.012)
Table 4.4: Multi-state model comparison by DIC values
Complete Model No Cured Fraction Parameters in 1→ 4,
2→ 4 same
# of Parameters 25 16 20
DIC
Trial 1 1093.7 1130.8 1099.4
Trial 2 1789.4 2106.3 1793.5
Trial 3 4206.5 4375.7 4212.0
Trial 4 4392.7 4507.4 4419.6
Trial 5 3572.5 3694.5 3591.7
Trial 6 3607.8 3740.2 3615.0
Trial 7 3176.4 3301.0 3209.4
Trial 8 4084.6 4303.0 4096.4
Trial 9 7677.2 8083.2 7684.4
Trial 10 7706.4 8061.3 7721.2
Trial 11 5225.7 5407.6 5238.6
Trial 12 7172.9 7349.0 7178.5
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Table 4.5: Simulation results from the multi-state cure model
Simulations 1 and 3 use informative prior distributions, simulation 2 uses weakly informative priors.
Simulation 1 (n=1000) Simulation 2 (n=1000) Simulation 3 (n=500)
Parameter Prior True Value Estimate (SD) PSD Coverage Prior True Value Estimate (SD) PSD Coverage Prior True Value Estimate (SD) PSD Coverage
log(α14) N(0,4) 1.8 1.79 (0.04) 0.04 0.94 N(0,25) 1.8 1.79 (0.04) 0.04 0.92 N(0,4) 1.8 1.79 (0.05) 0.05 0.98
ρ14 G(1,0.4) 2 1.94 (0.16) 0.16 0.94 G(1,1.6) 2 1.94 (0.18) 0.17 0.93 G(1,0.4) 2 1.94 (0.19) 0.20 0.95
βtrt14 N(0,0.06) 0 0.004 (0.10) 0.11 0.97 N(0,4) 0 0.006 (0.12) 0.12 0.94 N(0,0.06) 0 -0.0001 (0.10) 0.12 0.995
log(α23) N(0,4) 0.8 0.80 (0.07) 0.07 0.96 N(0,25) 0.8 0.79 (0.07) 0.07 0.95 N(0,4) 0.8 0.80 (0.09) 0.10 0.94
ρ23 G(1,0.4) 1.5 1.49 (0.08) 0.08 0.93 G(1,1.6) 1.5 1.49 (0.08) 0.08 0.93 G(1,0.4) 1.5 1.47 (0.10) 0.10 0.94
βtrt23 N(0,1) -0.5 -0.49 (0.16) 0.17 0.95 N(0,4) -0.5 -0.49 (0.17) 0.17 0.93 N(0,1) -0.5 -0.50 (0.19) 0.21 0.97
log(α24) N(0,4) 1.8 2.06 (0.35) 0.41 0.95 N(0,25) 1.8 2.25 (0.60) 0.61 0.91 N(0,4) 1.8 2.13 (0.37) 0.55 0.97
ρ24 G(1,0.4) 1 0.98 (0.13) 0.13 0.95 G(1,1.6) 1 0.96 (0.16) 0.16 0.92 G(1,0.4) 1 1.01 (0.15) 0.19 0.98
βtrt24 N(0,1) 0 -0.02 (0.25) 0.30 0.97 N(0,4) 0 -0.08 (0.36) 0.40 0.96 N(0,1) 0 -0.07 (0.34) 0.43 0.98
log(α34) N(0,4) 0.9 0.89 (0.08) 0.08 0.95 N(0,25) 0.9 0.89 (0.08) 0.08 0.95 N(0,4) 0.9 0.92 (0.09) 0.10 0.95
ρ34 G(1,0.4) 0.9 0.91 (0.05) 0.05 0.95 G(1,1.6) 0.9 0.91 (0.05) 0.05 0.94 G(1,0.4) 0.9 0.90 (0.06) 0.06 0.95
βtrt34 N(0,1) 0 0.007 (0.13) 0.14 0.98 N(0,4) 0 0.005 (0.13) 0.14 0.97 N(0,1) 0 0.002 (0.18) 0.18 0.95
βTr34 N(0,1) -0.1 -0.10 (0.06) 0.07 0.95 N(0,4) -0.1 -0.10 (0.06) 0.07 0.96 N(0,1) -0.1 -0.11 (0.08) 0.08 0.95
γ0 N(0,1) 0.5 0.52 (0.13) 0.14 0.94 N(0,4) 0.5 0.54 (0.15) 0.14 0.92 N(0,1) 0.5 0.53 (0.15) 0.18 0.97
γtrt N(0,1) 0.6 0.60 (0.16) 0.18 0.98 N(0,4) 0.6 0.61 (0.17) 0.19 0.97 N(0,1) 0.6 0.58 (0.22) 0.24 0.97
γstage N(0,1) -0.9 -0.90 (0.16) 0.17 0.97 N(0,4) -0.9 -0.92 (0.16) 0.17 0.96 N(0,1) -0.9 -0.87 (0.20) 0.23 0.98
Where N(x,y)==Normal(mean, variance), G(x,y)==Gamma(mean, variance)
Where SD denotes standard deviation of posterior means. PSD denotes average of the posterior standard deviations.
CHAPTER V
Improving Efficiency in Clinical Trials Using
Auxiliary Information; Application of a
Multi-state Cure Model
5.1 Introduction
There is much interest in the use of intermediate outcome variables as either
surrogate endpoints (Alonso and Molenberghs, 2008; Buyse and Molenberghs, 1998;
Wang and Taylor, 2003) or auxiliary variables for the true outcome of interest in
randomized clinical trials. A surrogate endpoint is one that is intended to replace the
true outcome of interest in evaluating therapy and an auxiliary variable is one that is
intended to be used to improve the efficiency of the analysis of the true endpoint. For
clinical trials in locally advanced colon cancer, overall survival is traditionally consid-
ered the definitive endpoint. However, the earlier endpoint of disease-free survival,
defined as the time to the first event of either death or cancer recurrence, has been
determined to be a good surrogate for overall survival (Chen, et al. 1998; Sargent, et
al. 2007). Therefore, disease free survival is now often used as the outcome in place
of overall survival in clinical trials of colon cancer. Here, we explore an alternative
use of recurrence in colon cancer trials, that of an auxiliary variable which can be
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used to improve the efficiency of analysis, as measured by smaller standard errors on
treatment effect estimates of the primary endpoint of interest, overall survival.
A variety of methods have been explored to utilize the information of an intermedi-
ate variable to improve the efficiency of the analysis of the final endpoint (Finkelstein
and Schoenfeld, 1994; Fleming, et al 1994; Kosorok and Fleming, 1993; Lagakos,
1977). Cook and Lawless (2001) used a three-stage model for a time-to-event inter-
mediate marker and true endpoint and showed that substantial gains in efficiency are
possible with parametric models that assume a close structural relationship between
the intermediate variable and true endpoint. Li, et al. (2011) used a parametric
model formulation and showed an increase in efficiency gains in the analysis of the
true endpoint when plausible prior assumptions are placed on certain model parame-
ters. In particular, they showed that gains in efficiency can be made if the treatment
effect on the true outcome, conditional on the intermediate variable, was adaptively
shrunk towards zero. Broglio and Berry (2009) partitioned overall survival time into
two parts, progression-free survival and survival post-progression and discuss the ben-
efits of considering the treatment effects on each of these endpoints separately. In the
situation of an auxiliary longitudinal variable and a censored event time of interest,
Faucett, et al. (2002) developed an approach for using auxiliary variables to recover
information from censored observations in survival analysis using a joint longitudi-
nal and survival model and a multiple imputation procedure for the event times of
censored subjects. Conlon, et al. (2011) considered the use of recurrence time as an
auxiliary variable for overall survival by building separate models for time to recur-
rence and time to death. A cure model was used to model time to recurrence and
a proportional hazards model with a Weibull baseline hazard function that included
recurrence as a time dependent covariate was used to model death. The model for
89
time to death was then used in a multiple imputation procedure to impute death
times for censored subjects, and these new data were used in the primary analyses
on overall survival. Using the same data as considered in this paper, they showed
modest but consistent gains in efficiency obtained by using the auxiliary information
in recurrence times. Here, we extend this idea by building a joint multi-state model
with an incorporated cured fraction for recurrence and death and use this model to
impute death times for censored subjects with the goal of improving the efficiency of
the analysis on overall survival. The model proposed here, while more complex and
more difficult to estimate than the model used by Conlon, et al. (2011), utilizes the
full data likelihood rather than a two-step procedure and offers the potential for larger
gains in efficiency. The multi-state model also allows for adaptation to the imputation
model on any of the individual sub-models that may lead to further efficiency gains.
The model that we propose for the recurrence and death events is a multi-state
model with a cured fraction, described in detail in Chapter IV. This model is moti-
vated by the disease process in colon cancer clinical trials. In these trials there are
two outcomes of interest, recurrence and death, where death can occur either without
prior recurrence or after a recurrence. Additionally, a proportion of subjects censored
for recurrence may be cured of disease, and would therefore have never experienced
a recurrence even if they had been followed for longer. For other censored subjects,
their recurrence time would occur after their censoring time with longer follow-up
and is therefore unobserved. To model these data, we use a multi-state model with
an incorporated cured fraction that jointly models the probability of being cured of
disease and the hazard of transitioning between disease states. A brief description of
this model is given here, with full details given in Chapter IV of this dissertation.
Our model includes four hazards for transitioning between the four disease states
90
which include: alive and cured of disease, alive and uncured of disease, alive with
recurrence and death. Transitions between these states are described by the multi-
state model. Multi-state models (Anderson and Keiding, 2002; Meira-Machado, et
al. 2009; Putter, Fiocco and Geskus, 2007) are a common way to jointly model
disease progression events by describing the progressions and transitions over time to
the various disease states through transition intensities, which can include covariates,
and provide the hazards for moving between states. The hazard of each transition is
modeled using a proportional hazard model with Weibull baseline hazard function.
The cured fraction is modeled using the mixture model formulation of the cure model,
introduced by Berkson and Gage (1952).
The proposed parametric model itself can be used to obtain efficiency gains relative
to Kaplan-Meier estimates in the estimation of quantities of interest such as the
difference in five year survival and the difference in three year disease free survival
between treatment arms can be derived. Once parameter estimates from the model
are obtained, the estimated five year survival and three year disease free survival can
be computed from the model, with the point estimates and standard errors compared
to the five year Kaplan-Meier survival estimate and the three year Kaplan-Meier
disease free survival estimate, respectively. In addition to gains in efficiency due to the
parametric assumptions, the multi-state model incorporates recurrence information
which also contributes to efficiency gains in estimating this quantity from the model
as compared to the Kaplan-Meier estimate.
In an alternative way to gain efficiency in the estimation of overall survival, the
model can be used in a slightly weaker way by utilizing it in a multiple imputation
procedure to impute death times for censored subjects. Patients who are alive at the
time of their last follow-up are right censored for death, which we consider as a form
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of missing data. A patient’s recurrence status prior to their censoring time is usually
known, and those who experience a recurrence are likely to die sooner than those
who are recurrence free. Therefore, the information on a patient’s recurrence time
and status may be useful in predicting their survival time.
Multiple imputation is a common strategy for dealing with missing data problems
(Rubin, 1978) and has been used to impute missing event times for censored obser-
vations in survival analysis (Faucett, et al. 2002; Hsu, et al. 2006). This strategy
fills in missing values by drawing from the posterior predictive distribution of the
missing data given the observed data. The procedure is then independently repeated
M times to produce separate datasets. These completed datasets can then be ana-
lyzed separately to get estimates of overall survival, such as Cox model estimates and
Kaplan-Meier estimates and their standard errors, and log-rank tests. The results
from each of these analyses are then combined following established rules (Rubin,
1987), with potential gains in efficiency obtained as compared to an analysis of the
original data.
We explore the use of some plausible restrictions that may be placed on model
parameters and the effect of these restrictions on the amount of efficiency gained in the
final analysis of the imputed data and in the estimation of model derived quantities
relating to survival. Additionally, we can obtain model based survival estimates and
apply the imputation procedure using estimates obtained from a hierarchical model
that facilitates the sharing of information from covariates with consistent effects across
trials and assess efficiency gains. The efficiency gains obtained in the treatment effect
estimates offer the potential for the length of trials to be shorter and for the sample
size of trials to be smaller.
The remainder of the paper is organized as follows: Section 5.2 describes the data
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and Section 5.3 describes the proposed model. In Section 5.4, ways in which efficiency
can be gained from the model or the trial can be shortened are explored. Section 5.5
provides details and results of the imputation procedure and simulation results are
provided in Section 5.6. Section 5.7 concludes with a discussion.
5.2 Data Description
The data we consider consist of a total of 13,983 subjects from 12 randomized
phase III adjuvant trials of locally advanced colon cancer. Ten of the trials are
included in the Sargent, et al. (2005) publication, with two additional new trials. A
detailed description of these data can be found in Chapter IV of this dissertation.
These 12 trials were previously analyzed by Conlon, et al. (2011), where a separate
cure model and Weibull model were used to model recurrence and death, respectively.
Of the 4346 observed recurrences, 3448 (79.3%) occurred within three years, 4075
(93.8%) occurred within five years, and 4281 (98.5%) occurred within seven years.
This type of event data where very few events happen after a fixed window of time is
characteristic of a cured group. Kaplan-Meier plots of time to recurrence show a clear
leveling off, indicating that this is data for which a cure model is appropriate. For
subjects who experienced a recurrence, 44.5% died within one year, 67.9% died within
2 years and 78.9% died within 3 years. Table 5.1 provides Kaplan-Meier estimates
of three year survival after recurrence for each trial. These estimates range from a
survival probability of 0.10 in trial 6 and 0.30 in trial 12, demonstrating the high
likelihood of dying quickly after recurring. Baseline covariates include age, cancer
stage and treatment arm. Each trial compared a different pair of treatments, with
one defined as the control arm and the other as the experimental arm. Five of the trials
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(1,2,3,6 and 7) compared surgery alone to surgery plus some form of chemotherapy. In
the other seven trials, both arms contained surgery plus some form of chemotherapy.
The primary goal of all 12 trials was to compare overall survival between the pairs of
treatments. A summary of the stage, age and treatment distributions for each trial,
as well as the number of recorded recurrences and deaths and longest follow-up time
for each trial can be seen in Table 4.1.
Table 5.1: Kaplan-Meier estimates for three year survival after recurrence for 12 trials
3 Year Survival
After Recurrence (95% CI)
Trial 1 0.13 (0.08, 0.21)
Trial 2 0.13 (0.08, 0.20)
Trial 3 0.16 (0.12, 0.20)
Trial 4 0.15 (0.12, 0.19)
Trial 5 0.21 (0.17, 0.26)
Trial 6 0.10 (0.07, 0.15)
Trial 7 0.24 (0.19, 0.31)
Trial 8 0.15 (0.12, 0.19)
Trial 9 0.15 (0.12, 0.18)
Trial 10 0.19 (0.16, 0.22)
Trial 11 0.25 (0.21, 0.30)
Trial 12 0.30 (0.26, 0.34)
5.3 Multistate model
We model the data from the 12 trials using a multi-state model with a cured
fraction, as described in Chapter IV. We provide a brief description of this model
here. Full details of the model can be found in Chapter IV. The proposed model
jointly models the recurrence and death events as well as a latent incorporated cured
fraction for the recurrence event. Deaths can occur either without a prior recurrence
or following a recurrence. The deaths that occur without a prior recurrence are
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known not to be directly due to the regrowth of the cancer, while deaths following a
recurrence may be due to the cancer or other causes. Cause of death is not available
and not considered in our models. We use the multi-state model to model four
transition intensities between four disease states, as described in Chapter IV, and
illustrated in Figure 4.1. We define State 1 to be alive and cured of disease, State 2
to be alive and not cured, State 3 to be alive with recurrence and State 4 to be death.
We model four transition times which include 1→ 4, 2→ 3, 2→ 4, and 3→ 4.
5.3.1 Notation and model specifications
Let Cir and Tir be the censoring and event times for recurrence and let Cid and
Tid be the censoring and event times for death for the ith subject, i = 1, ...n. Then
Yir = min(Cir, Tir) and the event indicator for recurrence, δir = I(Tir ≤ Cir), and
Yid = min(Cid, Tid) and the event indicator for death, δid = I(Tid ≤ Cid), are observed.
Let Zi, Si and Ai represent the baseline values of treatment group, cancer stage and
age for each subject.
Both the models for the time of entry into each state and for the probability of
cure, p, can depend on covariates. The multi-state process is characterized through
transition intensities defined as:
λkj(t) = lim∆t→0 pkj(t, t+ ∆t)/∆t
where pkj(s, t) = P (X(t) = j|X(s) = k,Hs−), for s ≤ t is the probability of being in
State j at time t, given that the process was in State k at time s and the history of
the process, Hs−. λkj(t) is then the instantaneous hazard of entering State j, given
that the previous state occupied was State k. From this hazard, we can define the
survival distributions for each transient state and their probability density functions.
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We use a proportional hazards model with a Weibull baseline hazard function.
















For transitions 1 → 4 and 2 → 4, ti is a death time. For transition 2 → 3, ti is a
recurrence time and for transition 3 → 4, ti is the gap time between entry into the
recurred state and death. Xi represents a vector of subject specific covariates. For
transitions 1 → 4, 2 → 3, and 2 → 4, and for the probability of cure we include the
covariates age, treatment group and stage. For transition 3 → 4, we include these
variables as covariates and also include recurrence time as a covariate.
5.3.2 Estimation
We use a Bayesian MCMC technique to estimate the parameters of the multi-state
model. There are a total of 25 parameters to estimate for each of the trials which
include a shape (ρ) and scale (α) parameter from the Weibull model for each of the
hazard rates, covariate effects for each of the hazard models and covariate effects in
the logistic model for the probability of cure. We place informative Normal(0,0.252)
priors on the treatment and stage coefficients in transition 1→ 4 as treatment group
and cancer stage are unlikely to have much affect on the hazard of death in patients
who are cured of disease. We place Normal(0,22) priors on the log(α)’s and gamma
priors with mean 1 and standard deviation 0.6 on the ρ’s. Normal(0,1) are placed
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on all of the remaining covariate coefficients in the hazard models and in the logistic
model. The impact of these mildly informative priors is evaluated in Chapter IV
of this dissertation. To aid in estimation, at each iteration of the chain, subject’s
without recurrence are placed in either the cured or uncured group by drawing a
Bernoulli(ci) random variable, where ci is the probability of being cured of disease,
given Yid, Yir, Xi and the current parameter draws.
A Bayesian estimation scheme using the Metropolis Hastings algorithm is used
to obtain parameter draws from the posterior distribution. Appendix J provides the
full data likelihood and details of the algorithm. For each parameter, we obtain 5000
draws from its posterior distribution.
5.4 Efficiency gains from the model
The typical analysis of the treatment effect on overall survival would be estimates
of hazard ratios using Cox models and estimates of differences in survival at specific
times points. Since the multi-state cure model does not result in the proportional
hazard being satisfied for time to death, we focus mainly on estimates of overall
survival. Once parameter estimates for the model have been obtained, the multi-
state cure model can be used to estimate the difference in five year overall survival
(OS) between the two treatment arms. The point estimate can be compared with
the Kaplan-Meier estimate to check the model fit and the standard error estimate
can be compared with that of the Kaplan-Meier estimate to assess gains in efficiency
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which are the survival distributions for remaining in State 1 or State 2, respectively.
Then, for each subject we can calculate their five year OS probability as:








where θ is the vector of parameter values. This probability is calculated separately for
subjects in the treatment group and in the control group, and then averaged across
the stage and age covariate values for each subject and across all of the parameter
posterior draws to obtain a population estimate. Similarly, three year disease free
survival (DFS), defined as the time to the first event of either death or recurrence
and often used as a surrogate for five year OS, can be calculated from the model
and compared to the three year Kaplan-Meier DFS estimate to assess efficiency gains
from using the proposed model at the earlier time point. For each subject, three year
DFS is calculated as:
P (DFSi > 3|Xi, θ) = piS1(3) + (1− pi)S2(3).
This probability is then averaged across covariate values for each subject and across
all parameter draws. Using the above model derived quantities, we estimate the
treatment effect for these two separate endpoints of interest, five year OS and three
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year DFS. For trials such as these in locally advanced colon cancer, five year OS
is often considered the definitive endpoint. In this setting, three year DFS has been
determined to be a valid surrogate marker for five year OS. Therefore, there is interest
in the treatment effect estimate at both of these endpoints.
5.4.1 Application of model for efficiency gains and shortening trial length:
Model based estimates
The above modeling strategy could be used to shorten the length of a clinical trial.
To illustrate this, we artificially censor each of the 12 trials at either two years after
the last patient accrual, or at the minimum length of time after the last accrual that
provides at least 5.5 years of patient follow-up time. This artificial censoring resulted
in an overall 9.8% reduction in the number of recurrences across all trials compared
to the original data with a maximum of 15.4% in Trial 3 and a minimum of 4.3% in
Trial 9. The overall reduction in the number of deaths was 30.9% with a maximum
of 44.2% in Trial 7 and a minimum of 21.0% in Trial 9. Appendix O provides accrual
length and maximum follow-up times before and after the artificial censoring for the
12 trials. Estimates of five year OS and three year DFS can then be obtained using
parameter estimates from the multi-state cure model on the reduced follow-up data.
The point estimates and posterior standard deviations of these quantities can then
be compared to the Kaplan-Meier estimates from the full follow-up data to assess
gains in efficiency from using the multi-state model and whether these quantities can
correctly be estimated using shorter follow-up data.
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5.4.2 Model restrictions
Extensions and adaptations could be made to the proposed model that may pro-
vide a better fit to the data and provide gains in efficiency in estimating overall
survival. Li, et al. (2011) showed that when an intermediate variable captures even
just a modest amount of the treatment effect on the final outcome, efficiency gains of
the estimated treatment effect on the final outcome can be achieved by shrinking the
treatment effect estimate in the conditional distribution of the final outcome given
the intermediate variable and treatment toward 0. In our setting, it is plausible that
much of the treatment effect is captured in the recurrence event by affecting the prob-
ability of being cured of disease and the time to recurrence. Therefore, one strategy
to potentially improve efficiency gains in the estimation of the treatment effect on
overall survival is to fit the multi-state cure model with prior assumptions placed on
the treatment effects of some transition times. Specifically, the treatment effect on
time to death for those who are cured (1→ 4 transition) and the treatment effect on
time to death for those who are not cured but without recurrence (2→ 4 transition)
are likely close to zero as the treatment may affect the probability of being cured,
but after this most likely has little or no effect on the hazard of death from other
causes if the person does not die from cancer. The treatment effect on time to death
after recurrence (3 → 4 transition) is also likely near zero, as patients often go off
treatment or start new treatment regimens after a recurrence. We fit one restricted
model with the above mentioned treatment effects shrunk towards zero with the use
of tighter prior distributions and another restricted model with these treatment ef-
fects forced to be zero. All other covariates in the logistic model for the probability
of cure and in the transition time models are the same as the full model. The fit of
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the restricted models can be compared to that of the full model by calculating the
DIC values for each model. Table 5.2 provides the DIC values for comparing the full
model to the models with the treatment effects for transitions 1 → 4, 2 → 4 and
3→ 4 either shrunk to zero or forced to be zero for the 12 trials for the full follow-up
data and the reduced follow-up data, with the DIC of the best fitting model in bold.
For a majority of the studies, a restricted model is preferred over the full model in
both the full follow-up and reduced follow-up data.
Table 5.2: Model comparison by DIC values- Restrictions on treatment effect param-
eters β14, β24, β34
Full Follow-up Reduced Follow-up
Complete Model β14, β24, β34 β14 = β24 = β34 = 0 Complete Model β14, β24, β34 β14 = β24 = β34 = 0
Shrunk to 0 Shrunk to 0
Trial 1 1093.7 1093.6 1092.4 894.1 909.4 909.1
Trial 2 1789.4 1789.2 1792.0 1441.7 1440.8 1443.2
Trial 3 4206.5 4197.2 4204.3 2615.7 2611.0 2617.3
Trial 4 4392.7 4393.4 4389.5 3263.0 3144.5 3142.7
Trial 5 3572.5 3573.1 3571.9 2674.0 2635.7 2609.6
Trial 6 3607.8 3616.8 3607.3 2346.1 2361.4 2363.9
Trial 7 3176.4 3176.0 3174.2 1992.0 2010.3 2010.2
Trial 8 4084.6 4089.1 4085.2 3210.6 3244.2 3247.0
Trial 9 7677.2 7689.3 7675.2 6346.7 6338.3 6292.6
Trial 10 7706.4 7713.4 7703.9 5706.3 5683.1 5667.2
Trial 11 5225.7 5235.4 5229.9 3885.1 3823.2 3850.7
Trial 12 7172.9 7174.0 7172.6 6074.1 6027.2 6074.2
5.4.3 Hierarchical model
Another way to extend the use of the multi-state model and potentially improve
upon the efficiency gains is to borrow information for other trials by use of a hi-
erarchical model. The original multi-state models fit to each individual trial pro-
vide evidence for common effects of some covariates on the probability of cure and
transition rates. In particular, the coefficients associated with age and stage in all
of the sub-models were quite similar. In addition, the coefficients associated with
Tr in the 3 → 4 transition and the shape parameters of the Weibull models were
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similar across trials. We can therefore use a hierarchical model to borrow infor-
mation across trials and shrink selected parameters towards common values. To
illustrate this, we let ρskj ∼ N(ρkj, σ2ρkj)I(ρskj ≥ 0), βSTskj ∼ N(βSTkj, σ2βST kj),
βAGEskj ∼ N(βAGEkj, σ2βAGEkj), βTrs34 ∼ N(βTr34, σ
2
βTr34
), γSTskj ∼ N(γSTkj, σ2γST kj),
and γAGEskj ∼ N(γAGEkj, σ2γAGEkj), where kj = {12, 23, 24, 34} corresponds to the
transition and s = 1, ..., 12 represents the study number. We place Gamma hyper-
priors with mean 1 and standard deviation 1 on ρkj and on σρkj, σβST kj, σβAGEkj,
σβTrkj, σγST kj, and σγAGEkj and N(0, 2
2) hyper-priors on βAGEkj, βSTkj, βTrkj, γSTkj,
and γAGEkj. The remaining parameters are independent across studies. For the full
follow-up data, we borrow information across the trials for the above parameters by
fitting the hierarchical model once using all 12 trials. For the reduced follow-up data,
we fit the hierarchical model separately 12 times, each time with 1 trial artificially
censored and the remaining 11 with their full follow-up data. The parameter esti-
mates obtained from the hierarchical models can then be used in estimating five year
OS and three year DFS.
Table 5.3 provides the Kaplan-Meier estimates and standard errors and multi-state
model estimates and posterior standard deviations for five year OS and three year
DFS for the full follow-up data and the reduced follow-up data using the full multi-
state cure model, the multi-state cure model with restrictions on certain treatment
effect coefficients, and the hierarchical model. For the 12 trials considered, both
the five year OS estimates and the three year DFS estimates from the multi-state
model are similar to the Kaplan-Meier estimates, with moderate gains in efficiency
obtained by using the multi-state model, as seen by the smaller posterior standard
deviations. There is also a small amount of additional efficiency gained for some
trials in the estimation of five year OS using the restricted models. Estimating these
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quantities using estimates from the hierarchical model does not, in general, result
in efficiency gains, likely due to the fact that these are all randomized trials and
thus estimates for age and stage are likely to be at most weakly correlated with the
estimate for treatment. The point estimates from the reduced follow-up data tend
to be near those from the full follow-up data for both five year OS and three year
DFS, with posterior standard deviations that are very close to the standard errors
of the Kaplan-Meier estimates from the full follow-up data, indicating that similar
conclusions about treatment effects on these quantities would be drawn using the
reduced follow-up data and the multi-state model estimates as compared to the full
follow-up data Kaplan-Meier estimates.
5.5 Efficiency gains through imputation
5.5.1 Imputation strategy
An alternative way that the multi-state model with a cured fraction can be used to
improve efficiency in the estimation of overall survival is through a multiple imputa-
tion strategy that imputes death times for people who are censored for death. Using
the proposed model in a multiple imputation procedure is a less model dependent
approach than the estimation procedure in Section 5.4.1 because the model is only
used to aid in estimation of the missing data, with the end analysis of the original
data augmented by the imputed data. The multiple imputation approach could be
used to improve efficiency of the analysis of overall survival or to shorten the length
of a clinical trial while still keeping the primary endpoint of overall survival.
The imputation procedure is performed as follows. For each set of parameter
draws, θ, from the posterior distribution, we impute a death time from the resid-
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Table 5.3: Kaplan-Meier treatment effect estimates (standard errors) and multi-state
model estimates (posterior standard deviations) for 12 colon cancer trials
∆S(5)∗ ∆DFS(3)∗∗
Full Follow-up Reduced Follow-up Full Follow-up Reduced Follow-up
Trial 1 Kaplan-Meier 0.090 (0.062) 0.098 (0.070) 0.122 (0.062) 0.132 (0.071)
Full Model 0.105 (0.049) 0.107 (0.057) 0.150 (0.051) 0.141 (0.057)
β14, β24, β34 Shrunk to 0 0.106 (0.047) 0.112 (0.054) 0.146 (0.052) 0.142 (0.055)
β14 = β24 = β34 = 0 0.121 (0.046) 0.116 (0.055) 0.153 (0.052) 0.142 (0.057)
Hierarchical model 0.098 (0.045) 0.103 (0.055) 0.147 (0.054) 0.144 (0.056)
Trial 2 Kaplan-Meier 0.057 (0.049) 0.039 (0.049) 0.056 (0.047) 0.076 (0.050)
Full Model 0.051 (0.042) 0.053 (0.043) 0.068 (0.042) 0.070 (0.042)
β14, β24, β34 Shrunk to 0 0.051 (0.040) 0.048 (0.043) 0.066 (0.043) 0.066 (0.045)
β14 = β24 = β34 = 0 0.050 (0.038) 0.051 (0.041) 0.059 (0.042) 0.065 (0.046)
Hierarchical model 0.046 (0.041) 0.043 (0.043) 0.064 (0.042) 0.062 (0.044)
Trial 3 Kaplan-Meier 0.074 (0.031) 0.115 (0.080) 0.110 (0.031) 0.210 (0.086)
Full Model 0.072 (0.026) 0.050 (0.028) 0.113 (0.027) 0.121 (0.030)
β14, β24, β34 Shrunk to 0 0.081 (0.026) 0.098 (0.029) 0.119 (0.027) 0.137 (0.030)
β14 = β24 = β34 = 0 0.086 (0.022) 0.124 (0.027) 0.118 (0.028) 0.138 (0.029)
Hierarchical model 0.067 (0.027) 0.070 (0.029) 0.110 (0.029) 0.115 (0.029)
Trial 4 Kaplan-Meier -0.023 (0.037) 0.027 (0.043) 0.004 (0.037) -0.003 (0.042)
Full Model -0.024 (0.032) -0.010 (0.027) -0.015 (0.034) -0.003 (0.032)
β14, β24, β34 Shrunk to 0 -0.023 (0.031) -0.009 (0.034) -0.017 (0.032) -0.005 (0.035)
β14 = β24 = β34 = 0 -0.011 (0.024) -0.005 (0.031) -0.020 (0.033) -0.008 (0.033)
Hierarchical model -0.023 (0.031) -0.014 (0.033) -0.016 (0.032) -0.007 (0.035)
Trial 5 Kaplan-Meier -0.023 (0.031) -0.009 (0.035) -0.015 (0.031) -0.026 (0.035)
Full Model -0.032 (0.027) -0.029 (0.024) -0.017 (0.028) -0.018 (0.028)
β14, β24, β34 Shrunk to 0 -0.026 (0.026) -0.029 (0.031) -0.013 (0.027) -0.020 (0.032)
β14 = β24 = β34 = 0 -0.013 (0.020) -0.017 (0.029) -0.015 (0.028) -0.017 (0.031)
Hierarchical model -0.029 (0.027) -0.028 (0.029) -0.013 (0.029) -0.018 (0.030)
Trial 6 Kaplan-Meier 0.037 (0.036) 0.026 (0.042) 0.048 (0.035) 0.031 (0.041)
Full Model 0.009 (0.030) 0.004 (0.032) 0.033 (0.029) 0.032 (0.038)
β14, β24, β34 Shrunk to 0 0.009 (0.030) 0.010 (0.034) 0.028 (0.031) 0.032 (0.034)
β14 = β24 = β34 = 0 0.018 (0.025) 0.022 (0.031) 0.026 (0.030) 0.032 (0.033)
Hierarchical model 0.009 (0.030) 0.010 (0.030) 0.034 (0.032) 0.039 (0.030)
Trial 7 Kaplan-Meier 0.080 (0.035) 0.122 (0.045) 0.037 (0.035) 0.082 (0.041)
Full Model 0.039 (0.029) 0.051 (0.028) 0.040 (0.030) 0.043 (0.028)
β14, β24, β34 Shrunk to 0 0.039 (0.026) 0.052 (0.033) 0.041 (0.029) 0.045 (0.033)
β14 = β24 = β34 = 0 0.028 (0.020) 0.029 (0.027) 0.038 (0.028) 0.032 (0.032)
Hierarchical model 0.036 (0.029) 0.045 (0.030) 0.041 (0.031) 0.035 (0.030)
Trial 8 Kaplan-Meier 0.105 (0.028) 0.112 (0.031) 0.084 (0.028) 0.116 (0.031)
Full Model 0.095 (0.025) 0.085 (0.024) 0.103 (0.026) 0.096 (0.025)
β14, β24, β34 Shrunk to 0 0.096 (0.024) 0.105 (0.029) 0.103 (0.025) 0.107 (0.030)
β14 = β24 = β34 = 0 0.074 (0.019) 0.102 (0.027) 0.099 (0.024) 0.108 (0.028)
Hierarchical model 0.092 (0.025) 0.089 (0.024) 0.101 (0.025) 0.093 (0.024)
Trial 9 Kaplan-Meier 0.034 (0.021) 0.050 (0.026) 0.032 (0.021) 0.042 (0.022)
Full Model 0.034 (0.018) 0.028 (0.018) 0.039 (0.019) 0.042 (0.020)
β14, β24, β34 Shrunk to 0 0.035 (0.018) 0.040 (0.021) 0.041 (0.019) 0.050 (0.021)
β14 = β24 = β34 = 0 0.028 (0.014) 0.043 (0.019) 0.039 (0.019) 0.049 (0.021)
Hierarchical model 0.034 (0.018) 0.034 (0.018) 0.039 (0.019) 0.042 (0.019)
Trial 10 Kaplan-Meier 0.004 (0.019) 0.012 (0.021) 0.007 (0.018) 0.018 (0.022)
Full Model 0.012 (0.016) 0.015 (0.015) 0.010 (0.017) 0.008 (0.017)
β14, β24, β34 Shrunk to 0 0.011 (0.016) 0.018 (0.019) 0.009 (0.017) 0.010 (0.020)
β14 = β24 = β34 = 0 0.007 (0.013) 0.009 (0.018) 0.010 (0.016) 0.011 (0.020)
Hierarchical model 0.013 (0.016) 0.016 (0.016) 0.010 (0.017) 0.008 (0.017)
Trial 11 Kaplan-Meier -0.0001 (0.021) 0.026 (0.030) -0.005 (0.021) -0.033 (0.026)
Full Model 0.011 (0.018) 0.017 (0.017) -0.004 (0.019) -0.008 (0.019)
β14, β24, β34 Shrunk to 0 0.006 (0.017) 0.011 (0.021) -0.006 (0.019) -0.007 (0.022)
β14 = β24 = β34 = 0 -0.001 (0.012) -0.008 (0.018) -0.007 (0.019) -0.009 (0.021)
Hierarchical model 0.009 (0.017) 0.016 (0.019) -0.006 (0.019) -0.002 (0.020)
Trial 12 Kaplan-Meier 0.018 (0.017) 0.029 (0.019) 0.032 (0.017) 0.048 (0.020)
Full Model 0.017 (0.015) 0.008 (0.013) 0.033 (0.017) 0.035 (0.016)
β14, β24, β34 Shrunk to 0 0.018 (0.015) 0.020 (0.018) 0.034 (0.016) 0.041 (0.019)
β14 = β24 = β34 = 0 0.021 (0.010) 0.034 (0.015) 0.033 (0.016) 0.041 (0.019)
Hierarchical model 0.016 (0.014) 0.016 (0.016) 0.032 (0.015) 0.033 (0.017)
∗∆S(5) = P (T > 5|Zi = 1)− P (T > 5|Zi = 0)
∗∗∆DFS(3) = P (DFS > 3|Zi = 1)− P (DFS > 3|Zi = 0)
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ual survival distribution, P (Tid > Yid + ai|Tid > Yid, δid = 0, Yir, δir, Xi, θ), for each
censored subject. Specifically, we set this function equal to a u ∼ U(0, 1) random
variable and solve for ai, the imputed time to death after Yid for each censored sub-
ject. For subjects with a recurrence prior to their censoring time (δir = 1), we







for ai. For subjects censored for recurrence
(δir = 0) we first calculate their probability of being in the cured group by drawing
a Bernoulli(ci) random variable, where ci is the probability of being cured of dis-
ease, given Yid, Yir, Xi and the current parameter draws. For subjects censored for




piλ14(Yid)δidS1(Yid) + (1− pi)λ24(Yid)δidS2(Yid)























and for those placed in the uncured group, we solve u = g(Yid+ai)
g(Yid)
for ai, where:























For each subject, we solve the appropriate equation using every 10th draw from the
posterior distribution of the parameters, giving a total of 500 data sets with imputed
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death times for censored subjects. The imputed death times are censored at the
longest follow-up time for a study. With death as the endpoint of interest, these new
imputed times are combined with the observed data and compared to analyses of the
original data to assess efficiency gains. Specific estimates of interest that are compared
include the treatment effect estimates from a Cox model (which also includes stage
and age as covariates), the log rank statistics, and the five year Kaplan Meier survival
estimates. Parameter estimates and standard errors of the Kaplan Meier estimate and
from the Cox model are obtained using the rules for multiple imputation established
by Rubin (1987). Log-Rank test Chi-Square statistics are combined using the methods
of Li, et al. (1991). Table 5.4 provides results from the analyses on the original data
and on the imputed data. The point estimates are consistent across the analyses,
suggesting that there was no distortion of the results introduced by the imputation,
but there is little gain in efficiency from using the imputed data. This is likely due
to the fact that these trials all had good follow-up. In the following section, we
demonstrate the potential of the model to shorten the length of a trial by artificially
censoring the 12 trials at an earlier time point and demonstrating the recovery of lost
information due to censoring through the imputation procedure.
5.5.2 Application of model for efficiency gains and shortening trial length:
Multiple Imputation
The artificially censored data described in Section 5.4.1 can be used to illustrate
the use of the multiple imputation procedure in shortening the length of a clinical
trial. We use the multiple imputation procedure described in Section 5.5.1 on the
reduced follow-up data with death as the endpoint of interest. These analyses are
then compared to analyses of the original, full follow-up data to assess efficiency
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Table 5.4: Analysis of the effect of treatment on survival, from original data, and
data with imputation
Study Data Log-Rank Cox model 5 year KM
P-Value Log Hazard Ratio (SE) Estimate (SE)
1 Original 0.224 -0.28 (0.188) 0.090 (0.062)
Imputed 0.149 -0.31 (0.183) 0.092 (0.062)
2 Original 0.094 -0.25 (0.155) 0.057 (0.049)
Imputed 0.105 -0.24 (0.154) 0.054 (0.048)
3 Original 0.004 -0.31 (0.098) 0.074 (0.031)
Imputed 0.007 -0.30 (0.098) 0.073 (0.031)
4 Original 0.642 0.05 (0.111) -0.023 (0.037)
Imputed 0.704 0.05 (0.109) -0.021 (0.037)
5 Original 0.352 0.09 (0.109) -0.023 (0.031)
Imputed 0.464 0.06 (0.108) -0.021 (0.031)
6 Original 0.804 -0.04 (0.101) 0.037 (0.036)
Imputed 0.734 -0.04 (0.100) 0.037 (0.036)
7 Original 0.075 -0.19 (0.115) 0.080 (0.035)
Imputed 0.070 -0.21 (0.114) 0.077 (0.035)
8 Original 0.0003 -0.37 (0.103) 0.105 (0.028)
Imputed 0.0004 -0.35 (0.102) 0.105 (0.028)
9 Original 0.037 -0.16 (0.077) 0.034 (0.021)
Imputed 0.026 -0.17 (0.077) 0.034 (0.021)
10 Original 0.855 -0.02 (0.076) 0.004 (0.019)
Imputed 0.788 -0.02 (0.076) 0.004 (0.018)
11 Original 0.838 0.008 (0.096) -0.0001 (0.021)
Imputed 0.930 0.02 (0.095) -0.002 (0.021)
12 Original 0.090 -0.14 (0.086) 0.018 (0.017)
Imputed 0.080 -0.14 (0.086) 0.018 (0.017)
gains. Table 5.5 provides log rank statistics, Cox model log hazard ratios and five
year Kaplan-Meier estimates from the original, artificially censored and imputed data.
The log rank tests and Cox models were stratified by cancer stage and the Cox models
also included age as a covariate. The imputation procedure on the reduced follow-up
data is performed using estimates obtained from the full multi-state cure model, the
multi-state cure model with restrictions on some treatment effect coefficients, and
the hierarchical model. The point estimates from the imputed data tend to be in
between those of the original data and the reduced follow-up data, indicating that
some of the information lost due to early censoring was correctly recovered using
the imputation procedure. Gains in efficiency in the estimation of the log hazard
ratio was achieved for some trials, as indicated by the smaller standard errors. The
standard errors of the Kaplan-Meier estimates from the imputed data are consistently
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smaller than those of the artificially censored data, and in many cases are very close
to the standard errors of the original data. The point estimates resulting from the
imputation procedure on the restricted models are nearly identical to those obtained
using the full multi-state model, and for most trials, the standard errors from the
imputation procedure on the restricted models are the same, or only barely smaller
than those obtained through the use of the full model. This is likely because for these
trials, much of the efficiency lost due to early censoring was recovered through the
imputation procedure that uses the recurrence time information with the full multi-
state model, leaving little further efficiency to be gained through the use of the more
restricted models. There is no gain in efficiency in estimating the treatment effects
on overall survival by using hierarchical model, probably due to the fact that these
are all randomized trials and thus estimates for age and stage are likely to be at most
weakly correlated with the estimate for treatment. Hence improving estimates for
age and stage through the use of the hierarchical model could have limited impact on
summary measures of the treatment effect. Table 5.5 also provides results using the
modeling and imputation procedure of Conlon, et al. (2011). For these 12 trials, the
simpler method of Conlon, et al. (2011) which models overall survival with recurrence
as a time dependent covariate and bases the multiple imputation procedure off of this
model appears to perform similarly to the more complex multi-state model with a
cure fraction.
5.6 Simulations
We conduct simulations to examine the performance of the proposed imputation
method using the multi-state cure model under the full and restricted models. We
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Table 5.5: Analysis of the effect of treatment on survival, from original data, censored
data and censored data with imputation
Study Data Log-Rank Cox model 5 year KM
P-Value Log Hazard Ratio (SE) Estimate (SE)
1 Original 0.136 -0.28 (0.188) 0.090 (0.062)
Censored 0.035 -0.45 (0.214) 0.098 (0.070)
Imputed Censored 0.047 -0.39 (0.197) 0.104 (0.063)
Imputed Censored, β14, β24, β34 shrunk to 0 0.045 -0.39 (0.197) 0.105 (0.063)
Imputed Censored, β14 = β24 = β34 = 0 0.040 -0.40 (0.197) 0.105 (0.063)
Imputed Censored, hierarchical model 0.057 -0.38 (0.203) 0.102 (0.063)
Conlon, et al. (2011) method 0.117 -0.31 (0.199) 0.101 (0.065)
2 Original 0.097 -0.25 (0.155) 0.057 (0.049)
Censored 0.255 -0.20 (0.179) 0.039 (0.049)
Imputed Censored 0.187 -0.23 (0.176) 0.051 (0.049)
Imputed Censored, β14, β24, β34 shrunk to 0 0.199 -0.23 (0.177) 0.051 (0.049)
Imputed Censored, β14 = β24 = β34 = 0 0.179 -0.24 (0.176) 0.051 (0.049)
Imputed Censored, hierarchical model 0.215 -0.22 (0.178) 0.048 (0.049)
Conlon et al. (2011) method 0.203 -0.22 (0.175) 0.053 (0.050)
3 Original 0.002 -0.31 (0.098) 0.074 (0.031)
Censored 0.045 -0.27 (0.131) 0.115 (0.080)
Imputed Censored 0.036 -0.26 (0.124) 0.076 (0.033)
Imputed Censored, β14, β24, β34 shrunk to 0 0.010 -0.31 (0.118) 0.082 (0.033)
Imputed Censored, β14 = β24 = β34 = 0 0.005 -0.33 (0.117) 0.092 (0.033)
Imputed Censored, hierarchical model 0.027 -0.27 (0.122) 0.072 (0.033)
Conlon et al. (2011) method 0.039 -0.25 (0.118) 0.068 (0.034)
4 Original 0.719 0.06 (0.111) -0.023 (0.037)
Censored 0.912 -0.005 (0.134) 0.027 (0.043)
Imputed Censored 0.843 0.003 (0.132) -0.005 (0.038)
Imputed Censored, β14, β24, β34 shrunk to 0 0.832 0.02 (0.130) -0.006 (0.038)
Imputed Censored, β14 = β24 = β34 = 0 0.841 0.01 (0.131) -0.004 (0.038)
Imputed Censored, hierarchical model 0.823 0.01 (0.132) -0.002 (0.038)
Conlon et al. (2011) method 0.739 0.05 (0.131) -0.007 (0.038)
5 Original 0.355 0.09 (0.109) -0.023 (0.031)
Censored 0.459 0.10 (0.134) -0.009 (0.035)
Imputed Censored 0.374 0.11 (0.129) -0.020 (0.032)
Imputed Censored, β14, β24, β34 shrunk to 0 0.405 0.10 (0.125) -0.019 (0.032)
Imputed Censored, β14 = β24 = β34 = 0 0.459 0.09 (0.124) -0.017 (0.032)
Imputed Censored, hierarchical model 0.385 0.11 (0.128) -0.019 (0.032)
Conlon et al. (2011) method 0.443 0.09 (0.121) -0.019 (0.034)
6 Original 0.695 -0.04 (0.101) 0.037 (0.036)
Censored 0.518 -0.08 (0.126) 0.026 (0.042)
Imputed Censored 0.451 -0.09 (0.122) 0.024 (0.037)
Imputed Censored, β14, β24, β34 shrunk to 0 0.384 -0.11 (0.121) 0.026 (0.038)
Imputed Censored, β14 = β24 = β34 = 0 0.387 -0.10 (0.119) 0.026 (0.037)
Imputed Censored, hierarchical model 0.465 -0.09 (0.123) 0.023 (0.038)
Conlon et al. (2011) method 0.578 -0.06 (0.119) 0.019 (0.036)
7 Original 0.053 -0.20 (0.115) 0.080 (0.035)
Censored 0.027 -0.33 (0.156) 0.122 (0.045)
Imputed Censored 0.027 -0.31 (0.147) 0.079 (0.036)
Imputed Censored, β14, β24, β34 shrunk to 0 0.026 -0.31 (0.144) 0.078 (0.036)
Imputed Censored, β14 = β24 = β34 = 0 0.037 -0.28 (0.142) 0.074 (0.036)
Imputed Censored, hierarchical model 0.026 -0.31 (0.147) 0.077 (0.036)
Conlon et al. (2011) method 0.014 -0.35 (0.146) 0.081 (0.037)
8 Original 0.0004 -0.36 (0.103) 0.105 (0.028)
Censored 0.0005 -0.41 (0.119) 0.112 (0.031)
Imputed Censored 0.0005 -0.40 (0.117) 0.103 (0.029)
Imputed Censored, β14, β24, β34 shrunk to 0 0.0005 -0.40 (0.115) 0.104 (0.029)
Imputed Censored, β14 = β24 = β34 = 0 0.0005 -0.40 (0.115) 0.103 (0.029)
Imputed Censored, hierarchical model 0.0005 -0.40 (0.117) 0.103 (0.029)
Conlon et al. method 0.0004 -0.41 (0.116) 0.103 (0.030)
9 Original 0.041 -0.16 (0.077) 0.034 (0.021)
Censored 0.105 -0.14 (0.087) 0.050 (0.026)
Imputed Censored 0.083 -0.15 (0.086) 0.035 (0.021)
Imputed Censored, β14, β24, β34 shrunk to 0 0.080 -0.15 (0.086) 0.035 (0.021)
Imputed Censored, β14 = β24 = β34 = 0 0.071 -0.15 (0.085) 0.035 (0.021)
Imputed Censored, hierarchical model 0.082 -0.15 (0.086) 0.035 (0.021)
Conlon et al. (2011) method 0.113 -0.14 (0.086) 0.035 (0.021)
10 Original 0.827 -0.02 (0.076) 0.004 (0.019)
Censored 0.398 -0.08 (0.092) 0.012 (0.021)
Imputed Censored 0.502 -0.06 (0.091) 0.009 (0.019)
Imputed Censored, β14, β24, β34 shrunk to 0 0.511 -0.06 (0.089) 0.008 (0.019)
Imputed Censored, β14 = β24 = β34 = 0 0.585 -0.05 (0.088) 0.007 (0.019)
Imputed Censored, hierarchical model 0.488 -0.07 (0.091) 0.009 (0.019)
Conlonet al. (2011) method 0.505 -0.06 (0.088) 0.010 (0.019)
11 Original 0.907 0.007 (0.096) -0.0001 (0.021)
Censored 0.456 -0.08 (0.118) 0.026 (0.030)
Imputed Censored 0.623 -0.05 (0.117) 0.005 (0.022)
Imputed Censored, β14, β24, β34 shrunk to 0 0.758 -0.01 (0.114) 0.003 (0.022)
Imputed Censored, β14 = β24 = β34 = 0 0.812 0.008 (0.113) -0.0002 (0.022)
Imputed Censored, hierarchical model 0.672 -0.03 (0.116) 0.007 (0.022)
Conlon et al. (2011) method 0.622 -0.05 (0.111) 0.007 (0.022)
12 Original 0.083 -0.14 (0.086) 0.018 (0.017)
Censored 0.273 -0.09 (0.097) 0.029 (0.019)
Imputed Censored 0.255 -0.09 (0.094) 0.019 (0.018)
Imputed Censored, β14, β24, β34 shrunk to 0 0.194 -0.12 (0.092) 0.020 (0.018)
Imputed Censored, β14 = β24 = β34 = 0 0.140 -0.12 (0.091) 0.023 (0.018)
Imputed Censored, hierarchical model 0.226 -0.11 (0.095) 0.019 (0.017)
Conlon et al. (2011) method 0.230 -0.10 (0.091) 0.018 (0.018)
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compare the performance of the proposed method to that of Conlon, et al. (2011)
where the imputation of death times was based on a survival model with a time
dependent covariate for recurrence.
Recurrence times and death times were first simulated from the multi-state cure
model to give “original data” with long follow up. These times were then censored at
an earlier time to give “censored data”. The modeling and imputation strategy are
then performed on the “censored data” using the full model, restricted models, and
the model of Conlon, et al. (2011) to give the “imputed censored data”. We then
assess the treatment effect on overall survival using the log-rank test, the estimated
relative hazard from a Cox model, and the five year Kaplan-Meier survival estimate.
Four different trial settings are explored, two with a treatment effect and two without
a treatment effect. For each setting, we generate 500 data sets, each with 500 subjects
per treatment arm, 750 subjects with stage 3 disease, and a five year accrual period
with eight years of additional follow-up to provide the “original data”. The “censored
data” is obtained by censoring these data sets either two years after the last accrual
(trials 1 and 3) or one year after the last accrual (trials 2 and 4) to provide a maximum
of seven years or six years, respectively, of follow-up time. The probability of being
cured of disease was first generated using pi =
exp(γ0+γ1Zi+γ2Si)
(1+exp(γ0+γ1Zi+γ2Si))
, where Zi denotes
treatment group and Si denotes stage. Each of these covariates are centered at 0 so
that Zi is equal to -0.5 for the control group and 0.5 for the treatment group and Si
is equal to -0.75 for stage 2 disease and 0.25 for stage 3 disease. We set γ0 = 0.8,
γ1 = −0.4 and γ2 = −1 in trials 1 and 2 and γ0 = 0.8, γ1 = 0 and γ2 = −1 in trials 3
and 4. For those who are cured of disease, we then generate a death time using hazard
model for transition 1→ 4 with log(λ14)= 4, ρ14 = 1.5, and the treatment and stage
effects set to 0. For those who are not cured of disease, we generate a recurrence time
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using the hazard model for transition 2→ 3 with log(λ23)= 1, ρ23 = 1.5, βst23 = 0.7,
and βtrt23 equal to -0.3 in trials 1 and 2 and 0.0 in trials 3 and 4, and a death time
using the hazard model for transition 2 → 4 with log(λ24)= 4, ρ24 = 1.5 and the
treatment and stage effects set to 0. If the death time for uncured subjects is less
than the recurrence time, then a 2→ 4 transition is made at the death time and the
recurrence is censored at the death time. If the recurrence time is less than the death
time, then a 2 → 3 transition is made at that time. For those who recur, the time
between their recurrence and death is generated using the hazard model for transition
3→ 4 with log(λ34)= 1.1, ρ34 = 0.9 βtrt34 = 0, βst34 = 0.3, and βTr = −0.1.
Tables 5.6 and 5.7 provide the size of the log-rank test and the average of the
estimated log hazard ratio for the treatment coefficient from a Cox model, both
stratified by stage, as well as the average Kaplan-Meier estimate of the difference in
five year survival between the treatment and control group. The empirical standard
deviations (SD) and average standard errors (S̄E) for these estimates is also provided.
Additionally, for the null cases (trials 3 and 4) coverage rates for the Cox model log
hazard ratio estimate and Kaplan-Meier five year survival difference are given. For
each trial, the first row provides estimates for the data with a long follow-up period
following the accrual period, which we call the “original data”. The second row
provides estimates for the data where all subjects could have the maximum amount
of follow-up time given in the artificially censored data. These two rows provide
a basis of comparison for the estimates obtained from the imputation procedure.
Comparison to the first row answers the question of whether or not the imputation
procedure performed on the reduced follow-up data results in similar conclusions to
those based on the full follow-up data, thus resulting in the potential to shorten the
length of the trial. Comparison to the second row answers the statistical question of
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the bias in the estimates from the imputation procedure which censors subjects at
the maximum follow-up time, as compared to those obtained when all subjects, from
the beginning of the study, can be followed for that length of time. We note that the
Cox model estimates for the treatment effect differ between the first two rows. This
is because the proportional hazards assumption for time to death is not satisfied and
the first row is based on a much longer follow-up than the second row.
The results show that there is some efficiency gained by using the imputation pro-
cedure, and when there is no treatment effect, the procedure preserves type I error.
We note that the size of the log-rank test is slightly over conservative for the multiply
imputed data. This is likely related to the issue of uncongeniality discussed by Meng
(1994) and Rubin (1996), where the model used in creating the imputed data sets and
the model used for analyzing the imputed data differ. Here, the model used to create
the imputations was based on the multi-state model and utilized information on re-
currence to obtain the imputed survival times. In these settings where the imputation
model and analysis model differ due to auxiliary information used in the imputation
procedure, the inference with multiple imputation tends to be conservative, but more
efficient than inference done without multiple imputation (Meng, 1994). This uncon-
geniality between the imputation and analysis model is also likely the cause of the
slight discrepancy between the empirical standard deviations and average standard
errors, where the standard errors tend to be overly conservative.
The simulations demonstrate that some of the information lost due to early cen-
soring can be correctly recovered through the imputation procedure. In the settings
where there is a treatment effect on overall survival (trials 1 and 2), the Cox model
log hazard ratio estimates from the imputed data are in between that from the “cen-
sored data” and from the “original data”, and very close to the estimates from the “7
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year follow-up data” (in the case of trial 1) and the “6 year follow-up” data (in the
case of trial 2). The Kaplan-Meier estimates of the difference in five year survival are
estimated within minimal bias in all four trials, with some small gains in efficiency
obtained through the imputation procedure, as seen in the smaller standard devia-
tions and smaller average standard errors as compared to the reduced follow-up data.
There is a small amount of additional efficiency gained in all four settings by using the
restricted multi-state cure model that shrinks the treatment effect estimates β14, β24
and β34 to zero and some further efficiency gained in all four settings by restricting
these treatment effects to be 0. The method of Conlon, et al. (2011) has slightly
smaller average standard errors for the log hazard ratio estimate than those from the
multi-state cure models, but has larger empirical standard deviations, indicating that
there is a small amount of efficiency gained through the use of the multi-state cure
model.
Table 5.6: Multiple imputation simulation results: treatment effect
Data Trial 1: Treatment Effect, 2 year censored
Size of Cox model Log Hazard Ratio ∆S(5) KM ∆S(5) KM
Log-Rank Log Hazard Ratio (SD) S̄E Estimate (SD) S̄E
Original (max 13 year follow-up) 0.772 -0.30 (0.110) 0.111 0.064 (0.025) 0.025
7 year follow-up 0.778 -0.35 (0.126) 0.126 0.064 (0.025) 0.025
Censored (max 7 year follow-up) 0.731 -0.39 (0.155) 0.154 0.064 (0.028) 0.029
Imputed Censored 0.754 -0.37 (0.130) 0.142 0.063 (0.024) 0.026
Imputed Censored, β14, β24, β34 shrunk to 0 0.764 -0.37 (0.128) 0.142 0.063 (0.024) 0.026
Imputed Censored, β14 = β24 = β34 = 0 0.764 -0.37 (0.120) 0.140 0.063 (0.023) 0.026
Conlon, et al. (2011) method 0.792 -0.38 (0.133) 0.137 0.065 (0.025) 0.026
Trial 2: Treatment Effect, 1 year censored
Original (max 13 year follow-up) 0.772 -0.30 (0.110) 0.111 0.064 (0.025) 0.025
6 year follow-up 0.762 -0.36 (0.134) 0.134 0.064 (0.025) 0.025
Censored (max 6 year follow-up) 0.632 -0.41 (0.182) 0.176 0.067 (0.034) 0.033
Imputed Censored 0.678 -0.39 (0.152) 0.163 0.060 (0.025) 0.026
Imputed Censored, β14, β24, β34 shrunk to 0 0.700 -0.39 (0.141) 0.160 0.060 (0.023) 0.025
Imputed Censored, β14 = β24 = β34 = 0 0.719 -0.39 (0.132) 0.157 0.060 (0.021) 0.025
Conlon, et al. (2011) method 0.714 -0.40 (0.153) 0.156 0.060 (0.024) 0.025
113
Table 5.7: Multiple imputation simulation results: no treatment effect
Data Trial 3: No Treatment Effect, 2 year censored
Size of Cox model Log Hazard Ratio ∆S(5) KM ∆S(5) KM
Log-Rank Log Hazard Ratio (SD) S̄E Coverage Estimate (SD) S̄E Coverage
Original (max 13 year follow-up) 0.068 0.00 (0.117) 0.111 0.93 0.000 (0.026) 0.025 0.94
7 year follow-up 0.066 0.00 (0.131) 0.125 0.94 0.000 (0.026) 0.025 0.94
Censored (max 7 year follow-up) 0.052 0.00 (0.155) 0.152 0.95 0.000 (0.030) 0.029 0.93
Imputed Censored 0.040 0.00 (0.132) 0.140 0.96 0.000 (0.025) 0.026 0.96
Imputed Censored, β14, β24, β34 shrunk to 0 0.036 0.00 (0.130) 0.140 0.96 0.000 (0.024) 0.026 0.96
Imputed Censored, β14 = β24 = β34 = 0 0.028 0.00 (0.124) 0.138 0.97 0.000 (0.024) 0.026 0.97
Conlon, et al. (2011) method 0.062 0.00 (0.143) 0.136 0.93 0.000 (0.026) 0.026 0.94
Trial 4: No Treatment Effect, 1 year censored
Original (max 13 year follow-up) 0.068 0.00 (0.117) 0.111 0.93 0.000 (0.026) 0.025 0.94
6 year follow-up 0.064 0.00 (0.142) 0.133 0.93 0.000(0.026) 0.025 0.94
Censored (max 6 year follow-up) 0.046 0.00 (0.171) 0.174 0.93 0.000 (0.034) 0.033 0.96
Imputed Censored 0.018 -0.01 (0.143) 0.158 0.98 0.000 (0.023) 0.026 0.97
Imputed Censored, β14, β24, β34 shrunk to 0 0.020 -0.01 (0.139) 0.157 0.98 0.000 (0.023) 0.025 0.98
Imputed Censored, β14 = β24 = β34 = 0 0.018 -0.01 (0.131) 0.154 0.98 0.000 (0.022) 0.025 0.98
Conlon, et al. (2011) method 0.036 -0.01 (0.147) 0.154 0.96 0.001 (0.023) 0.025 0.93
∆S(5) = P (T > 5 | Zi = 1)− P (T > 5 | Zi = 0)
5.7 Discussion
In this chapter, we propose a modeling and imputation procedure to assess the use
of cancer recurrence as an auxiliary variable that can be used to improve efficiency
in the analysis of overall survival. We explore the effects of plausible restrictions on
model parameters and explore the use of a hierarchical model to assess the potential
for further efficiency gains. The results show modest but consistent gains in efficiency,
as measured by smaller standard errors, by using the information from recurrence
time, with the potential for further gains by adding more restrictions to the models
in certain settings. The methods presented could be useful in shortening the planned
length of a trial and in reducing sample sizes. Although the changes in the width of
the uncertainty intervals are only modest, sample size requirements are driven by the
square of the standard deviation. Hence, if the proposed methodology were adopted,
the size of trials could be reduced by 10% to 20%. These methods could also be useful
in aiding data safety and monitoring boards in deciding whether or not to end a trial
at the time of interim analysis.
We have considered several different ways in which the multi-state cure model
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can be used to improve efficiency in the analysis of overall survival. First, we ex-
plored analyses of survival using the model itself, with the parametric assumptions of
the model and recurrence time contributing to gains in efficiency. Next we explored
methods in which the model is utilized in a weak way along with recurrence time
information in a multiple imputation procedure to impute death times for censored
subjects, with treatment effect estimates of survival obtained by combining the anal-
yses from the multiply imputed data sets. We then placed restrictions on certain
model parameters and used this adapted model in the multiple imputation proce-
dure. Lastly, we explored the effects of utilizing external data to obtain parameter
estimates for the multi-state model that was then used in the imputation procedure.
In the setting explored here, the first method of obtaining estimates directly from
the model and the imputation procedure using the multi-state cure model with no
restrictions or external data were found to be most effective in obtaining efficiency
gains.
The standard error estimates in the simulations are slightly conservative compared
to the empirical standard deviations. As we noted, this is likely due to the unconge-
nialty of the imputation and analysis models. Robins and Wang (2000) have proposed
a variance estimator for multiple imputation that is consistent when the imputation
and analysis models differ that could be used to obtain a less conservative estimate,
however, it is computationally much more difficult to obtain. We have focused on
the situation of colon cancer, where there is a strong relationship between recurrence
time and death. Cook and Lawless (2001) have noted that gains in efficiency for the
estimation of survival distributions are often small when the intermediate variable
and survival time are not highly correlated. When the intermediate variable and true
endpoint are closely related, the use of parametric models and reasonable assumptions
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about the effect of covariates on individual processes of the disease may contribute
to further gains in efficiency. For example, there may be settings in which all of the
treatment effect is on the probability of being cured, or where all of the treatment
effect is on the hazard of recurrence for those who are uncured. In these settings,
adding restrictions to the treatment effect coefficients of the full model may play a
larger role in contributing to gains in efficiency in the analysis of overall survival.
CHAPTER VI
Discussion
The identification of valid surrogate markers and the use of intermediate outcomes
as auxiliary variables has important implications in the clinical trial setting. By
utilizing early information, trials could be run faster and more cheaply, and the early
outcome information could aid regulatory boards in making preliminary decisions
about drug approval. We have considered the use of intermediate variables both
as surrogate markers for the true outcome of interest and as auxiliary variables to
improve the efficiency of the estimation of the final outcome. For candidate surrogate
markers, we proposed modeling and validation methods to assess the surrogate value
of S. For auxiliary variables, we proposed a joint model for recurrence and death in
colon cancer and demonstrated ways in which the information on recurrence times
could be used to improve efficiency in the estimation of overall survival. In this
Chapter, we summarize the ideas presented in Chapters II, III, IV and V and discuss
potential future work in the area of intermediate variables.
In Chapters II and III, we work under the “principal surrogacy” framework in-
troduced by Frangakis and Rubin (2002) and propose quantities to assess surrogacy
from the conditional distribution of the causal treatment effect on T given the causal
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treatment effect on S. We first consider the scenario where the potential outcomes
of S and the potential outcomes of T follow a multivariate normal distribution. A
Bayesian estimation strategy is used to estimate the parameters in this model and, as
some parameters in the model are unidentifiable, informative priors consistent with
reasonable assumptions in the surrogate marker setting are used to aid in estimation.
The assumptions made include restricting the unidentified correlation parameters
to be positive, which seems plausible when the identifiable correlation parameters
(cor(S(0), T (0)) and cor(S(1), T (1))) are positive, and assumptions that pertain to
the relationship between the correlations of the across treatment arm surrogate and
final outcomes (cor(S(1), T (0)) and cor(S(0), T (1))) and the other pairwise correla-
tions. Specifically, we constrain the across treatment arm surrogate and final outcome
correlations to be smaller than the other pairwise correlations with either a probabil-
ity of 1 or probability of 0.8. It seems reasonable to assume that the across treatment
arm correlations of S and T would be smaller than the correlation between S and T
within the same treatment arm, or the correlation between S(0) and S(1) or T (0) and
T (1). These assumptions, along with the requirement that the covariance matrix be
positive definite, restrict the ranges of possible values for the unidentified parameters.
A variety of quantities from the conditional distribution of p(T (1)−T (0) | S(1)−S(0))
are explored. The proposed quantities of γ0 and γ1, which are the intercept and slope
parameters, respectively, of the causal treatment effect on T conditional on the causal
treatment effect on S, are useful measures and easily interpretable, however proving
γ0 = 0, a necessary condition for a valid surrogate, is difficult to do in practice. The
CEP graph is also a useful tool, as it provides a way to estimate the expected treat-
ment effects on T when treatment effects on S are at relevant clinical values. The
measures proposed all consider the distribution of the causal effect of treatment on
118
the outcome conditional on the causal effect of treatment on the surrogate and can
be used in combination to provide evidence about the validity of S as a surrogate
marker for T .
The ideas explored in Chapter II are extended in Chapter III to settings in which
the potential outcomes of S and the potential outcomes of T do not arise from a
multivariate normal distribution. Here, we consider an ordinal categorical variable
as a surrogate for a censored time-to-event final outcome and use a Gaussian copula
to model the joint distribution of the potential outcomes. We again explore the use
of different prior distributions for unidentified parameters. The model is applied to
data from a trial in advanced colorectal cancer, where disease progression is assessed
as a surrogate for overall survival. Using the proposed model, the expected ratio of
log survival times within each of the principal strata of S(1)−S(0) can be estimated.
The results obtained using the Gaussian copula model are compared to those that
would have been obtained using the methods of Chapter II had the model been
misspecified and the data analyzed as multivariate normal. The results show some
gains in efficiency by fitting the Gaussian copula model using the more appropriate
marginal distributions for the data than by assuming multivariate normality when it
may not hold. Both the methods of Chapter II and Chapter III could be extended
to settings where T is partially missing, and the Gaussian copula model could be
applied to data arising from other, non-normal distributions such as the Poisson.
An interesting area of future research concerning principal surrogacy is in the
relationship between the principal stratification framework and structural models.
In the causal inference literature, there are two types of general approaches. One is
based on potential outcomes in the principal stratification framework, and one is based
on structural or graphical models. While VanderWeele (2011) has argued that the
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principal stratification framework is more appropriate for the surrogacy question, it is
also of interest to explore the structural model approach. Surrogacy validation under
the principal surrogacy framework considers the distribution of the causal treatment
effect on T conditional on the principal strata of S. However, due to the counterfactual
nature of the principal surrogacy framework, assumptions must be made to aid in the
estimation of unidentified parameters. Consider the following structural models:
Si(0) = α0 + α2Ui + ε
Si(0)
Si(1) = α0 + α1 + α2Ui + ε
Si(1)
Ti(0) = β0 + β2Si + β3Ui + ε
Ti(0)
Ti(1) = β0 + β1 + β2Si + β3Ui + ε
Ti(1)
where Ui ∼ N(0, σ2u) and is a confounder in the relationship between S and T , and
εSi(0) ∼ N(0, σ2S0), εSi(1) ∼ N(0, σ2S1), εTi(0) ∼ N(0, σ2T0), and εTi(1) ∼ N(0, σ2T1) are
uncorrelated errors terms. The parameters from these equations could be related
to those of the multivariate normal model described in Chapter II. For the above
structural models, we have (Si(0), Si(1), Ti(0), Ti(1))



















































































This model relates to the correlation parameters of the multivariate normal model of
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In the structural model setting, assumptions must be made to estimate the regression
coefficients, as only α0 and α1 are fully identifiable from the observed data. Various
functions of these parameters are identified, however, and some parameter values
are restricted by the requirement that Σ be positive definite. We could therefore
explore the relationship between the effects of the assumptions on the structural
model parameters and the assumptions that were placed on the model in Chapter II
to aid in estimation in the principal surrogacy setting, such as constraining certain
correlation coefficients to be positive.
In Chapters IV and V, we propose a multi-state model with an incorporated cured
fraction to model recurrence and survival in colon cancer. This model is then utilized
in a multiple imputation strategy for censored death times that uses recurrence as
an auxiliary variable to improve efficiency in the estimation of overall survival. The
model and imputation strategy are applied to data from 12 randomized trials in colon
cancer. First, in Chapter IV we describe the model and its application. The proposed
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multi-state model with a cured fraction is motivated by the disease process of colon
cancer, where there is known to be a significant proportion of patients whose tumors
are completely eliminated by the treatment and are therefore considered cured of
disease. The proposed multi-state model with an incorporated cured fraction can
be used to examine the effects of different covariates on all of the various aspects
of the disease process, including the probability of being cured of disease, time to
recurrence for those who are uncured, time to death for those who are cured, time
to death without recurrence for those who are uncured but die before experiencing a
recurrence, and time to death after recurrence. We show consistent effects of many
covariates across the 12 trials. Once parameter estimates for the model are obtained,
quantities of interest such as the differences in five year survival and three year disease
free survival between treatment arms can be estimated. We show that the point
estimates of these quantities are consistent with the Kaplan-Meier estimates, with
some efficiency gained through the use of the multi-state cure model. Additionally,
we propose the use of Cox-Snell residual plots and deviance residual plots as ways
to visually assess the adequacy of the model fit. In the formulation of this model,
recurrence times are treated as known. The model could be easily adapted to reflect
the more realistic scenario of recurrence times that are interval censored between
clinic visits if this information were available. The model could also be extended to
allow the possibility for patients to return to the disease-free state after recurrence
for those who live a long time after their recurrence, likely due to subsequent therapy.
In Chapter V, we utilize the multi-state model with a cured fraction and propose
a multiple imputation strategy for patients who are censored for death. By using the
proposed joint model for recurrence and death, the information on recurrence can be
used as an auxiliary variable in predicting the death times of censored subjects, with
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the goal of improving efficiency in the estimation of the treatment effect on overall
survival. We show the potential of the multiple imputation strategy to shorten the
length of a clinical trial by artificially censoring the 12 trials and performing the
multiple imputation procedure. The analyses of overall survival from the imputed
data sets are combined, and the results are compared to the analyses of overall sur-
vival on the original data. We show that some of the information lost due to early
censoring can be recovered through the imputation procedure and demonstrate gains
in efficiency in the estimates obtained from the imputed data as compared to the
artificially censored data. Additionally, we demonstrate ways in which model adap-
tations and a hierarchical model could be used to further gains in efficiency obtained
through the imputation procedure. We show some small gains in efficiency through
the imputation procedure using the proposed multi-state model with a cured fraction
as compared to the simpler model used by Conlon, et al. (2011), where separate
models were used for recurrence and death. The proposed model and imputation
procedure could therefore be useful to data safety and monitoring boards in decid-
ing whether or not to end a trial at the time of an interim analysis. Additionally,
as sample size requirements are driven by the square of the standard deviation, the
size of trials could be reduced by 10% to 20% by adopting the proposed methods.
Other adaptations to the proposed model, besides those explored here, are possible
and may improve efficiency gains obtained through the imputation procedure. For
example, semi-parametric alternatives to the Weibull model could be explored. This
may be especially useful in the transition between recurrence and death, where there
appeared to be a potential lack of fit using the Weibull model. Using the generalized
Weibull model described by Foucher, et al. (2005) or a semi-parametric alternative
for this transition may improve the efficiency gains of the imputation procedure.
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There is future work that could be explored in the area of intermediate markers.
One concern that arises in the assessment of surrogate makers is the presence of the
“surrogate paradox”, where S and T are positively correlated, there is a positive
treatment effect on S but the treatment effect on T is negative. As we noted in
Chapter II, in the principal surrogacy setting if both average causal necessity and
average causal sufficiency hold, then the surrogate paradox is avoided. Methods for
detecting the presence of the surrogate paradox would be useful in the meta-analytic
setting, where information is available from a large number of trials and, given the
effect of the treatment on S in a new trial, we are interested in the expected effect of
treatment on the outcome in this trial. In this setting, it would be useful to have a
measure of the probability that an expected positive effect of the treatment on T given
a positive effect of the treatment on S is not due to chance variation. Buyse, et al.
(2000) proposed the following bivariate mixed model to describe the joint distribution
of S and T in the meta-analytic setting:
Sij = αS + βSZij + aSi + bSiZij + εSij
Tij = αT + βTZij + aTi + bTiZij + εTij


































We could consider the joint distribution of the treatment effect on S, βS + bSi , and
the treatment effect on T , βT + bTi , across the trials, and estimate the proportion
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of the CDF of this distribution that corresponds to surrogate consistency (where the
treatment effect on both S and T is positive and where the treatment effect on both S
and T is negative) relative to the proportion of the CDF where the surrogate paradox
would occur (opposite treatment effects on S and T ). The proportion of the CDF
corresponding to the region where the surrogate paradox does not occur is given by
1 − Φ1(0 | βS, daa) − Φ1(0 | βT , dbb) + 2Φ2((0, 0) | (βS, βT ),Γ), where Φk(x | Θ,Ψ) is
the CDF of a k−variate normal distribution with mean Θ and variance Ψ evaluated
at x and Γ =
daa dab
dbb
. This approach could also be used to focus on subgroups





Prior densities for MVN model parameters
Figure A.1: Density plots for MVN model correlation parameters under Beta priors
(a) ρ̂00 = ρ̂11 = 0.8
















(b) ρ̂00 = ρ̂11 = 0.5


















(c) ρ̂00 = ρ̂11 = 0.3















Quadratic equations obtained from |R| = 0
Each component of Q and R are drawn one at a time. When drawing each element
of R, the range of possible values must first be determined in order to satisfy the
positive definite requirement, given that the other correlations are held fixed. The
range of values corresponding to a positive definite matrix are those in the interval
determined by the roots of the quadratic equation that result from solving |R| = 0.




, where a, b, and c for each correlation is given in
the following table.
Table B.1: Quadratic Equation Elements for Correlation Ranges
Correlation a b c
ρs ρ2t − 1 2ρ00ρ10 + 2ρ01ρ11 − 2ρ00ρ11ρt − 2ρ01ρ10ρt 1− ρ200 − ρ201 − ρ210 − ρ211 − ρ2t + ρ200ρ211 + ρ210ρ201 + 2ρ10ρ11ρt + 2ρ00ρ01ρt − 2ρ00ρ11ρ01ρ10
ρ00 ρ211 − 1 2ρsρ10 + 2ρ01ρt − 2ρsρ11ρt − 2ρ01ρ10ρ11 1− ρ2t − ρ210 − ρ211 − ρ2s − ρ201 + ρ2sρ2t + ρ201ρ210 + 2ρ10ρ11ρt + 2ρsρ01ρ11 − 2ρsρ10ρ01ρt
ρ01 ρ210 − 1 2ρsρ11 + 2ρ00ρt − 2ρsρ10ρ11 − 2ρ00ρ11ρ10 1− ρ2s − ρ200 − ρ210 − ρ211 − ρ2t + ρ2sρ2t + ρ200ρ211 + 2ρ10ρ11ρt + 2ρ00ρ10ρs − 2ρsρ00ρ11ρt
ρ10 ρ201 − 1 2ρtρ11 + 2ρ00ρs − 2ρsρ01ρt − 2ρ00ρ11ρ01 1− ρ2s − ρ200 − ρ201 − ρ211 − ρ2t + ρ2sρ2t + ρ200ρ211 + 2ρ01ρ11ρs + 2ρ00ρ01ρt − 2ρsρ00ρ11ρt
ρ11 ρ200 − 1 2ρtρ10 + 2ρ01ρs − 2ρsρ00ρt − 2ρ00ρ01ρ10 1− ρ2t − ρ210 − ρ2s − ρ200 − ρ201 + ρ2sρ2t + ρ201ρ210 + 2ρ10ρ00ρs + 2ρtρ01ρ00 − 2ρsρ10ρ01ρt
ρt ρ2s − 1 2ρ10ρ11 + 2ρ00ρ01 − 2ρsρ01ρ10 − 2ρsρ00ρ11 1− ρ2s − ρ200 − ρ201 − ρ210 − ρ211 + ρ200ρ211 + ρ210ρ201 + 2ρsρ00ρ10 + 2ρ01ρsρ11 − 2ρ00ρ11ρ01ρ10
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APPENDIX C
Gibbs sampler details for MVN model
As the posterior distributions for the components of Q and R can not be easily
sampled from, draws are made using the griddy Gibbs sampler (Ritter and Tanner,
1992).
Let Y = (S(0), S(1), T (0), T (1)), and θ = (µ, S,R). We impute the unobserved






 ,Σ11 − Σ12Σ−122 Σ21
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µ(l) and each component of S and R are then drawn from their posterior distributions:
µ(l)|Σl−1, Y ∼ N((nΣ−1(l−1) + Σ−10 )−1(nΣ−1(l−1)Ȳ ), (nΣ−1(l−1) + Σ−10 )−1)
For i = 1, ...4





i=1(Y − µ)Σ−1(Y − µ)′
)






i=1(Y − µ)Σ−1(Y − µ)′
)
p(ρj),
where p(ρj) corresponds to the prior distribution for ρj. The four different sets of
priors considered are detailed in section 2.4.
As the posterior distributions for the σ’s and ρ’s can not be easily sampled from, the
griddy Gibbs algorithm is used as follows:
• Evaluate p(σYi |·) over a grid of m = 200 points, separated by hundredths to
obtain x1, x2, ..., xm. The grid for each σ is centered around the estimated
standard deviation from the observed data.
• Approximate the inverse cdf using the discrete approximation p(σYij) = xj/
∑m
k=1 xk.
• Sample a uniform (0,1) random variable and transform the observation using
the approximated cdf.
• Obtain posterior draws for each of σS0 , σS1 , σT0 , and σT1
• Posterior draws for each ρ are done similarly, but with the grid of values over
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which each posterior distribution is evaluated those which result in a positive
definite matrix.
APPENDIX D
Robustness to multivariate normality assumption
Table D.1: Simulation results under MVN model when multivariate normality does
not hold
Normal Marginals Multivariate Normal Multivariate t3 Multivariate Normal Log Normal Multivariate Normal
Parameter True Mean (SD) ¯PSD True Mean (SD) ¯PSD True Mean (SD) ¯PSD True Mean (SD) ¯PSD True Mean (SD) ¯PSD True Mean (SD) ¯PSD
Value Value Value Value Value Value
µs0 0 0.002(0.08) 0.08 0 0.01 (0.08) 0.08 4 3.99 (0.13) 0.13 4 3.99 (0.13) 0.14 4.48 4.46 (0.50) 0.44 4.48 4.49 (0.49) 0.46
µs1 1 1.00(0.08) 0.08 1 1.00 (0.09) 0.08 6 5.99 (0.13) 0.13 6 6.00 (0.14) 0.14 7.39 7.36 (0.81) 0.85 7.39 7.44 (0.88) 0.83
µt0 0 0.0001(0.09) 0.08 0 0.007 (0.09) 0.08 8.4 8.39 (0.13) 0.13 8.4 8.39 (0.13) 0.14 4.48 4.43 (0.46) 0.49 4.48 4.51 (0.47) 0.48
µt1 2 1.99(0.08) 0.08 2 1.99 (0.08) 0.08 10 9.99 (0.14) 0.13 10 10.00 (0.14) 0.14 6.69 6.65 (0.69) 0.77 6.69 6.73 (0.75) 0.75
σs0 1 1.01(0.06) 0.06 1 1.01 (0.06) 0.06 1.7 1.61 (0.25) 0.09 1.7 1.69 (0.11) 0.10 5.87 5.41 (0.46) 0.18 5.87 5.67 (0.15) 0.20
σs1 1 1.01(0.06) 0.06 1 1.02 (0.06) 0.06 1.7 1.59 (0.23) 0.09 1.7 1.68 (0.09) 0.10 9.69 10.46 (1.31) 0.35 9.69 10.14 (0.35) 0.44
σt0 1 1.01(0.06) 0.06 1 1.00 (0.06) 0.06 1.7 1.62 (0.26) 0.09 1.7 1.69 (0.10) 0.10 5.87 5.99 (0.68) 0.19 5.87 5.88 (0.18) 0.23
σt1 1 1.01(0.06) 0.06 1 1.01 (0.06) 0.06 1.7 1.61 (0.22) 0.09 1.7 1.68 (0.10) 0.10 8.76 9.39 (1.06) 0.31 8.76 9.17 (0.27) 0.41
ρ00 0.28 0.28(0.10) 0.07 0.28 0.27 (0.07) 0.07 0.8 0.76 (0.10) 0.03 0.8 0.78 (0.03) 0.04 0.73 0.72 (0.09) 0.05 0.73 0.70 (0.04) 0.05
ρ11 0.28 0.27(0.10) 0.07 0.28 0.28 (0.07) 0.07 0.8 0.76 (0.08) 0.03 0.8 0.78 (0.03) 0.03 0.72 0.76 (0.09) 0.04 0.72 0.72 (0.04) 0.04
ρs 0 0.37(0.07) 0.21 0 0.37 (0.06) 0.21 0.4 0.44 (0.09) 0.17 0.4 0.43 (0.08) 0.17 0.29 0.41 (0.09) 0.16 0.29 0.45 (0.08) 0.18
ρ01 0 0.17(0.05) 0.16 0 0.17 (0.04) 0.16 0.3 0.41 (0.10) 0.18 0.3 0.40 (0.08) 0.18 0.22 0.36 (0.10) 0.18 0.22 0.40 (0.08) 0.19
ρ10 0 0.18(0.06) 0.16 0 0.17 (0.04) 0.16 0.3 0.40 (0.09) 0.18 0.3 0.42 (0.08) 0.17 0.22 0.39 (0.10) 0.18 0.22 0.42 (0.08) 0.19
ρt 0 0.38(0.07) 0.21 0 0.37 (0.06) 0.21 0.4 0.42 (0.09) 0.17 0.4 0.41 (0.08) 0.17 0.28 0.39 (0.09) 0.18 0.28 0.43 (0.08) 0.18
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Table D.2: Simulation results: Bias, variability and coverage rate of surrogacy pa-
rameters when multivariate normality does not hold
Normal Marginals Multivariate normal
Parameter True Value Mean (SD) ¯PSD 95% Coverage True Value Mean (SD) ¯PSD 95% Coverage
β1 1.72 1.71(0.14) 0.13 0.94 1.72 1.71 (0.13) 0.13 0.95
β2 0.28 0.28(0.10) 0.07 0.83 0.28 0.27 (0.07) 0.07 0.95
β3 0 -0.004(0.15) 0.10 0.80 0 0.005 (0.11) 0.11 0.94
γ0 1.72 1.79(0.17) 0.30 0.99 1.72 1.80 (0.14) 0.29 0.99
γ1 0.28 0.20(0.12) 0.27 0.99 0.28 0.19 (0.09) 0.27 1
ρST 0.28 0.19 (0.11) 0.23 0.995 0.28 0.19 (0.08) 0.23 1
Φ10(0) 0.90 0.94 (0.02) 0.04 0.89 0.90 0.95 (0.02) 0.04 0.92
Multivariate t3 Multivariate Normal
β1 0 0.04 (0.86) 0.40 0.72 0 0.01 (0.37) 0.39 0.96
β2 0.8 0.77 (0.13) 0.05 0.73 0.8 0.79 (0.05) 0.05 0.93
β3 0 0.003 (0.18) 0.07 0.69 0 0.002 (0.07) 0.07 0.96
γ0 -0.07 0.27 (0.38) 0.51 0.93 -0.07 0.22 (0.26) 0.53 0.995
γ1 0.83 0.66 (0.18) 0.25 0.93 0.83 0.69 (0.11) 0.25 0.995
ρST 0.83 0.63 (0.14) 0.18 0.90 0.83 0.66 (0.08) 0.18 0.96
Φ10(0) 0.47 0.57 (0.10) 0.15 0.92 0.47 0.55 (0.08) 0.16 0.98
Log Normal Multivariate Normal
β1 0.67 0.71 (1.00) 0.72 0.87 0.67 0.61 (0.73) 0.75 0.94
β2 0.73 0.80 (0.14) 0.06 0.52 0.73 0.73 (0.04) 0.06 0.99
β3 -0.08 -0.11 (0.19) 0.07 0.51 -0.08 -0.07 (0.06) 0.07 0.98
γ0 0.30 0.48 (0.66) 0.83 0.99 0.30 0.55 (0.74) 0.91 0.99
γ1 0.65 0.61 (0.16) 0.18 0.93 0.65 0.57 (0.10) 0.21 1
ρST 0.70 0.64 (0.13) 0.15 0.96 0.70 0.59 (0.09) 0.18 1
Φ10(0) 0.52 0.53 (0.04) 0.05 0.99 0.52 0.53 (0.05) 0.05 0.98
Table D.3: Simulation results: principal surrogacy assessment when multivariate
normality does not hold
Model Normal Marginals MVNorm Multivariate t3 MVNorm Log Normal MVNorm
Truth
PS Invalid Surrogate Valid Surrogate Moderate Surrogate
Prentice Invalid Surrogate Valid Surrogate Invalid Surrogate
Estimation Results
γ0 = 0 Not Rejected, Reject γ1 = 0 0 0 0.82 0.91 0.92 0.84
γ0 = 0 Not Rejected 0.01 0.01 0.96 0.995 0.98 0.93
Reject γ1 = 0 0.02 0 0.84 0.91 0.92 0.90
Reject ρST = 0 0.02 0 0.84 0.91 0.92 0.90
Φ10(0) = 0.5 Not Rejected 0.01 0.01 0.96 0.995 0.98 0.93
Prentice Criteria Not Rejected 0 0 0.64 0.95 0.43 0.80
APPENDIX E
Assessment of normality in age-related macular
degeneration data
Histograms and normal QQ plots for observed age-related macular degeneration data. S is
change in visual acuity at 6 months and T is change in visual acuity at 1 year, both with
BLUP estimates subtracted off to account for random center effects.
Figure E.1: Histograms and normal QQ plots for age related macular degeneration
data














































































































































QQ plot to assess bivariate normality. The plots were obtained by plotting the or-
dered Mahalanobis d2 measures (dj = (Xj − X̄)′S−1(Xj − X̄)), j = 1, ..., n, S =
(1/n)
∑n











, d2(j)}nj=1 should be a
straight line under normality (Holgersson, 2006).
Figure E.2: QQ plots to assess bivariate normality for age related macular degenera-
tion data




































Assessment of normality in ovarian cancer data
Histograms and normal QQ plots for observed ovarian cancer data. S(1/4) is the
fourth root of progression free survival time, in months, and T (1/4) is the fourth root
of overall survival time, in months.
Figure F.1: Histograms and normal QQ plots for ovarian cancer data


























































































































































QQ plot to assess bivariate normality. The plots were obtained by plotting the or-
dered Mahalanobis d2 measures (dj = (Xj − X̄)′S−1(Xj − X̄)), j = 1, ..., n, S =
(1/n)
∑n











, d2(j)}nj=1 should be a
straight line under normality (Holgersson, 2006).
Figure F.2: QQ plots to assess bivariate normality for ovarian cancer data





































Posterior predictive plots for ovarian cancer data
For each of the 4 prior distributions, there are 8 plots, one for each combination of
surrogate and treatment value. Each of the plots shows the Kaplan-Meier plot of the
observed data at the give S and Z value, with the posterior predictive mean and 95%
credible interval obtained from the Gaussian copula model overlayed on top. The
plots show that the proposed model appears to provide an adequate fit to the data.
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Figure G.1: Kaplan Meier plots for original data and posterior predictive distribution
from Gaussian copula–No restriction on ρ’s
(a) S=1, Z=0
























































































































































































Figure G.2: Kaplan Meier plots for original data and posterior predictive distribution
from Gaussian copula-ρ ≥ 0
(a) S=1, Z=0
























































































































































































Figure G.3: Kaplan Meier plots from original data and posterior predictive distribu-
tion from Gaussian copula-ρ ≥ 0 and ρ10, ρ01 < ρs, ρt, ρ00, ρ11
(a) S=1, Z=0
























































































































































































Figure G.4: Kaplan Meier plots, original data and posterior predictive distribution-
Beta Priors
(a) S=1, Z=0
























































































































































































Histograms and normal QQ plots of transformed
colorectal cancer data.
Histograms and QQ plots of the observed S and T after a transformation to approximately normalize
them. For each observed S = s, a uniform random variable between s− 1 and s was draw, and for
T , the third root was taken. Marginal normality appears to hold for T 1/3, while the transformed S
is right skewed.
Figure H.1: Histograms and normal QQ plots of transformed colorectal cancer data































































































































QQ plots to assess bivariate normality. The plots were obtained by plotting the
ordered Mahalanobis d2 measures (dj = (Xj − X̄)′S−1(Xj − X̄)), j = 1, ..., n, S =
(1/n)
∑n











, d2(j)}nj=1 should be
a straight line under normality (Holgersson, 2006). In this case, bivariate normally
appears to hold.
Figure H.2: QQ plots to assess bivariate normality for transformed colorectal cancer
data








































Kaplan-Meier plots of time to recurrence for 12
trials in conlon cancer
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Figure I.1: Kaplan-Meier plots of time to recurrence for the 12 trials. Patients who
died without recurrence are censored for recurrence at that time.





















































































































































































































































































Details of multi-state cure model estimation
procedure
Define the following indicator functions:
RDi = I(δir = 1, δid = 1, Yir < Yid)
RDsi = I(δir = 1, δid = 1, Yir = Yid)
RAi = I(δir = 1, δid = 0, Yir < Yid)
RAsi = I(δir = 1, δid = 0, Yir = Yid)
RAsi = I(δir = 1, δid = 0, Yir = Yid)
NRDi = I(δir = 0, δid = 1, Yir < Yid)
NRAi = I(δir = 0, δid = 0, Yir < Yid)
NRDsi = I(δir = 0, δid = 1, Yir = Yid)
NRAsi = I(δir = 0, δid = 0, Yir = Yid)
Zi = I(ci = 1)
The observed data likelihood is given by:∏n











[(1− pi)λ24(Yid)S2(Yid) + (1− pi)
∫ Yid
Yir











































































exp(βtrt34Ti + βst34Si + βage34Ai + βTr34Yir)
The integrals:∫ Yir
0
λ23(u)S2(u)λ34(Yid − u)δidS3(Yid | u)du∫ Yid
Yir
λ23(u)S2(u)λ34(Yid − u)δidS3(Yid | u)du
were computed by adaptive quadrature using the ’integrate’ function in R.
The Metropolis-Hastings algorithm is used to draw parameters. The chain is run
for 50,000 iterations, after a 10,000 iteration burn-in period with 5,000 draws from the
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posterior distribution saved for each parameter by taking every 100th draw from the
post burn-in iterations. All of the proposal distributions are normal and centered at
the most recent parameter draw. For the shape parameters, the proposal distribution
is truncated at 0. For each study, the variance of the proposal distribution for each
parameter is adjusted so that each of the resulting acceptance rates are close to 40%.
APPENDIX K
Estimated treatment effects from multi-state cure
model
Figure K.1: Treatment effect estimates for each of the five model components for 12
trials. Each line represents the 95% credible interval for the coefficient
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Multi-state cure model Cox-Snell residual plots
Figure L.1: Cox-Snell residual plots for time to recur. Results from 12 trials.












































































































































































































































































































































































































































































































































Figure L.2: Cox-Snell residual plots for time to death after recurrence. Results for
12 trials.
























































































































































































































































































































































































































































































































Multi-state cure model deviance residual plots
Figure M.1: Deviance residual plots for time to recurrence plotted against age.









































































































































































































































































Figure M.2: Deviance residual plots for time to death after recurrence plotted against
age.























































































































































































































































































































































































Figure M.3: Deviance residual plots for time to death after recurrence plotted against
time to recurrence.























































































































































































































































































































































































Figure M.4: Deviance residual plots for time to death plotted against age.



















































































































































































































































































































Cox-Snell residual plots for multi-state model with
no cured fraction
Figure N.1: Cox-Snell residual plots for time to death for model without a cured
fraction. Results from 12 trials.






































































































































































































































































































































































































































































































































Follow-up details for colon cancer trials
Table O.1: Accrual and follow-up details for 12 trials in colon cancer
Study Accrual Length Longest Follow-Up: Longest Follow-Up:
(Years) Original (Years) Artificially Censored (Years)
1 5.7 9.9 7.6
2 1.5 9.1 6
3 3.6 11.4 5.6
4 2 9.9 5.5
5 4.8 12.6 6.8
6 5.2 13.2 7.2
7 4.9 12.9 6.9
8 1.7 9.7 5.7
9 1.4 9.4 5.9
10 2.3 10.3 5.8
11 2 8 5.5
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